0001493152-19-011990.txt : 20190809 0001493152-19-011990.hdr.sgml : 20190809 20190809155244 ACCESSION NUMBER: 0001493152-19-011990 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190809 DATE AS OF CHANGE: 20190809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TearLab Corp CENTRAL INDEX KEY: 0001299139 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 593434771 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-51030 FILM NUMBER: 191012876 BUSINESS ADDRESS: STREET 1: 9980 HUENNEKENS ST. STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-794-1400 MAIL ADDRESS: STREET 1: 9980 HUENNEKENS ST. STREET 2: SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: OccuLogix, Inc. DATE OF NAME CHANGE: 20040730 10-Q 1 form10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: June 30, 2019

[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to _______________

Commission File Number: 000-51030

TearLab Corporation

(Exact name of registrant as

specified in its charter)

Delaware

59 343 4771

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer

Identification No.)

150 LaTerraza Blvd., Suite 101

Escondido, California

92025

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (858) 455-6006

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

The Company does not have any securities registered pursuant to Section 12(b) of the Act. The Company’s common stock is registered pursuant to Section 12(g) of the Act and traded on the OTCQB under the symbol “TEAR”.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]	Accelerated filer [ ]

Non-accelerated filer [X]	Smaller reporting company [X]

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes [ ] No [X]

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 12,560,635 as of August 2, 2019.

		Page

PART I.	FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)	4
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	29
Item 4.	Controls and Procedures	29

PART II.	OTHER INFORMATION

Item 1.	Legal Proceedings	30
Item 1A.	Risk Factors	31
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	43
Item 3.	Defaults Upon Senior Securities	43
Item 4.	Mine Safety Disclosures	43
Item 5.	Other Information	43
Item 6.	Exhibits	43

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements relating to future events and our future performance within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “pursue,” “potential” and similar expressions intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to future events, future results, and future economic conditions in general and statements about:

●	Our ability to continue as a going concern;
●	The adequacy of our funding and our forecast of the period of time through which our financial resources will be adequate to support our operations;
●	Our future strategy, structure, and business prospects and the ability to identify and execute any strategic alternatives;
●	Our ability to obtain additional financing for working capital on acceptable terms and in a timely manner while our common stock is traded on the OTCQB market;
●	The planned continued commercialization of our current product;
●	Our ability to expand into next generation products, including our expectations regarding the resubmission of our 510(k) application and the timeline for commencing commercial sales of the TearLab Discovery^TMPlatform;
●	Our ability to meet the financial covenants under our credit facilities;
●	Use of cash, cash needs and ability to raise capital;
●	The size and growth of the potential markets for our product and technology;
●	The effect of our strategy to streamline our organization and lower our costs, including the impact of our new business model adopted in December 2017;
●	The adequacy of current, and the development of new distributor, reseller, and supplier relationships, and our efforts to expand relationships with distributors and resellers in additional countries;
●	Our anticipated expansion of United States and international sales and operations;
●	Our ability to obtain and protect our intellectual property and proprietary rights;
●	The results of our clinical trials;
●	Our ability to maintain reimbursement for our product and support our pricing strategies;
●	Our ability to execute our marketing strategy to ensure visibility and evidence-based positioning of the TearLab® Osmolarity System among eye care professionals given our reduced commercial resources;
●	Our ability to attract and retain a sufficient number of scientists, clinicians, sales personnel and other key personnel with extensive experience in medical technology, who are in short supply;
●	Our beliefs about our employee relations;
●	Our efforts to assist our customers in obtaining their CLIA waiver or providing them with support from certified professionals; and
●	The impact of our common stock being traded on the OTCQB.

These statements involve known and unknown risks, uncertainties and other factors, including the risks described in Part II, Item 1A. of this Quarterly Report on Form 10-Q, which may cause our actual results, performance or achievements to be materially different from any future results, performances, time frames or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Information regarding market and industry statistics contained in this Quarterly Report on Form 10-Q is included based on information available to us that we believe is accurate. It is generally based on academic and other publications that are not produced for purposes of securities offerings or economic analysis. We have not reviewed or included data from all sources and cannot assure you of the accuracy of the market and industry data we have included.

Unless the context indicates or requires otherwise, in this Quarterly Report on Form 10-Q, references to the “Company” shall mean TearLab Corporation or TearLab Corp. and its subsidiaries. References to “$” or “dollars” shall mean U.S. dollars unless otherwise indicated.

TearLab Corporation

PART I.	FINANCIAL INFORMATION

ITEM 1.	FINANCIAL STATEMENTS (Unaudited)

CONDENSED CONSOLIDATED BALANCE SHEETS

(expressed in thousands of U.S. dollars except number of shares)

(Unaudited)

	June 30, 2019			December 31, 2018

ASSETS
Current assets
Cash	$	9,173		$	8,473
Accounts receivable, net		1,123			1,186
Inventory		2,832			1,987
Prepaid expenses and other current assets		356			690
Total current assets		13,484			12,336

Fixed assets, net		1,626			2,024
Intangible assets, net		2			2
Right of use assets		677			-
Other non-current assets		150			151
Total assets	$	15,939		$	14,513

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities
Accounts payable	$	1,425		$	681
Accrued liabilities		2,084			2,363
Deferred revenue/rent		4			13
Current portion of long-term debt		16,486			-
Current portion of lease liability		182			-
Total current liabilities		20,181			3,057

Long-term debt, net of current portion		18,278			32,014
Long-term lease liability, net of current portion		493			-
Long-term third party payable		119			111
Total liabilities		39,071			35,182

Commitments and contingencies (Note 8)

Stockholders’ deficit
Capital stock
Preferred Stock, $0.001 par value, 10,000,000 shares authorized, 160 and 556 issued and outstanding at June 30, 2019 and December 31, 2018, respectively		-			-
Common stock, $0.001 par value, 40,000,000 shares authorized, 12,196,998 and 11,296,998 issued and outstanding at June 30, 2019 and December 31, 2018, respectively		12			11
Additional paid-in capital		510,429			510,380
Accumulated deficit		(533,573	)		(531,060	)
Total stockholders’ deficit		(23,132	)		(20,669	)
Total liabilities and stockholders’ deficit	$	15,939		$	14,513

See accompanying notes to interim condensed consolidated financial statements

TearLab Corporation

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(expressed in thousands of U.S. dollars except shares and per share amounts)

(Unaudited)

	Three months ended
	June 30,
	2019			2018

Revenue
Product sales	$	5,157		$	5,679
Reader equipment rentals		694			734
Total revenue		5,851			6,413
Cost of goods sold
Cost of goods sold (excluding amortization of intangible assets)		2,041			2,355
Cost of goods sold - reader equipment depreciation		121			265
Gross profit		3,689			3,793
Operating expenses
Sales and marketing		995			959
Clinical, regulatory and research & development		1,007			996
General and administrative		1,455			1,340
Total operating expenses		3,457			3,295
Income from operations		232			498
Other income (expense)
Interest expense		(1,405	)		(1,149	)
Other, net		(1	)		(10	)
Total other income (expense)		(1,406	)		(1,159	)
Net loss and comprehensive loss	$	(1,174	)	$	(661	)
Weighted average shares outstanding - basic and fully diluted		12,041,442			10,609,131
Net loss per share	$	(0.10	)	$	(0.06	)

See accompanying notes to interim condensed consolidated financial statements

TearLab Corporation

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(expressed in thousands of U.S. dollars except shares and per share amounts)

(Unaudited)

	Six months ended
	June 30,
	2019			2018

Revenue
Product sales	$	10,153		$	11,454
Reader equipment rentals		1,381			1,405
Total revenue		11,534			12,859
Cost of goods sold
Cost of goods sold (excluding amortization of intangible assets)		3,971			4,190
Cost of goods sold - reader equipment depreciation		274			553
Gross profit		7,289			8,116
Operating expenses
Sales and marketing		1,870			1,978
Clinical, regulatory and research & development		1,881			2,038
General and administrative		3,299			3,385
Total operating expenses		7,050			7,401
Income from operations		239			715
Other income (expense)
Interest expense		(2,755	)		(2,254	)
Other, net		3			(5	)
Total other income (expense)		(2,752	)		(2,259	)
Net loss and comprehensive loss	$	(2,513	)	$	(1,544	)
Weighted average shares outstanding - basic and fully diluted		11,800,331			10,070,652
Net loss per share	$	(0.21	)	$	(0.15	)

See accompanying notes to interim condensed consolidated financial statements

TearLab Corporation

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

(expressed in thousands of U.S. dollars except number of shares)

(Unaudited)

	Common stock				Series A Convertible Preferred stock					Additional paid-in			Accumulated			Stockholders’
	Shares		Amount		Shares			Amount		Capital			Deficit			Deficit
Balance, January 1, 2019		11,296,998	$	11		556		$	-	$	510,380		$	(531,060	)	$	(20,669	)
Series A Convertible Preferred stock converted to common		400,000		1		(176	)		-		-			-			1
Stock-based compensation		-		-		-			-		31			-			31
Net loss and comprehensive loss		-		-		-			-		-			(1,339	)		(1,339	)
Balance, March 31, 2019		11,696,998	$	12		380		$	-	$	510,411		$	(532,399	)	$	(21,976	)
Series A Convertible Preferred stock converted to common		500,000		-		(220	)		-		(1	)		-			(1	)
Stock-based compensation		-		-		-			-		19			-			19
Net loss and comprehensive loss		-		-		-			-		-			(1,174	)		(1,174	)
Balance, June 30, 2019		12,196,998	$	12		160		$	-	$	510,429		$	(533,573	)	$	(23,132	)

	Common stock				Series A Convertible Preferred stock					Additional			Accumulated			Stockholders’
	Shares		Amount		Shares			Amount		Capital			Deficit			Deficit
Balance, January 1, 2018		7,986,998	$	8		2,012		$	-	$	510,235		$	(528,809	)	$	(18,566	)
Series A Convertible Preferred stock converted to common		2,452,000		2		(1,078	)		-		(2	)		-			-
Stock-based compensation		-		-		-			-		8			-			8
Common Stock Warrants issued		-		-		-			-		(3	)		-			(3	)
Net loss and comprehensive loss		-		-		-			-		-			(883	)		(883	)
Balance, March 31, 2018		10,438,998	$	10		934		$	-	$	510,238		$	(529,692	)	$	(19,444	)
Series A Convertible Preferred stock converted to common		358,000		1		(158	)		-		-			-			1
Stock-based compensation		-		-		-			-		72			-			72
Net loss and comprehensive loss		-		-		-			-		-			(661	)		(661	)
Balance, June 30, 2018		10,796,998	$	11		776		$	-	$	510,310		$	(530,353	)	$	(20,032	)

See accompanying notes to interim condensed consolidated financial statements

TearLab Corporation

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(expressed in thousands of U.S. dollars)

(Unaudited)

	Six months ended
	June 30,
	2019			2018

OPERATING ACTIVITIES
Net loss for the period	$	(2,513	)	$	(1,544	)
Adjustments to reconcile net loss to cash used in operating activities:
Stock-based compensation		50			80
Depreciation of fixed assets		412			679
Amortization of intangible assets		-			6
Deferred interest on long-term debt		2,061			1,838
Amortization of debt discount		697			419
Loss on disposal of equipment		28			1
Changes in operating assets and liabilities:
Accounts receivable, net		63			263
Inventory		(845	)		143
Prepaid expenses and other assets		335			243
Other non-current assets		-			(80	)
Accounts payable		744			(1,261	)
Accrued liabilities		(279	)		(552	)
Deferred rent/revenue		(11	)		(21	)
Cash provided by operating activities		742			214

INVESTING ACTIVITIES
Additions to fixed assets		(42	)		(119	)
Cash used in investing activities		(42	)		(119	)

FINANCING ACTIVITIES
Payment on term loan		-			(1,000	)
Cash used in financing activities		-			(1,000	)

Increase (decrease) in cash during the period		700			(905	)
Cash, beginning of period		8,473			7,272
Cash, end of period	$	9,173		$	6,367

Supplemental cash flow information
Right-of-use assets acquired through operating leases	$	801		$	-
Cash paid for operating leases		176			-

See accompanying notes to interim condensed consolidated financial statements

TearLab Corporation

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(expressed in thousands of U.S. dollars except as otherwise stated)

(Unaudited)

1. BASIS OF PRESENTATION

Nature of Operations

TearLab Corporation (“TearLab” or the “Company”), a Delaware corporation, is an ophthalmic device company that is commercializing a proprietary in vitro diagnostic tear testing platform, the TearLab® Osmolarity System to test for dry eye disease, or DED, which enables eye care practitioners to test for highly sensitive and specific biomarkers using nanoliters of tear film at the point-of-care.

The accompanying condensed consolidated financial statements include the accounts of the Company and all of its wholly owned subsidiaries. Intercompany accounts and transactions have been eliminated on consolidation.

Liquidity and Going Concern

The accompanying condensed consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will continue to operate as a going concern and which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has sustained substantial losses of $2,513 and $1,544 for the six months ended June 30, 2019 and 2018, respectively. Based on the Company’s expected rate of cash consumption in the latter quarters of 2019, the Company estimates it will need additional capital in the first quarter of 2020 and its prospects for obtaining that capital are uncertain. The Company may be able to raise either additional debt financing or additional equity financing. However, the Company can make no assurances that it will be able to raise the required additional capital, either through debt or equity financing, on acceptable terms or at all. Unless the Company succeeds in raising additional capital or successfully increases cash generated from operations, the Company anticipates that it will be unable to continue operations through the end of the first quarter of 2020 without violating an existing covenant on the Term Loan Agreement, including the inability to make our debt payment due within twelve months (see Note 5). As a result of the Company’s historical losses and financial condition, there is substantial doubt about the Company’s ability to continue as a going concern.

2. SIGNIFICANT ACCOUNTING POLICIES

The Condensed Consolidated Balance Sheet at December 31, 2018 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States (“U.S. GAAP”) for complete financial statements. These unaudited interim condensed consolidated financial statements have been prepared using significant accounting policies that are consistent with the policies used in preparing the Company’s audited consolidated financial statements for the year ended December 31, 2018. The audited financial statements for the year ended December 31, 2018, filed with the SEC with the Company’s annual report on Form 10-K on March 22, 2019 include a summary of significant accounting policies and should be read in conjunction with this Form 10-Q. Management believes that all adjustments necessary for the fair presentation of results, consisting of normal recurring items, have been included in the unaudited condensed consolidated financial statements for the interim periods presented.

TearLab Corporation

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The principal areas of judgment relate to revenue and inventory reserves, allowance for doubtful accounts, impairment of long-lived and intangible assets, and the fair value of stock options and warrants.

Revenue Recognition

Revenue is recognized when obligations under the terms of a contract with our customer are satisfied; generally, this occurs with the transfer of control of our products or services. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services which includes estimates of variable consideration that results from returns, rebates or test card replacements. The Company records allowances for returns or rebates and reports revenue net of such amounts which was $27 and $6 for the three months ended June 30, 2019 and 2018, respectively and $55 and $6 for the six months ended June 30, 2019 and 2018, respectively. Sales and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. The Company’s payment terms are typically upon shipment or net 30.

The Company sells its proprietary TearLab® Osmolality System and related test cards to external customers, who are primarily eye care professionals, for use in osmolality testing procedures. Revenue is primarily derived from the sale of disposable test cards. Products are generally shipped from a distribution and warehousing facility located in San Diego, California. The Company’s sales are currently direct to customers in the United States and to distributors in the rest of the world.

The Company enters into contracts where revenue is derived either from agreements whereby the customer is provided the right to use the TearLab® Osmolarity System (reader equipment) at no separate cost to the customer in consideration for a minimum or implied purchase commitment of disposable test cards over the related contract term (referred to as either “Use Agreements”, “Masters Agreements” or “Flex Agreements”), or from agreements to sell the reader equipment and disposable test cards at their stand-alone selling price with no contractual future purchase commitment (referred to as “Purchase Agreements”).

Use, Masters, and Flex Agreements

Purchase commitments for Use Agreements and Flex Agreements are expressed in the agreement for a specified period of time (generally one to three years). The purchase commitment for Masters Agreements is implied for large physician practices with an expectation of purchasing certain levels of test cards. The Company recovers the cost of providing the reader equipment in the amount charged for disposable test cards. Two performance obligations exist under these contracts, related to the customers’ right to use the reader equipment and orders of test cards. As the customer has the ability and right to operate the reader equipment in a manner it determines as well as obtain the output from using the reader equipment, the revenue related to the reader equipment use performance obligation is recognized in accordance with ASC 842 – Leases, wherein revenue related to the reader equipment is recognized over the defined contract term. Revenue related to disposable test cards is recognized as the disposable test cards are shipped. Based on the nature of these contracts, which provide terms for the future purchase of test cards but do not contractually obligate the customer to do so, each purchase of test cards is treated as its own distinct contract with a performance obligation to provide the test cards ordered, memorialized by the customers’ purchase order/request. Revenue under such agreements is allocated between the lease of the reader equipment and the sale of the disposables based upon each component’s relative standalone selling price, which is estimated using the selling prices of the reader device and test cards under Purchase Agreements, discussed further below.

When reader equipment is placed with a customer at no separate cost, the Company retains title to the equipment and it remains capitalized on the Company’s Consolidated Balance Sheet as equipment classified within fixed assets, net. The equipment is depreciated on a straight-line basis once shipped to a customer location over its estimated useful life and depreciation expense is included in cost of goods sold within the Condensed Consolidated Statements of Operations and Comprehensive Loss.

Purchase Agreements

Revenue recognition for Purchase Agreements is based on the individual performance obligations determined to exist in the contract. Since the reader equipment and the test cards are separate and distinct delivered items, the delivery of each are considered separate performance obligations. The reader equipment and test cards are separately identified under the Purchase Agreements and are sold at their standalone selling price. The Company recognizes revenue for each of the performance obligations only when it determines that all applicable recognition criteria have been met, which is usually upon shipment to the customer. Under Purchase Agreements, the customer is not contractually obligated to purchase additional test cards, and each subsequent order of test cards represents a separate and distinct contract with the performance obligation to provide the test cards ordered.

Amounts billed to customers for shipping and handling of a sales transaction are included as revenue. The Company recognized revenue from shipping and handling of $36 and $38 for the three months ended June 30, 2019 and 2018, respectively. The Company recognized revenue from shipping and handling of $69 and $77 for the six months ended June 30, 2019 and 2018, respectively.

TearLab Corporation

The following table presents our revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues:

	Three months ended				Six months ended
	June 30,				June 30,
	2019		2018		2019		2018

Product Sales	$	5,157	$	5,679	$	10,153	$	11,454
Reader Equipment Rentals		694		734		1,381		1,405
	$	5,851	$	6,413	$	11,534	$	12,859

Arrangements with Multiple Performance Obligations

Our contracts with customers may include multiple performance obligations. For such arrangements, we allocate revenue to each performance obligation based on its relative standalone selling price. We generally determine standalone selling prices based on the separate prices charged to customers for the reader device and test cards under Purchase Agreements.

Return Reserve

Although the Company has a no return policy for its products, the Company has established a return reserve for product sales that contain an implicit right of return. The Company reserves for estimated returns or refunds by reducing revenue at the time of shipment based on historical experience. The reserve of $5 and $6 as of June 30, 2019 and December 31, 2018, respectively, has been recorded as a reduction of revenue and is included in accounts receivable.

Practical Expedients and Exemptions

We generally expense outside sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within sales and marketing expenses.

We do not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.

Leases

On January 1, 2019, the Company adopted the Financial Accounting Standards Board (‘FASB’) Accounting Standards Update (‘ASU’) 2016-02, Leases, which requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous guidance. The original guidance required application on a modified retrospective basis with the earliest period presented. In August 2018, the FASB issued ASU 2018-11, Targeted Improvements to ASC 842, which included an option to not restate comparative periods in transition and elect to use the effective date of ASC 842, Leases, as the date of initial application of transition, which the Company elected. Lease arrangements are determined at the inception of the contract with and included in right-of-use (“ROU”) assets and long-term lease liabilities on the consolidated balance sheets. The adoption of ASC 842 had an immaterial impact on our Condensed Consolidated Statement of Operations and Comprehensive Loss and Condensed Consolidated Statement of Cash Flows for the three and six month periods ended June 30, 2019. Additionally, the Company has elected the package practical expedient with respect to lease definition, classification and direct costs. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 month or less. Additional information and disclosures required by the new standard are contained in Note 8.

Recent accounting pronouncements

In June 2018, the FASB issued Accounting Standards Update (“ASU”) No. 2018-07, “Compensation – Stock Compensation (Topic 718).” ASU 2018-07 simplifies the accounting for nonemployee share-based payment transactions. This ASU is effective for public entities for interim and annual reporting periods beginning after December 15, 2018. The Company adopted ASU 2018-07 effective January 1, 2019 with an immaterial impact to our financial statements.

TearLab Corporation

3. BALANCE SHEET DETAILS

Accounts receivable

	June 30, 2019			December 31, 2018

Trade receivables	$	1,214		$	1,324
Allowance for doubtful accounts		(91	)		(138	)
	$	1,123		$	1,186

Inventory

Inventory is recorded at the lower of cost and net realizable value on a first-in, first-out basis and consists of finished goods.

	June 30, 2019		December 31, 2018

Finished goods	$	2,832	$	1,987
Inventory reserves		-		-
	$	2,832	$	1,987

The Company evaluates inventory for estimated excess quantities and obsolescence, based on expected future sales levels and projections of future demand, and establishes inventory reserves for obsolete and excess inventories. In addition, the Company assesses the impact of changing technology and market conditions. The Company has entered into a long-term purchase commitment to buy the test cards from MiniFAB (Note 8). As part of its analysis of excess or obsolete inventories, the Company considers future annual minimum purchases, estimated future usage and the expiry dating of the cards to determine if any inventory reserve is needed.

Prepaid expenses and other current assets

	June 30, 2019		December 31, 2018
Prepaid trade shows	$	20	$	18
Prepaid insurance		110		322
Manufacturing deposits		111		111
Subscriptions		91		140
Other fees and services		22		98
Other current assets		2		1
	$	356	$	690

TearLab Corporation

Fixed assets

	June 30, 2019			December 31, 2018
Capitalized TearLab equipment	$	6,643		$	6,922
Manufacturing equipment		317			317
Leasehold improvements		13			13
Computer equipment and software		306			846
Furniture and office equipment		368			368
Medical equipment		1,430			1,366
	$	9,077		$	9,832
Less accumulated depreciation		(7,451	)		(7,808	)
	$	1,626		$	2,024

Depreciation expense was $191 and $326 during the three months ended June 30, 2019 and 2018, respectively. Depreciation expense was $412 and $679 during the six months ended June 30, 2019 and 2018, respectively.

Accrued liabilities

	June 30, 2019		December 31, 2018
Due to professionals	$	17	$	17
Due to employees and directors		945		1,289
Sales and use tax liabilities		262		257
Royalty liability		278		290
Warranty		45		74
Other		537		436
	$	2,084	$	2,363

TearLab Corporation

4. INTANGIBLE ASSETS

The Company’s intangible assets consist of the value of TearLab® Technology acquired in the acquisition of TearLab Research, Inc., a wholly-owned subsidiary of the Company and a prescriber list. The TearLab Technology, which consists of a disposable lab card and card reader, supported by an array of patents and patent applications that are either held or in-licensed by the Company. Amortization expense for the three months ended June 30, 2019 and 2018 was $0.1 and $3, respectively. Amortization expense for the six months ended June 30, 2019 and 2018 was $0.2 and $6, respectively.

Intangible assets subject to amortization consist of the following:

	Remaining Useful Life	Gross Value at		Accumulated			Net Book Value at
	(Years)	June 30, 2019		Amortization			June 30, 2019

TearLab® technology	0	$	12,172	$	(12,172	)	$	-
Patents and trademarks	1		271		(269	)		2
Prescriber list	0		90		(90	)		-
Total		$	12,533	$	(12,531	)	$	2

	Gross Value at		Accumulated			Net Book Value at
	December 31, 2018		Amortization			December 31, 2018

TearLab® technology	$	12,172	$	(12,172	)	$	-
Patents and trademarks		271		(269	)		2
Prescriber list		90		(90	)		-
Total	$	12,533	$	(12,531	)	$	2

The estimated amortization expense for the intangible assets for the remainder of 2019 and thereafter is as follows:

	Amortization
	of intangible
	assets

Remainder of 2019	$	1
Thereafter		1
	$	2

5. TERM LOAN

On March 4, 2015, the Company executed a term loan agreement (the “Term Loan Agreement”) with CRG LP and certain of its affiliate funds (“CRG”) as lenders providing the Company with access of up to $35,000 under the arrangement. The Company received $15,000 in gross proceeds under the arrangement on March 4, 2015, and an additional $10,000 on October 6, 2015. The Term Loan Agreement matures on December 31, 2020 and bears interest at 13% per annum, with quarterly payments of interest only for the first four years. While interest on the loan is accrued at 13% per annum, the Company may elect to make interest-only payments at 8.5% per annum. The unpaid interest of 4.5% is added to the principal of the loan and is subject to additional accrued interest (“PIK interest”). The accrued interest can be deferred and paid together with the principal in the fifth and sixth years.

As part of Amendment No. 2 to the Term Loan Agreement, and funding of the second tranche, CRG received 35,000 warrants dated as of October 6, 2015 to purchase common shares of the Company at a price of $50.00 per share (the “2015 CRG Warrants”). The 2015 CRG Warrants have a five-year life and are classified as equity on the Consolidated Balance Sheets as of June 30, 2019 and 2018. The 2015 CRG Warrants were valued at their issuance date using the Black-Scholes Merton model. The related reduction of the long-term debt will be amortized over the life of the debt. On April 7, 2016, the Company entered into Amendment No. 4 to the Term Loan Agreement and the company issued CRG additional warrants to purchase 35,000 common shares of the Company’s stock at $15.00 per share (the “2016 CRG Warrants” and together with the 2015 CRG Warrants, the “CRG Warrants”), which expire 5 years after issuance.

On October 12, 2017, the Company entered into Amendment No. 5 to the Term Loan Agreement. This amendment reduced the exercise price of all of the CRG Warrants from $15.00 per share to $1.50 per share and provided broad anti-dilution protection such that the CRG Warrants maintained the same 1.22% ownership following any capital raises the Company completed through March 31, 2018.

On April 4, 2018 with an effective date of March 31, 2018, the Company entered into Amendment No. 6 to the Term Loan Agreement. Pursuant to the terms of this amendment, the cash interest payments due in 2018 were deferred and added to the principal balance under the Loan Agreement at the end of each quarter. This amendment also provided for an additional facility fee equal to 3% of the sum of the aggregate amount of the principal drawn under the Term Loan Agreement and any PIK loans issued, so that the total facility fee shall be 9.5%, applicable to the entire balance (the “Facility Fee”). The Facility Fee is being accrued to interest expense using the effective interest method. In addition, this amendment reduced the minimum liquidity covenant to $3 million. Concurrent with the reduction of the liquidity covenant the Company agreed to repay CRG $1.0 million of principal on the Term Loan Agreement in April 2018. Lastly, this amendment reduced the strike price of the existing CRG Warrants to $0.44 per share (see Note 6). The Amendment was accounted for as a modification in accordance with U.S. GAAP.

On November 12, 2018 the Company entered into Amendment No. 7 to the Term Loan Agreement. Pursuant to the terms of the agreement, the Amendment extended the “Interest-Only Period” under the Term Loan Agreement from the sixteenth (16^th) payment date to the twentieth (20^th) payment date following the first borrowing date, which has the effect of pushing out the principal payments to 2020. In addition, the cash interest payments under the Term Loan Agreement for periods ending on March 31, 2019 and June 30, 2019 will be deferred and added to the principal balance under the Term Loan Agreement at the end of each such quarter. The Company evaluated the amendment and it was accounted for as a modification in accordance with GAAP, with no incremental expense incurred. Additionally, if the Federal Drug Administration (“FDA”) had received and accepted our application for review of our Discovery^TM Platform on or before June 30, 2019 the Company would have been entitled to pay the interest on the outstanding principal amount of the loans under the Term Loan Agreement payable during the quarter ended September 30, 2019 entirely in the form of a PIK Loan. The Company did not file an updated 510K with the FDA prior to June 30, 2019 and expects it will be required to make an interest payment at the end of the third quarter of 2019. Finally, the Amendment reduced the minimum required revenue for 2018 under the Term Loan Agreement from $25 million to $24 million.

TearLab Corporation

The loan is collateralized by all assets of the Company. Additionally, the terms of the Term Loan Agreement contain various affirmative and negative covenants agreed to by the Company. Among them, the Company must attain minimum certain annual revenue and minimum cash threshold levels. The minimum revenue is $38,000 for 2019 and $45,000 for 2020.

If the Company does not have annual revenue greater or equal to the annual revenue covenant in a calendar year, the Company will have the right within 90 days of the end of the respective calendar year to raise subordinated debt or equity (the “CRG Equity Cure”) equal to twice the difference between the annual revenue and the revenue covenant, with the total proceeds from this financing to be used to reduce the principal of the Term Loan Agreement. In the event of a default, the Company may be required to repay any outstanding amounts earlier than anticipated, and CRG may foreclose on their security interest in the Company’s assets.

At June 30, 2019, the Company was in compliance with all of the covenants.

The Company incurred financing and legal fees associated with the debt of $606, which were recorded as a direct discount to the debt and are being amortized using the effective interest method. The Company presents the debt issuance costs related to the recognized debt liability on the Consolidated Balance Sheet as a reduction of the liability.

The Term Loan Agreement provided for prepayment fees of 5% of the outstanding balance of the loan if the loan was repaid prior to March 31, 2016. The prepayment fee is reduced 1% per year for each subsequent year until maturity.

The following is a summary of the Term Loan Agreement as of June 30, 2019 and related maturities of outstanding principal:

Principal balance outstanding	$	24,000
PIK interest		8,971
Facility fee		2,033
less discount on term loan:
deferred financing fees, net		(111	)
detachable warrants, net		(129	)
	$	34,764
Less: current portion of Term loan		(16,486	)
Total Term Loan	$	18,278

TearLab Corporation

Principal due for each of the next two years:

2019	$	-
2020		35,004
Total principal due		35,004
Less: discount on term loan		(240	)
Total term loan	$	34,764

6. STOCKHOLDERS’ EQUITY

(a) Authorized share capital

On October 12, 2017, the stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 9,500,000 to 40,000,000. Each share of common stock has a par value of $0.001 per share. The total number of authorized shares of preferred stock of the Company is 10,000,000. Each share of preferred stock has a par value of $0.001 per share.

(b) Common and preferred shares

On December 8, 2017, the Company issued 2,013,636 shares of common stock, 2,114 shares of Series A Convertible Preferred Stock (“Preferred Stock”), Series A warrants to purchase 6,818,181 shares of common Stock (“Series A Warrants”) and Series B warrants to purchase 6,818,181 shares of common stock (“Series B Warrants”) for gross proceeds of $3,000, less issuance costs of $596. Additionally, the Company granted the placement agent compensation warrants to purchase 477,273 shares of common stock. The Preferred Stock is convertible, subject to certain limitations, into an aggregate of 4,804,545 shares of common stock, contains no voting rights, participates in any common stock dividends and is treated as if converted upon any ordinary liquidation event.

As of June 30, 2019, 1,954 shares of Series A Preferred Stock have been converted into 4,440,909 shares of common stock.

TearLab Corporation

(c) Stock Incentive Plan

On June 23, 2017, the Company’s stockholders approved an amendment to the 2002 Stock Incentive Plan (the “Stock Incentive Plan”), to increase the total number of shares reserved for issuance to 1,070,000 from 720,000. Stock Incentive Plan shares are available for grant to employees, directors and consultants. Shares granted under the Stock Incentive Plan may be either incentive stock options or non-statutory stock options. Under the terms of the Stock Incentive Plan, the exercise price per share for an incentive stock option shall not be less than the fair market value of a share of stock on the effective date of grant and the exercise price per share for non-statutory stock options shall not be less than 85% of the fair market value of a share of stock on the date of grant. No option granted to a holder of more than 10% of the Company’s common stock shall have an exercise price per share less than 110% of the fair market value of a share of stock on the effective date of grant.

Options granted are typically service-based options. Generally, options expire 10 years after the date of grant. No incentive stock options granted to a 10% owner optionee shall be exercisable after the expiration of five years after the effective date of grant of such option, no option has been granted to a prospective employee, prospective consultant or prospective director prior to the date on which such person commences service, and with the exception of an option granted to an officer, director or consultant, no incentive option shall become exercisable at a rate less than 20% per annum over a period of five years from the effective date of grant of such option unless otherwise approved by the Board.

Share-based payment transactions with employees are recognized in the condensed consolidated financial statements based on their fair value and recognized as compensation expense over the vesting period. The amount of expense recognized during the period is affected by subjective assumptions, including: estimates of the Company’s future volatility, the expected term for its stock options, option exercise behavior, the number of options expected to ultimately vest, and the timing of vesting for the Company’s share-based awards.

The following table sets forth the total stock-based compensation expense resulting from stock options and the employee stock purchase plan included in the Company’s condensed consolidated statements of operations and comprehensive loss (in thousands):

	Three months ended					Six months ended
	June 30,					June 30,
	2019			2018		2019		2018

Sales and marketing	$	(5	)	$	20	$	3	$	38
Clinical, regulatory and research and development		4			8		8		16
General and administrative		20			44		39		26
Stock-based compensation expense before income taxes	$	19		$	72	$	50	$	80

TearLab Corporation

(d) Employee Stock Purchase Plan

In July 2014, the Company’s Board of Directors adopted the 2014 Employee Stock Purchase Plan (the “ESPP”) which was approved by the Company’s stockholders in June 2014 at the Company’s Annual Meeting of Stockholders. A total of 28,601 shares of the Company’s common stock were reserved for issuance under the plan, which permits eligible employees to purchase common stock at a discount through payroll deductions. In 2018 the Company’s Board of Directors terminated the ESPP.

(e) Warrants

On October 8, 2015, as part of Amendment No. 2 to the Term Loan Agreement and funding of the $10,000 tranche, CRG received warrants to purchase 35,000 common shares in the Company at a price of $50.00 per share (the “2015 CRG Warrants”). The 2015 CRG Warrants are exercisable any time prior to October 8, 2020. The 2015 CRG Warrants are classified as equity on the Condensed Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018. The 2015 CRG Warrants were valued at $290 upon issuance using the Black-Scholes Merton model assuming volatility of 73%, an expected life of 5.0 years, a risk-free interest rate of 1.71%, and 0% dividend yield. No CRG Warrants were exercised during the six months ended June 30, 2019 or 2018.

On April 7, 2016, as part of Amendment No. 4 to the Term Loan Agreement, the exercise price of the 2015 CRG Warrants was changed to allow the holder to purchase 35,000 common shares in the Company at a price of $15.00 per share and CRG was issued an additional 35,000 warrants to purchase common shares at an exercise price of $15.00 (the “2016 CRG Warrants” and, together with the 2015 CRG Warrants, the “CRG Warrants”). The modification to the terms of the 2015 CRG Warrants resulted in a change in fair value of $54 which was included as interest expense. The change in fair value was calculated using the Black-Scholes Merton model with both exercise prices, assuming volatility of 76%, an expected life of 4.5 years, a risk-free interest rate of 1.06%, and 0% dividend yield. The 2016 CRG Warrants were valued at $106 upon issuance using the Black-Scholes Merton model assuming volatility of 76%, an expected life of 5.0 years, a risk-free interest rate of 1.30% and 0% dividend yield.

On May 9, 2016, the Company issued Series A Warrants to purchase 1,253,500 shares of common stock for $11.25 per common share attached to shares of common and Series A Convertible Preferred Stock issued on the same date. The Series A Warrants can be exercised after May 9, 2017 (the “Initial Exercise Date”) and expire 5 years after the Initial Exercise Date. Fair value of the Series A Warrants, for purposes of allocating the net proceeds of the equity offering, was determined using the Black-Scholes Merton model assuming volatility of 76%, an expected life of 6.0 years, a risk-free interest rate of 1.30%, and 0% dividend yield.

On October 12, 2017, as part of Amendment No. 5 to the Term Loan Agreement, the exercise price of the CRG Warrants was changed to allow the holder to purchase common shares in the Company at a price of $1.50 per share as well as provide broad anti-dilution protection such that the CRG Warrants shall maintain the same 1.22% ownership following any capital raises the Company completed through March 31, 2018. The modification to the terms of the CRG Warrants resulted in a change in fair value of $44 which was included as interest expense. The 2015 CRG Warrants change in fair value was calculated using the Black-Scholes Merton model with both exercise prices, assuming volatility of 94%, an expected life of 2.99 years, a risk-free interest rate of 1.70% and 0% dividend yield. The 2016 CRG Warrants change in fair value was calculated using the Black-Scholes Merton model with both exercise prices, assuming volatility of 90%, an expected life of 3.48 years, a risk-free interest rate of 1.80% and 0% dividend yield.

On December 8, 2017, the Company issued Series A Warrants to purchase 6,818,181 shares of common stock for $0.44 per share and Series B Warrants to purchase 6,818,181 shares of common stock for $0.44 per share in conjunction with shares of common stock and Series A Convertible Preferred stock issued on that same date. The Series A Warrants were exercisable immediately and expire 5 years after the issuance date. Fair Value of the Series A Warrants, for purposes of allocating the net proceeds of the equity offering, was determined using the Black-Scholes Merton model assuming volatility of 88%, an expected life of 5 years, a risk free interest rate of 2.14% and a 0% dividend yield and are classified as equity on the Condensed Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018. The Series B Warrants were exercisable immediately and expired 6 months after the issuance date. Fair value of the Series B Warrants for purposes of allocating the net proceeds of the equity offering, was determined using the Black-Scholes Merton model assuming a volatility of 158.6%, an expected life of 6 months, a risk free rate of 1.45% and a 0% dividend yield and are classified as equity on the Condensed Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018. All Series B Warrants expired on June 7, 2018 with no warrants exercised. In addition, we granted the placement agent compensation warrants to purchase 477,273 shares of common stock at $0.55 per share. The compensation warrants are in the same form as Series A Warrants, excluding the exercise price, and will terminate on the five-year anniversary date. The placement agent warrants are classified as equity on the Condensed Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018.

In connection with the December 2017 offering the Company issued CRG warrants to purchase 83,240 shares of common stock at an exercise price of $1.50 (“2017 CRG Warrants”) as a result of triggering the anti-dilution clause of the debt amendment (see Note 5). The anti-dilution clause is considered down-round protection, however the Company early adopted ASU 2017-11 and therefore the down-round feature is excluded from the consideration of whether the warrants are indexed to the Company’s own stock and therefore the warrants are not required to be liabilities under the guidance. The 2017 CRG Warrants are classified as equity on the Condensed Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018 and were valued at $30 upon issuance using the Black-Scholes Merton model assuming volatility of 88%, an expected life of 5 years, a risk-free interest rate of 2.14% and 0% dividend yield. On April 4, 2018, in connection with Amendment No. 6 to the Term Loan Agreement, the strike price of all existing CRG warrants was reduced to $0.44 per share (see Note 5). The modification to the terms of the CRG Warrants and the 2017 CRG Warrants resulted in a change in fair value of $10 which was included as interest expense.

TearLab Corporation

7. NET INCOME (LOSS) PER SHARE

Basic earnings per share (“EPS”) excludes dilutive securities and is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding for the year. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted and the resulting additional shares are dilutive because their inclusion decreases the amount of EPS.

The following securities were not included in the calculation of diluted earnings per share because their effects were anti-dilutive:

(in thousands of shares)	As of June 30,
	2019		2018
Stock options		879		599
Warrants		8,702		8,702
Convertible preferred shares		-		1

Total		9,581		9,302

8. COMMITMENTS AND CONTINGENCIES

Leases

Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, we use an incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option.

The Company has commitments relating to operating leases recognized on a straight-line basis over the term of the lease for rental of two office spaces and various equipment from unrelated parties. Our California office lease was signed May 1, 2018, with a commencement date of July 1, 2018, expires on November 30, 2023 and has an option for a 5-year extension and escalating payments. On December 21, 2018 the Company entered into a fourth amendment to our Texas office lease to extend the term of the lease until December 31, 2019. In addition, the Company has vehicle leases expiring at various times through January 2021, and an equipment lease expiring in December 2021.

The adoption of ASC Topic 842 resulted in the Company recognizing right of use assets of $738 and a lease liability of $739, with the difference due the write-off of prior recorded deferred rent.

The components of lease costs were as follows:

	Three months ended		Six months ended
	June 30, 2019		June 30, 2019
Operating lease costs	$	87	$	175
Short-term lease costs		-		-
Variable lease costs		-		-
	$	87	$	175

Future minimum lease payments under non-cancellable leases as of June 30, 2019 were as follows:

2019	$	151
2020		202
2021		184
2022		164
2023		169
Total lease payments		870
Less: present value discount		(195	)
Present value of lease liabilities	$	675
Weighted average remaining lease term		3.8
Weighted average discount rate		13	%

Commitments

On May 1, 2018 with an effective date of July 1, 2017 the Company entered into a Restated License Agreement (the “Agreement”) to its exclusive license agreement for the commercial development of the invention disclosed in UCSD Disclosure Docket No. SD2002-180 and titled “Volume Independent Tear Film Osmometer” (UCSD License Agreement #2003-03-0433), dated as of March 12, 2003, as amended by Amendment 1, dated as of June 9, 2003, Amendment 2, dated as of September 5, 2005, Amendment 3, dated as of July 7, 2006, Amendment 4, dated as of October 9, 2006, and Amendment 5, dated as of July 9, 2007, by and among the Company and The Regents of the University of California (collectively the “Existing License”) to amend certain terms related to royalties under the Agreement and treatment upon a change of control transaction. The Company is required to make royalty payments of anywhere from 3% to 4.25% based on quarterly net sales. Additionally, the Company is required to pay a royalty of 20% of any sublicense fees it receives. Should a change of control transaction occur during the term of the agreement the royalty rates would range anywhere from 3.5% to 4.75% based on quarterly net sales and the Company would have to make a milestone payment of $0.5 million. In addition, if the Company had not commenced commercial sales of the TearLab Discovery^TM Platform on or before July 1, 2019 the Company would have be required to pay a milestone payment of 1.25% of cumulative net sales for the two-year period following the effective date of the amendment. The Company completed its first commercial sale of the TearLab Discovery^TMPlatform prior to the July 1, 2019 deadline.

TearLab Corporation

Effective October 1, 2006 the Company entered into a second patent license and royalty agreement with the University of California San Diego to obtain an exclusive license to make, use, sell, offer for sale, and import TearLab technology in development. Starting in 2009, the Company was required to make minimum royalty payments of $35 or 5.5% of gross sales per year, whichever is higher. However, if this new technology is combined with existing technology, the maximum royalty payable on the sale of the combined products would be 5.5% of gross sales per year. As the new technology is currently in development, there is no revenue and the minimum royalty payment of $35 is applicable.

Future minimum royalty payments under this agreement as of June 30, 2019 are as follows:

2020		35
2021		35
2022		35
2023		35
2024		35
Thereafter		210
Total	$	385

On March 7, 2016, the Company, through its subsidiary, TearLab Research, Inc., entered into a supply and development agreement (“Supply Agreement”) with MiniFAB (Aust) Pty Ltd (“MiniFAB”). The agreement is an exclusive supply agreement through June 2021, for the purchase and delivery of individual osmolarity test cards with the freight costs borne by MiniFab. The Company has the benefit of a lower purchase price and certain savings from freight costs will remain in place throughout the agreement. The Supply Agreement requires, in any given 6 calendar months, the Company must place aggregate purchase orders equal to at least 50% of the orders forecasted for that 6-month period at its onset. The Supply Agreement can be extended by either party for a term of five years with the option for the Company to buyout the exclusive supply provision during any extended term. This Supply Agreement replaces the August 2011 agreement between MiniFAB and the Company. On August 9, 2018 the Company entered into an addendum to the 2016 Manufacturing and Supply and Development Agreement with MiniFab. The amendment fixes the price of the osmolarity test cards at their current price until the earlier of: the average monthly order volume of osmolarity cards on a rolling six month average falls below 20,000 cards; or the aggregate product volume in the calendar year commencing 12 months after the launch of the Discovery^TM product is below 2.4 million cards; or the aggregate product volume in any calendar year after 24 months after the launch of the Discovery^TM product is below 3.0 million cards at which point the Company and MiniFab will renegotiate pricing.

On August 9, 2018, the Company entered into a manufacturing, supply and development agreement (the “MiniFAB Agreement”) with MiniFAB. Pursuant to the terms of the MiniFAB Agreement, MiniFAB will manufacture and supply test cards for the Company’s next generation platform, the TearLab Discovery™ System. The MiniFAB Agreement is exclusive through the first term of 10 years and automatically renews for an additional term of 5 years unless either party cancels. TearLab will pay for 65% of the capital expenditures under the MiniFAB Agreement (“capex”) as incurred and MiniFAB will pay for the remaining 35% of capex, which will be recoverable from TearLab through an amortized cost component in the price for the product charged to TearLab once the monthly card volumes reach 200,000 per month. The capex amounts are limited to an aggregate of $1.0 million AUD for the initial development and production phase (“Phase 1”) and anticipated to be in the vicinity of $3.0 million AUD for further investment of production capacity (“Phase 2”). In addition, TearLab will be responsible for the payment or reimbursement of all non-recurrent expenditure and tooling, limited to $1.2 million AUD for Phase 1 and estimated at $2.0 million AUD for Phase 2. In December 2018, the Company made an initial capex investment of $317 for a machine that was placed into fixed assets and is being amortized over a 15-year period. The Company has a corresponding $119 of long-term third-party payable for capex to be amortized through the card cost component for the six months ended June 30, 2019.

In the normal course of business, the Company enters into purchase obligations for future goods and services needed for the operations of the business. Such commitments are not in excess of expected requirements and are not reasonably likely to result in performance penalties or payments that would have a material adverse effect on the Company’s liquidity.

Contingencies

We are not currently a party to any litigation, nor are we aware of any pending or threatened litigation against us, that we believe would materially affect our business, operating results, financial condition or cash flows. Our industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, we may be involved in various legal proceedings from time to time.

We initiated a patent infringement lawsuit against i-Med Pharma, Inc. in February 2016 alleging infringement of our Canadian patent. In February 2018, the Federal Court of Canada issued a ruling in favor of i-Med Pharma, Inc. which invalidated specific claims in our Canadian patent which were alleged to be infringed. We are appealed this ruling to the Canadian Federal Appellate Court. As part of the ruling, the Federal Court ruling awarded costs to i-Med Pharma, Inc., for $0.5 million. The final $0.2 million was paid in April 2018. In June 2019 the Canadian Federal Appellate Court dismissed the appeal.

9. RELATED PARTY

The Company has an agreement with its Chief Scientific Officer whereas if the Company enters into an agreement with UCSD to reduce the overall royalty rate the Company shall pay to its Chief Scientific Officer a royalty on net sales equal to one and a half percent of the percent change in the UCSD royalty rate. The restated UCSD patent license and royalty agreement (see Note 8) resulted in a royalty due at a rate of 0.68%. Related party royalty expense was $77 and $178 as of June 30, 2019 and 2018, respectively. The Company had $77 and $40 in accrued royalties at June 30, 2019 and December 31, 2018, respectively for the related party.

TearLab Corporation

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and related notes, included in Item 1 of this Report. Unless otherwise specified, all dollar amounts are U.S. dollars.

Overview

We are an in-vitro diagnostic company that has commercialized a proprietary tear testing platform, the TearLab® Osmolarity System that enables eye care practitioners to test for a highly sensitive and specific biomarker using nanoliters of tear film at the point-of-care. Our first product measures tear film osmolarity for the diagnosis of Dry Eye Disease or DED.

We develop technologies to enable eye care practitioners to test a wide range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Commercializing and further development of that tear testing platform is now the focus of our business.

Our product, the TearLab® Osmolarity System, enables the rapid measurement of tear osmolarity in the doctor’s office. Osmolarity is a quantitative and highly specific biomarker that has been shown to assist in the diagnosis and disease management of DED. Based on the Beaver Dam Offspring Study (2005-2008), prevalence of DED was 14.5% across an adult population aged 21-84, impacting 17.9% of women and 10.5% of men in the study. The innovation of the TearLab® Osmolarity System is its ability to precisely and rapidly measure osmolarity in nanoliter volumes of tear samples, using a highly efficient and novel tear collection system at the point of care. Historically, eye care researchers have relied on expensive instruments to perform tear biomarker analysis. In addition to their cost, these conventional systems are slow, highly variable in their measurement readings, and not categorized as waived by the United States Food and Drug Administration, or the FDA, under regulations promulgated under the Clinical Laboratory Improvement Amendments, or CLIA.

The TearLab® Osmolarity System consists of the following three components: (1) the TearLab disposable, which is a single-use microfluidic microchip; (2) the TearLab Pen, which is a hand-held device that interfaces with the TearLab disposable; and (3) the TearLab Reader, which is a small desktop unit that allows for the docking of the TearLab Pen and provides a quantitative reading for the operator.

We enter into contracts where revenue is derived either from agreements whereby the customer is provided the right to use the TearLab® Osmolarity System at no separate cost to the customer in consideration for a minimum purchase commitment or implied minimum purchase commitment of disposable test cards over the related contract term (which we refer to as either “Use Agreements”, “Masters Agreements” or “Flex Agreements”), or from agreements with separate sales of the reader equipment and disposable test cards (“Purchase Agreements”).

In October 2008, the TearLab® Osmolarity System received CE mark approval, clearing the way for sales in the European Union and all countries recognizing the CE mark. In connection with the CE mark clearance, we have entered into multi-year agreements with numerous distributors for distribution of the TearLab® Osmolarity System. Currently, we have signed distribution agreements in Central and South America, Europe, Asia, Canada, and Australia. We sell directly to the customer in the United States.

In May 2018, the TearLab Discovery^TM System received CE mark approval, clearing the way for sales in the European Union and all countries recognizing the CE mark.

On January 4, 2018, we announced that we had submitted a 510(k) application to the FDA for the potential clearance of the TearLab Discovery^TM Platform. The submission covered Discovery and the MMP-9 biomarker. On February 14, 2018, we announced that the application had successfully passed the acceptance review phase with the FDA. On April 11, 2018 we announced that we received written feedback from the FDA, requesting that we provide additional information to establish correlation to the FDA-cleared predicate chosen to establish 510(k) substantial equivalence. On September 4, 2018, we submitted, and the FDA accepted, our response to the FDA’s comments regarding the 510(k) application for the Discovery Platform. On October 10, 2018, we announced that the FDA determined that the TearLab Discovery™ MMP-9 test, had not met the criteria for substantial equivalence based upon data and information we had submitted. We plan to utilize the guidance provided by the FDA to compile the additional information necessary to resubmit for 510(k) clearance. After securing FDA clearance, we intend to pursue a CLIA waiver in an effort to prepare for commercialization in the US market.

TearLab Corporation

RESULTS OF OPERATIONS

Revenue, Cost of Sales and Gross Margin

(in thousands)	Three months ended June 30,									Six months ended June 30,
	2019			2018			Change			2019			2018			Change

TearLab revenue	$	5,851		$	6,413		$	(562	)	$	11,534		$	12,859		$	(1,325	)
TearLab – cost of sales		2,162			2,620			(458	)		4,245			4,743			(498	)
TearLab gross profit		3,689			3,793			(104	)		7,289			8,116			(827	)
Gross profit percentage		63	%		59	%					63	%		63	%

Revenue

TearLab revenue consists of sales of the TearLab® Osmolarity System, which is a hand-held tear film test for the measurement of tear osmolarity, a quantitative and highly specific biomarker that has shown to correlate with dry eye disease (“DED”).

The TearLab® Osmolarity System consists of the following three components: (1) the TearLab disposable, which is a single-use microfluidic lab test card; (2) the TearLab pen, which is a hand-held device that interfaces with the TearLab disposable; and (3) the TearLab reader, which is a small desktop unit that allows for the docking of the TearLab disposable and the TearLab pen and provides a quantitative reading for the operator.

Having received 510(K) clearance and a CLIA waiver from the FDA in the United States, we sell to customers in the United States who hold CLIA licenses and actively support and assist our customers to obtain their licenses or provide them with support from certified professionals. This CLIA waiver documentation allows us to sell our product to the approximately 50,000 eye care practitioners in the United States that are candidates to operate under a CLIA waiver certification.

We are working with our established distributors in Central and South America, Europe, Asia, Canada, and Australia to increase sales. The ability for reimbursement to be obtained in many of the countries where we have distributors will facilitate our ability to increase sales and stimulate the commercialization process. In countries where we have distributors, we are supporting physicians in local clinical trials and providing them with the required guidance to understand the relationship between DED and osmolarity and how to manage their patients with objective diagnostic data.

TearLab revenue for the three months ended June 30, 2019 was $5.9 million compared to $6.4 million for the three months ended June 30, 2018. TearLab revenue for the six months ended June 30, 2019 was $11.5 million compared to $12.9 million for the six months ended June 30, 2018. This decrease was driven by the decrease in both reader revenue and test card revenue compared to the first two quarters of 2018.

TearLab Corporation

Cost of Sales

TearLab cost of sales includes costs of goods sold, depreciation of reader systems, warranty, and royalty costs. Our cost of goods sold consists primarily of costs for the manufacture of the TearLab® Osmolarity System, including the costs we incur for the purchase of component parts from our suppliers, applicable freight and shipping costs, fees related to warehousing and logistics inventory management.

TearLab cost of sales decreased 17% for the three months ended June 30, 2019 compared to June 30, 2018. Cost of sales decreased 11% for the six months ended June 30, 2019 compared to June 30, 2018. The decrease was driven by reduced warranty costs, lower depreciation as our systems become fully amortized, a credit from one of our suppliers for inventory damaged in transit as well as lower royalty from lower revenue volume.

Gross Profit

TearLab gross profit for the three months ended June 30, 2019 was $3.7 million compared to the $3.8 million for the three months ended June 30, 2018. The gross profit percentage of revenue for the three months ended June 30, 2019 was 63% compared to 59% for the three months ended June 30, 2018. Excluding the impact of the Q2 2018 $0.2 million related party royalty true up in connection with the restated patent license and royalty agreement with the University of California San Diego (“UCSD”),(see Note 8), gross profit for the three months ended June 30, 3018 would have been 62%.

TearLab gross profit for the six months ended June 30, 2019 was $7.3 million compared to the $8.1 million for the six months ended June 30, 2018. The gross profit percentage of revenue for the six months ended June 30, 2019 and June 30, 2018 were 63%, respectively. Excluding the 2017 impact of the restated patent license and royalty agreement with UCSD of $0.3 million and the second quarter of 2018 $0.2 million related party royalty true-up, 2018 gross profit percentage would have been 61% for the six months ended June 30, 2018. Additionally, the change in gross profit was driven by lower depreciation as our systems become fully amortized.

Operating Expenses

(in thousands)	Three months ended June 30,						Six months ended June 30,
	2019		2018		Change		2019		2018		Change

Sales and marketing	$	995	$	959	$	36	$	1,870	$	1,978	$	(108	)
Clinical, regulatory and research and development		1,007		996		11		1,881		2,038		(157	)
General and administrative		1,455		1,340		115		3,299		3,385		(86	)

Operating expenses	$	3,457	$	3,295	$	162	$	7,050	$	7,401	$	(351	)

Sales and Marketing Expense

Sales and marketing expenses increased by $0.04 million or 3.8% in the three months ended June 30, 2019, as compared with the three months ended June 30, 2018. This increase in sales and marketing expenses is attributable to the increase in marketing activity.

Sales and marketing expenses decreased by $0.1 million or 5.5% for the six months ended June 30, 2019 compared to the six months ended June 30, 2018. This reduction in sales and marketing expenses is attributable to both reduced commission payouts and reduced bad debt expense due to strong collections.

Clinical, Regulatory and Research and Development Expenses

Total clinical, regulatory and research and development expenses increased 1% in the three months ended June 30, 2019 as compared with the three months ended June 30, 2018. The increase was primarily due to an increase in the product development costs of the TearLab Discovery™ platform, which we expect to continue for the remainder of the year.

Total clinical, regulatory and research and development expenses decreased $0.2 million or 7.7% during the six months ended June 30, 2019 as compared with the six months ended June 30, 2018. The decrease was primarily due to the lower development costs of the TearLab Discovery^TM Platform during the first quarter of 2019.

General and Administrative Expenses

Total general and administrative expenses increased $0.1 million or 8.6% in the three months ended June 30, 2019 as compared with the three months ended June 30, 2018. The increase was due to tax related costs.

Total general and administrative expenses decreased 2.5% during the six months ended June 30, 2019 as compared with the six months ended June 30, 2018. The decrease was primarily due to the impact of our December 2017 business model that is aimed at reducing costs.

TearLab Corporation

Other Income (Expense)

(in thousands)	Three Months Ended June 30,									Six Months Ended June 30,
	2019			2018			Change			2019			2018			Change

Interest income (expense)	$	(1,405	)	$	(1,149	)	$	(256	)	$	(2,755	)	$	(2,254	)	$	(501	)
Other, net		(1	)		(10	)		9			3			(5	)		8
Other income (expense)	$	(1,406	)	$	(1,159	)	$	(247	)	$	(2,752	)	$	(2,259	)	$	(493	)

Interest Income (Expense)

Interest expense for the three and six months ended June 30, 2019 and 2018 was from our long-term debt under the Term Loan Agreement, which was most recently amended on November 12, 2018. Interest expense increased $0.3 million and $0.5 million for the three and six months ended June 30, 2019 compared to the three and six months ended June 30, 2018. Interest expense increased based on larger average balances of long-term debt outstanding.

Other (net)

Other income (loss) for the three and six months ended June 30, 2019 and 2018 consists primarily of foreign exchange transaction gains and losses, based on fluctuations of the Company’s foreign denominated currencies.

TearLab Corporation

Liquidity and Capital Resources

(in thousands)	June 30, 2019			December 31, 2018			Change
Cash and cash equivalents	$	9,173		$	8,473		$	700
Percentage of total assets		57.6	%		58.4	%

Working capital	$	(6,697	)	$	9,279		$	(15,976	)

Financial Condition

In December 2017 TearLab raised $3 million in gross proceeds through a registered direct offering to support our operations and regulatory expenses. In addition, in April 2018, with an effective date of March 31, 2018, we renegotiated our Term Loan Agreement with CRG. This new agreement lowers the minimum liquidity requirement from an end of the day cash balance of $5 million to $3 million and it defers cash interest payments due in 2018. These changes will allow our current funding to provide us with the time needed to gain our 510(k) approval for the Discovery™ Platform from the FDA as the Discovery™ Platform is critical to our success moving forward. In November 2018, with amendment No.6 CRG further extended our “Interest-only period,” which has the effect of pushing out the principal payments to 2020. Based on our current rate of cash consumption in addition to our projections, we estimate we will need additional capital in the first quarter of 2020. Our prospects for obtaining that capital are uncertain. Due to the Company’s historical losses and financial condition, there is substantial doubt about the Company’s ability to continue as a going concern.

Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties. Actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong. We could utilize our available capital resources sooner than we currently expect. Our future funding requirements will depend on many factors, including but not limited to:

	●	Our ability to execute our commercial strategy with our current resources, under our new business model;
	●	the cost and results of continuing development of our next generation TearLab Discovery™ Platform including the cost of suppliers and service providers that require advance payment;
	●	whether government and third-party payers agree to continue reimbursement of the TearLab® Osmolarity System at current levels;
	●	the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and
	●	the effect of competing technological and market developments.

At the present time, our only product is the TearLab® Osmolarity System, and although we have received 510(k) approval from the FDA and a CLIA waiver approval from the FDA, at this time we do not know when we will generate revenue from the TearLab® Osmolarity System in the United States sufficient to fully fund our operations. If events or circumstances occur such that we do not meet our plans to fund the business, we may be required to reduce operating expenses and reduce the planned levels of inventory and fixed assets which could have an adverse impact on our ability to achieve our intended business objectives and/or continue the development of the TearLab Discovery™ Platform.

TearLab Corporation

Indebtedness

As part of Amendment No. 2 to the Term Loan Agreement, and funding of the second tranche, CRG received 35,000 warrants dated as of October 6, 2015 to purchase common shares of the Company at a price of $50.00 per share (the “2015 CRG Warrants”). The 2015 CRG Warrants have a five-year life and are classified as equity on the Consolidated Balance Sheets as of June 30, 2019 and 2018. The 2015 CRG Warrants were valued at their issuance date using the Black-Scholes Merton model. The related reduction of the long-term debt will be amortized over the life of the debt. On April 7, 2016, the Company entered into Amendment No. 4 to the Term Loan Agreement and the Company issued CRG additional warrants to purchase 35,000 common shares of the Company’s stock at 15.00 per share (the “2016 CRG Warrants” and together with the 2015 CRG Warrants, the “CRG Warrants”), which expire 5 years after issuance.

In connection with the December 2017 offering the Company issued CRG additional warrants to purchase 83,240 shares of commons stock at an exercise price of $1.50 (“2017 CRG Warrants”).

On April 4, 2018 with an effective date of March 31, 2018, the Company entered into Amendment No. 6 to the Term Loan Agreement. Pursuant to the terms of this amendment, the cash interest payments due in 2018 were deferred and added to the principal balance under the Term Loan Agreement at the end of each quarter. This amendment also provides for an additional facility fee equal to 3% of the sum of the aggregate amount of the principal drawn under the Term Loan Agreement and any PIK loans issued, so that the total facility fee shall be 9.5%, applicable to the entire balance. In addition, this amendment reduces the minimum liquidity covenant to $3 million. Concurrent with the reduction of the liquidity covenant the Company agreed to repay CRG $1.0 million of principal on the Term Loan Agreement in April 2018. Lastly, this amendment reduced the strike price of the existing CRG Warrants and the 2017 CRG Warrants to $0.44 per share. This amendment was accounted for as a modification in accordance with U.S. GAAP.

On November 12, 2018 the Company entered into Amendment No. 7 to the Term Loan Agreement. Pursuant to the terms of the agreement, the Amendment extends the “Interest-Only Period” under the Term Loan Agreement from the sixteenth (16^th) payment date to the twentieth (20^th) payment date following the first borrowing date, which has the effect of pushing out the principal payments to 2020. In addition, the cash interest payments under the Term Loan Agreement for periods ending on March 31, 2019 and June 30, 2019 will be deferred and added to the principal balance under the Term Loan Agreement at the end of each such quarter. Additionally, if the Federal Drug Administration (“FDA”) had received and accepted our application for review of our Discovery^TM Platform on or before June 30, 2019 the Company would have been entitled to pay the interest on the outstanding principal amount of the loans under the Term Loan Agreement payable during the quarter ended September 30, 2019 entirely in the form of a PIK Loan. The Company did not file an updated 510K with the FDA prior to June 30, 2019 and expects it will be required to make an interest payment at the end of the third quarter of 2019. Finally, the Amendment reduced the minimum required revenue for 2018 under the Term Loan Agreement from $25 million to $24 million.

TearLab Corporation

The Term Loan Agreement is collateralized by all assets of the Company. Additionally, the terms of the Term Loan Agreement contain various affirmative and negative covenants agreed to by the Company. Among them, the Company must attain minimum certain annual revenue and minimum cash threshold levels. The minimum annual revenue threshold level required by the Term Loan Agreement is $38.0 million, and $45 million, respectively, for the calendar years 2019 and 2020. The minimum cash balance required is $3.0 million, subject to certain conditions.

If the Company does not have annual revenue greater or equal to the annual revenue covenant in a calendar year, the Company will have to raise subordinated debt or equity (the “CRG Equity Cure”) equal to twice the difference between the annual revenue and the revenue covenant, with the total proceeds from this financing to be used to reduce the principal of the Term Loan Agreement. In the event the Company does not achieve the minimum revenue threshold and it cannot complete the CRG Equity Cure, it may be in default of the Term Loan Agreement. In the event of a default, we may be required to repay any outstanding amounts earlier than anticipated, and the lenders may foreclose on their security interest in our assets.

Ongoing Sources and Uses of Cash

We anticipate that our cash and cash equivalents and cash generated from revenue will be sufficient to sustain our operations into the first quarter of 2020. We continually evaluate various financing possibilities but we typically expect our primary sources of cash will be related to the collection of accounts receivable. Our accounts receivable collections will be impacted by our ability to maintain current customers and annuity revenue base, while reducing costs as per our new business model.

We expect our primary uses of cash will be to fund our operating expenses and the development and generation of clinical data for our next generation platform.

Changes in Cash Flows

Cash Provided by Operating Activities

Net cash provided by operating activities during the six months ended June 30, 2019 was $0.7 million. Net cash provided by operating activities during the six-month period was more than our net loss of $2.5 million primarily due to the depreciation of fixed assets, stock-based compensation expense and deferred interest and the amortization of the discount on our long-term debt. In aggregate, these non-cash items totaled $3.3 million.

TearLab Corporation

The net change in working capital and non-current asset balances related to operations for the six months ended June 30, 2019 and 2018 consists of the following:

	Six Months Ended
(in thousands)	June 30,
	2019			2018
Changes in operating assets and liabilities:

Accounts receivable, net	$	63		$	263
Inventory		(845	)		143
Prepaid expenses and other assets		335			243
Other non-current assets		-			(80	)
Accounts payable		744			(1,261	)
Accrued liabilities		(279	)		(552	)
Deferred rent/revenue		(11	)		(21	)
	$	7		$	(1,265	)

Explanations of the more significant net changes in working capital and non-current asset balances are as follows:

	●	Inventory levels of test cards on hand increased in the six months ended June 30, 2019 due to lower sales volumes and an overall effort to manage inventory levels;

	●	Accounts payable had a net increase during the six months ended June 30, 2019, mostly due to invoices received for professional services and an increase in work performed relating to both marketing and the development of our next generation of product; and

	●	Accrued liabilities had a net decrease during the six months ended June 30, 2019, primarily due to lower royalties expected based on the decline in sales. In addition, there were some residual restructuring costs accrued during this period in 2018.

Cash Used in Investing Activities

Net cash used in investing activities for the six months ended June 30, 2019 and 2018 was $0.04 million and $0.1 million, respectively, to acquire fixed assets.

Cash Provided by Financing Activities

There was zero in net cash provided by financing activities during the six months ended June 30, 2019. For the six months ended June 30, 2018, $1.0 million was used to reduce the principal of the CRG loan.

Off-Balance-Sheet Arrangements

As of June 30, 2019, we did not have any material off-balance-sheet arrangements as defined in Item 303(1)(4)(ii) of SEC Regulation S-K.

TearLab Corporation

Critical Accounting Policies and Estimates

Management’s discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements which are prepared in accordance with accounting principles that are generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, related disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. We continually evaluate our estimates and judgments, the most critical of which are those related to revenue recognition and inventory valuation. We base our estimates and judgments on historical experience and other factors that we believe to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known.

There were no significant changes during the six months ended June 30, 2019 to the items that we disclosed as our critical accounting policies and estimates in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. For further clarification with regards to the Company’s specific policies for revenue recognition, see Note 2 of the Notes to the Unaudited Condensed Consolidated Financial Statements for the three and six months ended June 30, 2019 included in Item 1.

Recent Accounting Pronouncements

For information on the recent accounting pronouncements impacting our business, see Note 2 of the Notes to the Unaudited Condensed Consolidated Financial Statements for the three and six months ended June 30, 2019 included in Item 1.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Currency Fluctuations and Exchange Risk

Our sales are denominated primarily in U.S. dollars. Most of our expenses are denominated in U.S. dollars, however, a minor portion of our other expenses are in Canadian dollars, Australian dollars, Euro and pounds sterling. We cannot predict any future trends in the exchange rate of the Canadian dollar, Australian dollar, euro or pound sterling against the U.S. dollar. Any strengthening of the Canadian dollar, Australian dollar, euro or pound sterling in relation to the U.S. dollar would increase the U.S. dollar cost of our operations, and affect our U.S. dollar measured results of operations. We maintain bank accounts in Canadian dollars to meet short term operating requirements. We do not engage in any hedging or other transactions intended to manage these risks. In the future, we may undertake hedging or other similar transactions or invest in market risk sensitive instruments if we determine that is advisable to offset these risks.

Interest Rate Risk

Our long-term debt carries a fixed rate of 13% interest. A decrease in market interest rates would increase the fair value of our long-term debt.

ITEM 4. CONTROLS AND PROCEDURES.

(a)	Disclosure Controls and Procedures.

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to the our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefit of controls must be considered relative to their costs. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

TearLab Corporation

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)). Based on that evaluation, our chief executive officer and chief financial officer concluded that, as at June 30, 2019 our disclosure controls and procedures were effective at the reasonable assurance level.

(b)	Changes in Internal Control over Financial Reporting.

During the second quarter of 2019, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

We are not currently a party to any litigation, nor are we aware of any pending or threatened litigation against us that we believe would materially affect our business, operating results, financial condition or cash flows. However, our industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, we may be involved in various legal proceedings from time to time.

We initiated a patent infringement lawsuit against i-Med Pharma, Inc. in February 2016 alleging infringement of our Canadian patent. In February 2018, the Federal Court of Canada issued a ruling in favor of i-Med Pharma, Inc. which invalidated specific claims in our Canadian patent which were alleged to be infringed. We appealed this ruling to the Canadian Federal Appellate Court. As part of the ruling, the Federal Court ruling awarded costs to i-Med Pharma, Inc., for $0.5 million. The final $0.2 million was paid in April 2018. In June 2019, the Canadian Federal Appellate Court dismissed the appeal.

TearLab Corporation

ITEM 1A. RISK FACTORS.

Risks Relating to Our Financial Condition

We may need to raise additional capital in the future. Such capital, may not be available to us on reasonable terms, if at all, when or as we require additional funding. If we issue additional shares of our common stock or other securities that may be convertible into or exercisable or exchangeable for our common stock, our existing stockholders would experience further dilution.

Based on a revised operating model that we implemented in December 2017, we expect that we will need to raise additional capital prior to the end of the first quarter of 2020. This estimate is subject to risk based primarily on our success in implementing the revised operating model, maintaining certain revenue levels despite a reduction in our commercial resources that was made in order to reduce our cash burn and accurately forecasting the remaining development expenses required to gain FDA clearance of our next generation diagnostic platform, and we cannot assure you that we will be successful in implementing this new model. Any financings undertaken to raise needed capital may involve the issuance of debt, equity and/or securities convertible into or exercisable or exchangeable for our equity securities. These financings may not be available to us on reasonable terms or at all when and as we require funding. Any failure to obtain additional working capital when required would have a material adverse effect on our business and financial condition, our ability to continue as a going concern and would be expected to result in a decline in our stock price. If we consummate such financings, the terms of such financings may adversely affect the interests of our existing stockholders. Any issuances of our common stock, preferred stock, or securities such as warrants or notes that are convertible into, exercisable or exchangeable for our capital stock, would have a dilutive effect on the voting and economic interest of our existing stockholders. If access to sufficient capital is not available as and when needed, our business will be materially impaired and we may be required to cease operations, curtail product development, manufacturing improvements, or sales generation programs, attempt to obtain funds through licensing certain technologies or products, or we may be required to significantly reduce expense, sell assets, seek a merger or joint venture partner, file for protection from creditors, liquidate all our assets or cease operations and wind down our business.

We have limited working capital and a history of losses that raise substantial doubts as to whether we will be able to continue as a going concern.

We have prepared our condensed consolidated financial statements on the basis that we would continue as a going concern. However, we have incurred losses in each year since our inception and there is substantial doubt about our ability to continue as a going concern. We do not currently have any available borrowing under our term loan or credit facility. Our condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary if we were not able to continue as a going concern. If we are unable to generate positive cash flows from operations, we would need to undertake a review of potential business alternatives, which may include, but are not limited to, a merger or sale of the company or ceasing operations and winding down the business.

We have incurred losses since inception and anticipate that we will incur continued losses for the foreseeable future.

We have incurred losses in each year since our inception. As of June 30, 2019, we had an accumulated deficit of $533.6 million. Our losses have resulted primarily from expenses incurred in research and development of our product candidates from the former retina and glaucoma business divisions. We do not know when or if we will successfully commercialize the TearLab® Osmolarity System in the United States or in international markets or receive approval to commercialize our next generation TearLab Discovery^TMPlatform on a scale that will allow us to achieve and sustain profitability. As a result, and because of the numerous risks and uncertainties facing us, it is difficult to provide the extent of any future losses or the time required to achieve profitability, if at all. Any failure to become and remain profitable would require us to undertake a review of the potential business alternatives discussed above.

TearLab Corporation

We may not be able to generate sufficient cash to service our indebtedness, which currently consists of our credit facility with CRG. We may not be able to satisfy our minimum revenue and cash covenants, as required by the CRG term loan. If our annual sales revenue levels do not meet or exceed the levels required by the CRG covenants, we will be required to raise additional equity or subordinated debt, with the proceeds paid to reduce the outstanding principal of the CRG term loan. This financing could dilute existing shareholders and impact the value of their investment.

On March 4, 2015, we executed a term loan agreement with CRG as lenders (the “Term Loan Agreement”) providing us with access of up to $35.0 million under the Term Loan Agreement. We entered into an amendment of the Term Loan Agreement with CRG on August 6, 2015. We received $25.0 million in gross proceeds during 2015. We can make no assurance that we will be able to raise either additional debt financing or additional equity capital. There can be no assurances that there will be adequate financing available to us on acceptable terms or at all.

Our ability to make scheduled payments or to refinance our debt obligations depends on numerous factors, including the amount of our cash reserves and our actual and projected financial and operating performance. These amounts and our performance are subject to certain financial and business factors, as well as prevailing economic and competitive conditions, some of which may be beyond our control. We cannot assure you that we will maintain a level of cash reserves or cash flows from operating activities sufficient to permit us to pay the principal, facility fee, and interest on our existing or future indebtedness. If our cash flows and capital resources are insufficient to fund our debt service obligations, we may be forced to reduce or delay capital expenditures, sell assets or operations, seek additional capital or restructure or refinance our indebtedness. We cannot assure you that we would be able to take any of these actions, or that these actions would permit us to meet our scheduled debt service obligations. In addition, in the event of our breach of the Term Loan Agreement, we may be required to repay any outstanding amounts earlier than anticipated, and the lenders may foreclose on their security interest in our assets.

The CRG loan is collateralized by all our assets. Additionally, the Term Loan Agreement contains various affirmative and negative covenants agreed to by the Company. Among them, we must attain minimum annual revenue and minimum cash threshold levels. The minimum annual revenue threshold levels required by the Term Loan Agreement are $38.0 million and $45.0 million for calendar years 2019 and 2020, respectively. The minimum cash balance required is $3.0 million, subject to certain conditions.

If we do not have annual revenue greater or equal to the annual revenue covenant in a calendar year, we will have the right to cure by raising subordinated debt or equity equal to twice the difference between the annual revenue and the revenue covenant, with the total proceeds from this financing to be used to reduce the principal of the Term Loan Agreement. We cannot assure you that we will be able to achieve the annual revenue thresholds and the daily cash threshold. We cannot assure you that we would be able to raise the financing described above, if required. In addition, in the event of our breach of the Term Loan Agreement, we may not be allowed to draw additional amounts under the Term Loan Agreement, we may be required to repay any outstanding amounts earlier than anticipated, and the lenders may foreclose on their security interest in our assets.

Borrowings under the Term Loan Agreement are subject to certain conditions, including the non-occurrence of a material adverse change in our business or operations (financial or otherwise), or a material impairment of the prospect of repayment of obligations. We do not currently have any available borrowing under the Term Loan Agreement.

Our existing Term Loan Agreement contains restrictive and financial covenants that may limit our operating flexibility.

The Term Loan Agreement contains certain restrictive covenants that limit our ability to incur additional indebtedness and liens, merge with other companies or consummate certain changes of control, acquire other companies, engage in new lines of business, make certain investments, pay dividends, transfer or dispose of assets, amend certain material agreements or enter into various specified transactions. We therefore may not be able to engage in any of the foregoing transactions unless we obtain the consent of CRG or terminate the Term Loan Agreement. There is no guarantee that we will be able to generate sufficient cash flow or sales to meet the financial covenants or pay the principal and interest under the agreement. Furthermore, there is no guarantee that future working capital, borrowings or equity financing will be available to repay or refinance the amounts outstanding under the Term Loan Agreement.

TearLab Corporation

Our financial results may vary significantly from year-to-year and quarter-to-quarter due to a number of factors, which may lead to volatility in the trading price of our common stock.

Our annual and quarterly revenue and results of operations have varied in the past and may continue to vary significantly from year-to-year and quarter-to-quarter. The variability in our annual and quarterly results of operations may lead to volatility in our stock price as research analysts and investors respond to these annual fluctuations. These fluctuations are due to numerous factors that are difficult to forecast, including:

	●	fluctuations in demand for our products;
	●	changes in customer budget cycles and capital spending;
	●	seasonal variations in customer operations that could occur during holiday or summer vacation periods;
	●	tendencies among some customers to defer purchase decisions until the end of the quarter or fiscal year;
	●	the unit value of our systems;
	●	changes in our pricing and sales policies or the pricing and sales policies of our competitors;
	●	changes in reimbursement levels that might negatively impact our pricing policies;
	●	our ability to design, manufacture and deliver products to our customers in a timely and cost-effective manner;
	●	quality control or yield problems in our manufacturing suppliers;
	●	our ability to timely obtain adequate quantities of the components used in our products;
	●	new product introductions or enhancements by us and our competitors;
	●	unanticipated increases in costs or expenses;
	●	our complex, variable and, at times, lengthy sales cycle;
	●	global economic conditions; and
	●	fluctuations in foreign currency exchange rates.

The foregoing factors, as well as other factors, could materially and adversely affect our quarterly and annual results of operations. In addition, a significant amount of our operating expenses are relatively fixed due to our manufacturing, research and development, and sales and general administrative efforts. Any failure to adjust spending quickly enough to compensate for a revenue shortfall could magnify the adverse impact of such revenue shortfall on our results of operations. We expect that our sales will continue to fluctuate on a quarterly basis and our financial results for some periods may differ from those projected by securities analysts, which could significantly decrease the price of our common stock.

TearLab Corporation

Risks Related to Our Business

Our near-term success is highly dependent on the success of the TearLab® Osmolarity System, and we cannot be certain that it will be successfully commercialized in the United States.

The TearLab® Osmolarity System is currently our only commercialized product in the United States. Our product is currently sold outside of the United States pursuant to CE mark approval; in Canada pursuant to a Health Canada Medical Device License; and in the United States as a result of having received 510(k) approval from the FDA to market the TearLab® Osmolarity System to those reference and physician operated laboratories with CLIA waiver certifications. Even though the TearLab® Osmolarity System has received all regulatory approvals in the United States, it may never generate sufficient sales to achieve profitability. If the TearLab® Osmolarity System is not as successfully commercialized as expected, we may not be able to generate sufficient revenue to become profitable or continue our operations. Any failure of the TearLab® Osmolarity System to be successfully commercialized in the United States would have a material adverse effect on our business, operating results, financial condition and cash flows and could result in a substantial decline in the price of our common stock.

Our near-term success is highly dependent on increasing sales of the TearLab® Osmolarity System outside the United States, and we cannot be certain that we will successfully increase such sales.

Our product is currently sold outside of the United States pursuant to CE mark approval and Health Canada Approval in Canada. Our near-term success is highly dependent on increasing our international sales. We may also be required to register our product with health departments in our foreign market countries. A failure to successfully register in such markets would negatively affect our sales in any such markets. In addition, import taxes are levied on our product in certain foreign markets. Other countries may adopt taxation codes on imported products. Increases in such taxes or other restrictions on our product could negatively affect our ability to import, distribute and price our product.

We have outstanding liabilities, which could adversely affect our ability to adjust our business to respond to competitive pressures and to obtain sufficient funds to satisfy our future research and development needs, and to defend our intellectual property.

As of June 30, 2019, our total liabilities were $39.1 million including $18.3 million of long-term obligations under our Term Loan Agreement. Our significant liability service requirements could adversely affect our ability to operate our business and may limit our ability to take advantage of potential business opportunities. For example, our liabilities present the following risks:

	●	our liabilities increase our vulnerability to economic downturns and adverse competitive and industry conditions and could place us at a competitive disadvantage compared to those of our competitors that are less leveraged;
	●	our liabilities could limit our flexibility in planning for, or reacting to, changes in our business and our industry and could limit our ability to pursue other business opportunities, borrow money for operations or capital in the future and implement our business strategies;
	●	our liabilities could cause our suppliers to change their payment terms, require us to pay for needed goods or services in advance or choose not to do business with us at all which could negatively impact our cash flows, supply chain and our ability to supply products to our customers when needed; and
	●	our liabilities may restrict us from raising additional funds on satisfactory terms to fund working capital, capital expenditures, product development efforts, strategic acquisitions, investments and alliances, and other general corporate requirements.

If we are at any time unable to generate sufficient cash flow to service our liabilities when payment is due, we may be required to attempt to renegotiate the terms of the instruments relating to the liabilities, seek to refinance all or a portion of the liabilities or obtain financing. There can be no assurance that we will be able to successfully renegotiate such terms, that any such refinancing would be possible or that any additional financing could be obtained on terms that are favorable or acceptable to us.

TearLab Corporation

We continue to face challenges in bringing the TearLab® Osmolarity System to market in the United States and may not succeed in executing our business plan.

There are numerous risks and uncertainties inherent in the development of new medical technologies. In addition to our requirement for additional capital, our ability to bring the TearLab® Osmolarity System to market in the United States and to execute our business plan successfully is subject to the following risks, among others:

	●	The TearLab® Osmolarity System is rated under a CLIA waiver certification which requires our customers to be certified under the CLIA waiver requirements to be reimbursed under Medicare, including certain parallel state requirements. If our customers are unwilling or unable to comply with such requirements, it could have an adverse effect on their acceptance of and on our ability to market the TearLab® Osmolarity System in the United States.
	●	Our suppliers and we will be subject to numerous FDA requirements covering the design, testing, manufacturing, quality control, labeling, advertising, promotion and export of the TearLab® Osmolarity System and other matters. If our suppliers or we fail to comply with these regulatory requirements, the TearLab® Osmolarity System could be subject to restrictions or withdrawals from the market and we could become subject to penalties.
	●	We may be unable to achieve widespread acceptance of the TearLab® Osmolarity System among physicians as a result of our inability to establish adequate sales and marketing capabilities, address competition effectively, obtain and enforce patents to protect proprietary rights from use by would-be competitors, retain key personnel, maintain adequate reimbursement for our product to support our pricing policies and ensure sufficient manufacturing capacity and inventory to support commercialization plans.

Our business is subject to health care industry cost-containment measures that could result in reduced sales of our TearLab® Osmolarity System.

Most of our customers rely on third-party payers, including government programs and private health insurance plans, to reimburse some or all of the cost of the procedures which use our TearLab® Osmolarity System. The continuing efforts of governmental authorities, insurance companies, and other health care payers to contain or reduce these costs could lead to patients being unable to obtain approval for payment from these third-party payers. If patients cannot obtain third-party payer payment approval, the use of our TearLab® Osmolarity System may decline significantly and our customers may reduce or eliminate the use of our system. The cost-containment measures that health care providers are instituting, both in the U.S. and internationally, could harm our ability to operate profitably. For example, managed care organizations have successfully negotiated volume discounts for pharmaceuticals. While this type of discount pricing does not currently exist for the medical systems we supply, if managed care or other organizations were able to affect discount pricing for such systems, it could result in lower prices to our customers from their customers and, in turn, reduce the amounts we can charge our customers for our products.

In addition to general health care industry cost-containment, the Centers for Medicare and Medicaid Services (CMS) released its final rule implementing section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) that will require reporting entities to report private payer rates paid to laboratories for lab tests, which will be used to calculate Medicare payment rates. This final rule announced CMS’ decision to move the implementation date for the private payer rate-based fee schedule to January 1, 2018. Reporting entities, which would primarily be certain qualifying customers in the U.S. that derive a certain percentage and volume of their revenue from laboratory tests from Medicare, will report private payer rates for our laboratory tests which will serve under the act as a baseline for future reimbursement. Our product was only minimally impacted by PAMA for the year 2018 through 2020. However, should reimbursement for our products be reduced as a result of PAMA or other cost savings initiatives, this could negatively impact our pricing and commercialization of our products in the U.S.

TearLab Corporation

If we are subject to regulatory enforcement action as a result of our failure to comply with regulatory requirements, our commercial operations would be harmed.

While we received the 510(k) clearance and CLIA waiver that we were seeking, we will be subject to significant ongoing regulatory requirements, and if we fail to comply with these requirements, we could be subject to enforcement action by the FDA or state agencies, including:

	●	adverse publicity, warning letters, fines, injunctions, consent decrees and civil penalties;
	●	repair, replacement, refunds, recall or seizure of our product;
	●	operating restrictions or partial suspension or total shutdown of production;
	●	delay or refusal of our requests for 510(k) clearance or premarket approval of new products or of new intended uses or modifications to our existing product;
	●	refusal to grant export approval for our products;
	●	withdrawing 510(k) clearances or premarket approvals that have already been granted; and
	●	criminal prosecution.

If the government initiated any of these enforcement actions, our business could be harmed.

We are required to demonstrate and maintain compliance with the FDA’s Quality System Regulation, or the QSR. The QSR is a complex regulatory scheme that covers the methods and documentation of the design, testing, control, manufacturing, labeling, quality assurance, packaging, storage and shipping of our products. The FDA must determine that the facilities which manufacture and assemble our products that are intended for sale in the United States, as well as the manufacturing controls and specifications for these products, are compliant with applicable regulatory requirements, including the QSR. The FDA enforces the QSR through periodic unannounced inspections. The FDA has not yet inspected our facilities, and we cannot assure you that we will pass any future FDA inspection. Our failure, or the failure of our suppliers, to take satisfactory corrective action in response to an adverse QSR inspection could result in enforcement actions, including a public warning letter, a shutdown of our manufacturing operations, a recall of our product, civil or criminal penalties or other sanctions, which would significantly harm our available inventory and sales and cause our business to suffer.

If we are unable to fully comply with federal and state “fraud and abuse laws,” we could face substantial penalties, which may adversely affect our business, financial condition and results of operations.

We are subject to various laws pertaining to health care fraud and abuse, including the U.S. Anti- Kickback Statute, physician self-referral laws (the “Stark Law”), the U.S. False Claims Act, the U.S. False Statements Statute, the Physician Payment Sunshine Act, and state law equivalents to these U.S. federal laws, which may not be limited to government-reimbursed items and may not contain identical exceptions. Violations of these laws are punishable by criminal and civil sanctions, including, in some instances, civil and criminal penalties, damages, fines, exclusion from participation in U.S. federal and state health care programs, including Medicare and Medicaid, and the curtailment or restructuring of operations. Any action against us for violation of these laws could have a significant impact on our business. In addition, we are subject to the U.S. Foreign Corrupt Practices Act. Any action against us for violation by us or our agents or distributors of this act could have a significant impact on our business.

TearLab Corporation

If we fail to comply with contractual obligations and applicable laws and regulations governing the handling of patient identifiable medical information, we could suffer material losses or be adversely affected by exposure to material penalties and liabilities.

Many, if not all of our customers, are covered entities under the Health Insurance Portability and Accountability Act of August 1996 or HIPAA. As part of the operation of our business, we provide reimbursement assistance to certain of our customers and as a result we act in the capacity of a business associate with respect to any patient-identifiable medical information, or PHI, we receive in connection with these services. We and our customers must comply with a variety of requirements related to the handling of patient information, including laws and regulations protecting the privacy, confidentiality and security of PHI. The provisions of HIPAA require our customers to have business associate agreements with us under which we are required to appropriately safeguard the PHI we create or receive on their behalf. Further, we and our customers are required to comply with HIPAA security regulations that require us and them to implement certain administrative, physical and technical safeguards to ensure the confidentiality, integrity and availability of electronic PHI, or EPHI. We are required by regulation and contract to protect the security of EPHI that we create, receive, maintain or transmit for our customers consistent with these regulations. To comply with our regulatory and contractual obligations, we may have to reorganize processes and invest in new technologies. We also are required to train personnel regarding HIPAA requirements. If we, or any of our employees or consultants, are unable to maintain the privacy, confidentiality and security of the PHI that is entrusted to us, we and/or our customers could be subject to civil and criminal fines and sanctions and we could be found to have breached our contracts with our customers. Under the Health Information Technology for Economic and Clinical Health Act, or HITECH Act, and recent omnibus revisions to the HIPAA regulations, we are directly subject to HIPAA’s criminal and civil penalties for breaches of our privacy and security obligations and are required to comply with security breach notification requirements. The direct applicability of the HIPAA privacy and security provisions and compliance with the notification requirements requires us to incur additional costs and may restrict our business operations.

Our patents may not be valid, and we may not obtain and enforce patents to protect our proprietary rights from use by would-be competitors. Companies with other patents could require us to stop using or pay to use required technology.

Our owned and licensed patents may not be valid, and we may not obtain and enforce patents to maintain trade secret protection for our technology. The extent to which we are unable to do so could materially harm our business.

We have applied for, and intend to continue to apply for, patents relating to the TearLab® Osmolarity System and related technology and processes. Such applications may not result in the issuance of any patents, and any patents now held or that may be issued may not provide adequate protection from competition. Furthermore, it is possible that patents issued or licensed to us may be challenged successfully. In that event, if we have a preferred competitive position because of any such patents, any preferred position would be lost. If we are unable to secure or to continue to maintain a preferred position, the TearLab® Osmolarity System could become subject to competition from the sale of generic products.

Patents issued or licensed to us may be infringed by the products or processes of others. The cost of enforcing patent rights against infringers, if such enforcement is required, could be significant and the time demands could interfere with our normal operations. There has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical, biotechnology and medical technology industries. For example, we have recently been involved in litigation defending our patent rights in Canada. Efforts to defend our rights could incur significant costs and may or may not be resolved in our favor. We could become a party to additional patent litigation and other proceedings. The cost to us of any patent litigation, even if resolved in our favor, could be substantial. Some of our would-be competitors may sustain the costs of such litigation more effectively than we can because of their greater financial resources. Litigation also may absorb significant management time.

TearLab Corporation

Unpatented trade secrets, improvements, confidential know-how and continuing technological innovation are important to our future scientific and commercial success. Although we attempt, and will continue to attempt, to protect our proprietary information through reliance on trade secret laws and the use of confidentiality agreements with corporate partners, collaborators, employees and consultants and other appropriate means, these measures may not effectively prevent disclosure of our proprietary information, and, in any event, others may develop independently, or obtain access to, the same or similar information.

Certain of our patent rights are licensed to us by third parties. If we fail to comply with the terms of these license agreements, our rights to those patents may be terminated, and we will be unable to conduct our business.

It is possible that a court may find us to be infringing upon validly issued patents of third parties. In that event, in addition to the cost of defending the underlying suit for infringement, we may have to pay license fees and/or damages and may be enjoined from conducting certain activities. Obtaining licenses under third-party patents can be costly, and such licenses may not be available at all.

We may face future product liability claims.

The testing, manufacturing, marketing and sale of therapeutic and diagnostic products entail significant inherent risks of allegations of product liability. Our past use of the RHEO System and the components of the SOLX Glaucoma System in clinical trials and the commercial sale of those products may have exposed us to potential liability claims. Our use of the TearLab® Osmolarity System and its commercial sale could also expose us to liability claims. All of such claims might be made directly by patients, health care providers or others selling the products. We carry clinical trials and product liability insurance to cover certain claims that could arise, or that could have arisen, during our clinical trials or during the commercial use of our products. We currently maintain clinical trials and product liability insurance with aggregate annual coverage limits of $2.0 million. Such coverage, and any coverage obtained in the future, may be inadequate to protect us in the event of successful product liability claims, and we may not increase the amount of such insurance coverage or even renew it. A successful product liability claim could materially harm our business. In addition, substantial, complex or extended litigation could result in the incurrence of large expenditures and the diversion of significant resources.

If we do not introduce new commercially successful products in a timely manner, our products may become obsolete over time, customers may not buy our products and our revenue and profitability may decline.

Demand for our products may change in ways we may not anticipate because of:

	●	evolving customer needs;
	●	the introduction of new products and technologies; and
	●	evolving industry standards.

TearLab Corporation

Without the timely introduction of new commercially successful products and enhancements, our products may become obsolete over time, in which case our sales and operating results would suffer. The success of our new product offerings will depend on several factors, including our ability to:

	●	properly identify and anticipate customer needs;
	●	commercialize new products in a cost-effective and timely manner;
	●	manufacture and deliver products in sufficient volumes on time;
	●	obtain and maintain regulatory approval for such new products;
	●	differentiate our offerings from competitors’ offerings;
	●	achieve positive clinical outcomes; and
	●	provide adequate medical and/or consumer education relating to new products.

Moreover, innovations generally will require a substantial investment in research and development before we can determine the commercial viability of these innovations and we may not have the financial resources necessary to fund these innovations. In addition, even if we successfully develop enhancements or new generations of our products, these enhancements or new generations of products may not produce revenue in excess of the costs of development and they may be quickly rendered obsolete by changing customer preferences or the introduction by our competitors of products embodying new technologies or features.

We rely on a limited number of suppliers of each of the key components of the TearLab® Osmolarity System and are vulnerable to fluctuations in the availability and price of our suppliers’ products and services.

We purchase each of the key components of the TearLab® Osmolarity System from a limited number of third-party suppliers. Our suppliers may not provide the components or other products needed by us in the quantities requested, in a timely manner or at a price we are willing to pay. In the event we were unable to renew our agreements with our suppliers or they were to become unable or unwilling to continue to provide important components in the required volumes and quality levels or in a timely manner, or if regulations affecting the components were to change, we would be required to identify and obtain acceptable replacement supply sources. We may not be able to obtain alternative suppliers or vendors on a timely basis, or at all, which could disrupt or delay, or halt altogether, our ability to manufacture or deliver the TearLab® Osmolarity System. If any of these events should occur, our business, financial condition, cash flows and results of operations could be materially adversely affected.

We face intense competition, and our failure to compete effectively could have a material adverse effect on our results of operations.

We face intense competition in the markets for ophthalmic products and these markets are subject to rapid and significant technological change. Although we have no direct competitors, we have numerous potential competitors in the United States and abroad. We face potential competition from industry participants marketing conventional technologies for the measurement of osmolarity and other in-lab testing technologies, and commercially available methods, such as the Schirmer Test and ocular surface staining. Many of our potential competitors have substantially more resources and a greater marketing scale than we do. If we are unable to develop and produce or market our products to effectively compete against our competitors, our operating results will materially suffer.

TearLab Corporation

If we lose key personnel, or we do not attract and retain highly qualified personnel on a cost-effective basis, it would be more difficult for us to manage our existing business operations and to identify and pursue new growth opportunities.

Our success depends, in large part, upon our ability to attract and retain highly qualified scientific, clinical, manufacturing and management personnel. In addition, any difficulties in retaining key personnel or managing this growth could disrupt our operations. Future growth will require us to continue to implement and improve our managerial, operational and financial systems, and to continue to recruit, train and retain, additional qualified personnel, which may impose a strain on our administrative and operational infrastructure. The competition for qualified personnel in the medical technology field is intense. We are highly dependent on our continued ability to attract, motivate and retain highly qualified management, clinical and scientific personnel.

Due to our limited resources, we may not effectively recruit, train and retain additional qualified personnel. If we do not retain key personnel or manage our growth effectively, we may not implement our business plan effectively.

Furthermore, we have not entered into non-competition agreements with our key employees. In addition, we do not maintain “key person” life insurance on any of our officers, employees or consultants. The loss of the services of existing personnel, the failure to recruit additional key scientific, technical and managerial personnel in a timely manner, and the loss of our employees to our competitors would harm our research and development programs and our business.

If we fail to establish and maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired, which would adversely affect our consolidated operating results, our ability to operate our business and our stock price.

Ensuring that we have adequate internal financial and accounting controls and procedures in place to produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently. Failure on our part to maintain effective internal financial and accounting controls would cause our financial reporting to be unreliable, could have a material adverse effect on our business, operating results, financial condition and cash flows, and could cause the trading price of our common stock to fall dramatically.

Maintaining proper and effective internal controls will require substantial management time and attention and may result in our incurring substantial incremental expenses, including with respect to increasing the breadth and depth of our finance organization to ensure that we have personnel with the appropriate qualifications and training in certain key accounting roles and adherence to certain control disciplines within the accounting and reporting function. Any failure in internal controls or any errors or delays in our financial reporting would have a material adverse effect on our business and results of operations and could have a substantial adverse impact on the trading price of our common stock.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Our management does not expect that our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Our management has identified control deficiencies in the past and may identify additional deficiencies in the future.

We cannot be certain that the actions we are taking to improve our internal controls over financial reporting will be sufficient or that any changes in processes and procedures can be completed in a timely manner. In future periods, if the process required by Section 404 of the Sarbanes-Oxley Act of 2002 reveals material weaknesses or significant deficiencies, the correction of any such material weaknesses or significant deficiencies could require additional remedial measures which could be costly and time-consuming. In addition, we may be unable to produce accurate financial statements on a timely basis. Any of the foregoing could cause investors to lose confidence in the reliability of our consolidated financial statements, which could cause the market price of our common stock to decline and make it more difficult for us to finance our operations and growth.

TearLab Corporation

Risks Related to Our Common Stock

Our common stock was delisted from The Nasdaq Capital Market, which could make trading in our common stock more difficult for investors, potentially leading to declines in our share price and liquidity and could limit our ability to raise additional capital.

Effective at the open of business on November 9, 2017, our common stock was suspended and effectively delisted from The Nasdaq Capital Market and began trading on the OTCQB. The delisting was the result of our non-compliance with Nasdaq Listing Rule 5550(b).

Our delisting from The Nasdaq Capital Market could make trading in our common stock more difficult for investors, potentially leading to declines in our share price and liquidity. Without The Nasdaq Capital Market listing, stockholders may have a difficult time getting a quote for the sale or purchase of our stock, the sale or purchase of our stock will likely be made more difficult and the trading volume and liquidity of our stock could decline. Our delisting from The Nasdaq Capital Market could also result in negative publicity and could also make it more difficult for us to raise additional capital. The absence of such a listing may adversely impact the acceptance of our common stock as currency or the value accorded by other parties. Further, following our delisting, we will also incur additional costs under state blue sky laws in connection with any sales of our securities. These requirements could severely limit the market liquidity of our common stock and the ability of our stockholders to sell our common stock in the secondary market.

Because our common stock is traded on an over the counter quotation system, an investor may find it more difficult to sell our stock or obtain accurate quotations as to the market value of our common stock.

Our common stock falls within the definition of a “penny stock” as defined in the Securities Exchange Act of 1934, or the Exchange Act, and is covered by Rule 15g-9 of the Exchange Act. Rule 15g-9 imposes additional sales practice requirements on broker-dealers who sell securities to persons other than established customers and accredited investors. For transactions covered by Rule 15g-9, the broker-dealer must make a special suitability determination for the purchaser and receive the purchaser’s written agreement to the transaction prior to the sale. Consequently, Rule 15g-9 will affect the ability or willingness of broker-dealers to sell our securities, and accordingly will affect the ability of stockholders to sell their securities in the public market. These additional procedures could also limit our ability to raise additional capital in the future.

The trading price of our common stock may be volatile.

The market prices for, and the trading volumes of, securities of medical device companies, such as ours, have been historically volatile. The market has experienced, from time to time, significant price and volume fluctuations unrelated to the operating performance of particular companies. In addition, the fact that our common stock now trades on the OTCQB market could contribute to trading volumes in our shares being sporadic and volatility in the share price. If adverse market conditions exist, you may have difficulty selling your shares. The market price of our common shares may fluctuate significantly due to a variety of factors, including:

	●	the results of pre-clinical testing and clinical trials by us, our collaborators and/or our competitors;
	●	technological innovations or new diagnostic products;
	●	governmental regulations;
	●	developments in patent or other proprietary rights;
	●	litigation;
	●	public concern regarding the safety of products developed by us or others;
	●	comments by securities analysts;
	●	the issuance of additional shares to obtain financing or for acquisitions;
	●	general market conditions in our industry or in the economy as a whole;
	●	political instability, natural disasters, war and/or events of terrorism.

In addition, the stock market in general has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of individual companies. Broad market and industry factors may seriously affect the market price of our stock, regardless of actual operating performance. In the past, securities class action litigation often follows periods of volatility in the overall market and market price of a particular company’s securities. This litigation, if instituted against us, could result in substantial costs and a diversion of our management’s attention and resources.

TearLab Corporation

Because we do not expect to pay dividends on our common stock, stockholders will benefit from an investment in our common stock only if it appreciates in value.

We have never paid cash dividends on our common stock and have no present intention to pay any dividends in the future. We are not profitable and may not earn sufficient revenue to meet all operating cash needs. As a result, we intend to use all available cash and liquid assets in the development of our business. Any future determination about the payment of dividends will be made at the discretion of our board of directors and will depend upon our earnings, if any, our capital requirements, our operating and financial conditions and on such other factors as our board of directors may deem relevant. As a result, the success of an investment in our common stock will depend upon any future appreciation in its value. There is no guarantee that our common stock will appreciate in value or even maintain the price at which stockholders have purchased their shares.

Warrant holders will not be entitled to any of the rights of common stockholders, but will be subject to all changes made with respect thereto.

If you hold warrants, you will not be entitled to any rights with respect to our common stock (including, without limitation, voting rights and rights to receive any dividends or other distributions on our common stock), but you will be subject to all changes affecting our common stock. You will have rights with respect to our common stock only if you receive our common stock upon exercise of the warrants and only as of the date when you become a record owner of the shares of our common stock upon such exercise. For example, if a proposed amendment to our charter or bylaws requires stockholder approval and the record date for determining the stockholders of record entitled to vote on the amendment occurs prior to the date that you are deemed to be the owner of the shares of our common stock due upon exercise of your warrants, you will not be entitled to vote on the amendment; although, you will nevertheless be subject to any changes in the powers, preferences or special rights of our common stock.

We can issue shares of preferred stock that may adversely affect the rights of holders of our common stock.

Our certificate of incorporation authorizes us to issue up to 10.0 million shares of preferred stock with designations, rights, and preferences determined from time to time by our board of directors. Accordingly, our board of directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, conversion, voting or other rights superior to those of holders of our common stock. For example, an issuance of shares of preferred stock could:

	●	adversely affect the voting power of the holders of our common stock;
	●	make it more difficult for a third party to gain control of us;
	●	discourage bids for our common stock at a premium;
	●	limit or eliminate any payments that the holders of our common stock could expect to receive upon our liquidation; or
	●	otherwise adversely affect the market price or our common stock.

TearLab Corporation

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION.

ITEM 6. EXHIBITS

Exhibit Number	Exhibit Description	Incorporated by Reference

31.1	CEO’s Certification required by Rule 13A-14(a) of the Securities Exchange Act of 1934.

31.2	CFO’s Certification required by Rule 13A-14(a) of the Securities Exchange Act of 1934.

32.1+	CEO’s Certification of periodic financial reports pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, U.S.C. Section 1350.

32.2+	CFO’s Certification of periodic financial reports pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, U.S.C. Section 1350.

101.INS*	XBRL Instance

101.SCH*	XBRL Taxonomy Schema

101.CAL*	XBRL Taxonomy Extension Calculation

101.DEF*	XBRL Taxonomy Extension Definition

101.LAB*	XBRL Taxonomy Extension Labels

101.PRE*	SXBRL Taxonomy Extension Presentation

*XBRL information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of section.

+In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 33-8238 and 34-47986, Final Rule: Management’s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished pursuant to this item will not be deemed “filed” for purposes of Section 18 of the Exchange Act (15 U.S.C. 78r), or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference

TearLab Corporation

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	TearLab Corp.
	(Registrant)

Date: August 9, 2019	/s/ Joseph Jensen
	Joseph Jensen
	Chief Executive Officer

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION PURSUANT TO RULE 13A-14 OR 15D-14 OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Joseph Jensen, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of TearLab Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4.	The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

	a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under the Company’s supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under the Company’s supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report the Company’s conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

5.	The Registrant’s other certifying officer and I have disclosed, based on the Company’s most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of Registrant’s board of directors (or persons performing the equivalent function):

	a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

	b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

Dated: August 9, 2019

	/s/ Joseph Jensen
	Joseph Jensen
	Chief Executive Officer

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATION PURSUANT TO RULE 13A-14 OR 15D-14 OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael Marquez, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of TearLab Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4.	The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

	a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under the Company’s supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under the Company’s supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report the Company’s conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

5.	The Registrant’s other certifying officer and I have disclosed, based on the Company’s most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of Registrant’s board of directors (or persons performing the equivalent function):

	a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

	b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

Dated: August 9, 2019

	/s/ Michael Marquez
	Michael Marquez
	Chief Financial Officer

EX-32.1 4 ex32-1.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of TearLab Corporation (the “Company”) for the quarter ended June 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joseph Jensen, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	By:	/s/ Joseph Jensen
		Joseph Jensen
		Chief Executive Officer

Dated: August 9, 2019

EX-32.2 5 ex32-2.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of TearLab Corporation (the “Company”) for the quarter ended June 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael Marquez, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	By:	/s/ Michael Marquez
		Michael Marquez
		Chief Financial Officer

Dated: August 9, 2019

EX-101.INS 6 tear-20190630.xml XBRL INSTANCE FILE 0001299139 2019-01-01 2019-06-30 0001299139 2017-12-31 0001299139 TEAR:StockIncentivePlanMember TEAR:EmployeesDirectorsAndConsultantsMember 2017-06-23 0001299139 TEAR:StockIncentivePlanMember TEAR:NonStatutoryStockOptionsMember srt:MaximumMember 2017-06-22 2017-06-23 0001299139 TEAR:TermLoanMember TEAR:CrglpMember 2015-03-04 0001299139 TEAR:TermLoanMember TEAR:CrglpMember 2015-03-03 2015-03-04 0001299139 TEAR:TermLoanMember TEAR:CrglpMember 2015-10-05 2015-10-06 0001299139 TEAR:StockIncentivePlanMember srt:MaximumMember 2017-06-22 2017-06-23 0001299139 TEAR:StockIncentivePlanMember srt:MinimumMember 2017-06-22 2017-06-23 0001299139 TEAR:EmployeeStockPurchasePlan2014Member 2019-06-30 0001299139 TEAR:TermLoanMember TEAR:CrglpMember us-gaap:InterestOnlyStripMember 2015-03-04 0001299139 TEAR:TermLoanMember TEAR:CrglpMember 2015-10-06 0001299139 TEAR:StockIncentivePlanMember TEAR:OfficerDirectorOrConsultantMember srt:MaximumMember 2018-12-31 0001299139 TEAR:TermLoanAgreementMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2015-10-07 2015-10-08 0001299139 TEAR:CRGWarrantsMember 2015-10-08 0001299139 TEAR:SeptemberThirtyTwoThousandAndNineteenMember TEAR:TermLoanMember TEAR:CrglpMember 2019-01-01 2019-06-30 0001299139 TEAR:CRGWarrantsMember 2015-10-07 2015-10-08 0001299139 TEAR:CRGWarrantsMember 2016-04-07 0001299139 us-gaap:StockOptionMember 2019-01-01 2019-06-30 0001299139 us-gaap:WarrantMember 2019-01-01 2019-06-30 0001299139 us-gaap:StockOptionMember 2018-01-01 2018-06-30 0001299139 TEAR:SupplyAgreementMember TEAR:MiniFABMember 2016-03-06 2016-03-07 0001299139 TEAR:TermLoanMember TEAR:CrglpAdditionalWarrantsMember TEAR:BlackScholesMertonModelMember 2016-04-06 2016-04-07 0001299139 TEAR:TermLoanMember TEAR:CRGWarrantsMember TEAR:BlackScholesMertonModelMember 2016-04-06 2016-04-07 0001299139 TEAR:SeriesAWarrantsMember TEAR:BlackScholesMertonModelMember 2016-05-08 2016-05-09 0001299139 us-gaap:ConvertiblePreferredStockMember 2018-01-01 2018-06-30 0001299139 us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-06-30 0001299139 2006-09-29 2006-10-01 0001299139 TEAR:SeriesAWarrantsMember TEAR:BlackScholesMertonModelMember 2016-05-09 0001299139 TEAR:CapitalizedTearLabEquipmentMember 2018-12-31 0001299139 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001299139 us-gaap:ComputerSoftwareIntangibleAssetMember 2018-12-31 0001299139 us-gaap:OfficeEquipmentMember 2018-12-31 0001299139 TEAR:MedicalEquipmentMember 2018-12-31 0001299139 TEAR:TearLabTechnologyMember 2018-12-31 0001299139 TEAR:PatentsAndTrademarksMember 2018-12-31 0001299139 TEAR:PrescriberListMember 2018-12-31 0001299139 us-gaap:SellingAndMarketingExpenseMember 2018-01-01 2018-06-30 0001299139 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-06-30 0001299139 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-06-30 0001299139 TEAR:StockIncentivePlanMember TEAR:EmployeesDirectorsAndConsultantsMember srt:MaximumMember 2017-06-23 0001299139 TEAR:TermLoanMember TEAR:CrglpAdditionalWarrantsMember 2016-04-07 0001299139 2017-10-12 0001299139 2017-12-06 2017-12-08 0001299139 TEAR:SeriesAConvertiblePreferredStockMember 2017-12-08 0001299139 TEAR:SeriesAWarrantsMember 2017-12-08 0001299139 TEAR:SeriesBWarrantsMember 2017-12-08 0001299139 TEAR:SeriesBWarrantsMember 2017-12-06 2017-12-08 0001299139 TEAR:PlacementAgentWarrantsMember 2017-12-08 0001299139 us-gaap:CommonStockMember 2017-12-06 2017-12-08 0001299139 TEAR:TermLoanMember TEAR:CrglpAdditionalWarrantsMember 2017-10-12 0001299139 TEAR:TermLoanMember TEAR:CrglpAdditionalWarrantsMember TEAR:BlackScholesMertonModelMember 2017-10-10 2017-10-12 0001299139 TEAR:TermLoanMember TEAR:CRGWarrantsMember TEAR:BlackScholesMertonModelMember 2017-10-10 2017-10-12 0001299139 TEAR:SeriesAWarrantsMember TEAR:BlackScholesMertonModelMember 2017-12-08 0001299139 TEAR:SeriesAWarrantsMember TEAR:BlackScholesMertonModelMember 2017-12-06 2017-12-08 0001299139 TEAR:SeriesBWarrantsMember TEAR:BlackScholesMertonModelMember 2017-12-08 0001299139 TEAR:SeriesBWarrantsMember TEAR:BlackScholesMertonModelMember 2017-12-06 2017-12-08 0001299139 2018-12-31 0001299139 TEAR:TermLoanAgreementMember TEAR:CrglpMember 2018-04-03 2018-04-04 0001299139 TEAR:TermLoanAgreementMember TEAR:CrglpMember 2018-04-04 0001299139 TEAR:TermLoanAgreementMember TEAR:CrglpMember TEAR:CRGWarrantsMember 2018-04-04 0001299139 TEAR:TermLoanMember TEAR:CrglpMember 2016-06-30 0001299139 TEAR:CRGWarrantsMember TEAR:BlackScholesMertonModelMember 2017-12-31 0001299139 TEAR:CRGWarrantsMember TEAR:BlackScholesMertonModelMember 2018-01-01 2018-12-31 0001299139 us-gaap:WarrantMember 2018-01-01 2018-06-30 0001299139 TEAR:RestatedLicenseAgreementMember 2018-04-29 2018-05-01 0001299139 TEAR:RestatedLicenseAgreementMember srt:MinimumMember 2018-04-29 2018-05-01 0001299139 TEAR:RestatedLicenseAgreementMember srt:MaximumMember 2018-04-29 2018-05-01 0001299139 TEAR:RestatedLicenseAgreementMember srt:MinimumMember 2019-01-01 2019-06-30 0001299139 TEAR:RestatedLicenseAgreementMember srt:MaximumMember 2019-01-01 2019-06-30 0001299139 TEAR:RestatedLicenseAgreementMember 2019-01-01 2019-06-30 0001299139 TEAR:IMedPharmaIncMember 2018-02-01 2018-02-28 0001299139 TEAR:TermLoanMember TEAR:CrglpMember us-gaap:PrincipalOnlyStripMember 2015-03-04 0001299139 TEAR:IMedPharmaIncMember 2018-04-01 2018-04-30 0001299139 TEAR:TermLoanMember TEAR:CrglpMember srt:MinimumMember 2017-10-12 0001299139 TEAR:TermLoanMember TEAR:CrglpMember srt:MaximumMember 2017-10-12 0001299139 TEAR:TermLoanMember TEAR:CrglpMember 2017-10-12 0001299139 2019-08-02 0001299139 us-gaap:ProductMember 2019-01-01 2019-06-30 0001299139 us-gaap:ProductMember 2018-01-01 2018-06-30 0001299139 TEAR:ReaderEquipmentRentalsMember 2019-01-01 2019-06-30 0001299139 TEAR:ReaderEquipmentRentalsMember 2018-01-01 2018-06-30 0001299139 us-gaap:CommonStockMember 2017-12-31 0001299139 us-gaap:PreferredStockMember 2017-12-31 0001299139 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001299139 us-gaap:RetainedEarningsMember 2017-12-31 0001299139 us-gaap:CommonStockMember 2018-12-31 0001299139 us-gaap:PreferredStockMember 2018-12-31 0001299139 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001299139 us-gaap:RetainedEarningsMember 2018-12-31 0001299139 TEAR:ManufacturingEquipmentMember 2018-12-31 0001299139 TEAR:MiniFABAgreementMember 2018-08-08 2018-08-09 0001299139 TEAR:MiniFABAgreementMember TEAR:MiniFABMember 2019-08-08 2019-08-09 0001299139 TEAR:MiniFABAgreementMember TEAR:TearLabMember 2018-08-08 2018-08-09 0001299139 TEAR:MiniFABAgreementMember TEAR:PhaseOneMember TEAR:AUDMember 2019-08-08 2019-08-09 0001299139 TEAR:MiniFABAgreementMember TEAR:PhaseTwoMember TEAR:AUDMember 2019-08-08 2019-08-09 0001299139 2019-06-30 0001299139 2018-01-01 2018-06-30 0001299139 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0001299139 us-gaap:CommonStockMember 2018-06-30 0001299139 us-gaap:CommonStockMember 2019-06-30 0001299139 us-gaap:PreferredStockMember 2018-06-30 0001299139 us-gaap:PreferredStockMember 2019-06-30 0001299139 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001299139 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001299139 us-gaap:RetainedEarningsMember 2018-06-30 0001299139 us-gaap:RetainedEarningsMember 2019-06-30 0001299139 2018-06-30 0001299139 us-gaap:ShippingAndHandlingMember 2019-01-01 2019-06-30 0001299139 us-gaap:ShippingAndHandlingMember 2018-01-01 2018-06-30 0001299139 TEAR:CapitalizedTearLabEquipmentMember 2019-06-30 0001299139 TEAR:ManufacturingEquipmentMember 2019-06-30 0001299139 us-gaap:LeaseholdImprovementsMember 2019-06-30 0001299139 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-06-30 0001299139 us-gaap:OfficeEquipmentMember 2019-06-30 0001299139 TEAR:MedicalEquipmentMember 2019-06-30 0001299139 TEAR:TearLabTechnologyMember 2019-01-01 2019-06-30 0001299139 TEAR:PatentsAndTrademarksMember 2019-01-01 2019-06-30 0001299139 TEAR:PrescriberListMember 2019-01-01 2019-06-30 0001299139 TEAR:TearLabTechnologyMember 2019-06-30 0001299139 TEAR:PatentsAndTrademarksMember 2019-06-30 0001299139 TEAR:PrescriberListMember 2019-06-30 0001299139 us-gaap:IndefinitelivedIntangibleAssetsMember 2019-06-30 0001299139 TEAR:TermLoanAgreementMember TEAR:TwoThousandandNineteenMember 2019-01-01 2019-06-30 0001299139 TEAR:TermLoanAgreementMember TEAR:TwoThousandandTwentyMember 2019-01-01 2019-06-30 0001299139 TEAR:TermLoanMember TEAR:CrglpMember 2019-06-30 0001299139 TEAR:TermLoanMember 2019-06-30 0001299139 us-gaap:SeriesAPreferredStockMember 2019-01-01 2019-06-30 0001299139 TEAR:StockIncentivePlanMember 2019-01-01 2019-06-30 0001299139 TEAR:WarrantsMember TEAR:BlackScholesMertonModelMember 2019-06-30 0001299139 TEAR:WarrantsMember TEAR:BlackScholesMertonModelMember us-gaap:ValuationTechniqueOptionPricingModelMember 2019-01-01 2019-06-30 0001299139 TEAR:CRGWarrantsMember TEAR:BlackScholesMertonModelMember 2019-01-01 2019-06-30 0001299139 TEAR:CRGWarrantsMember TEAR:TermLoanAgreementMember 2018-04-03 2018-04-04 0001299139 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-06-30 0001299139 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0001299139 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0001299139 TEAR:VehicleLeasesMember 2019-01-01 2019-06-30 0001299139 TEAR:EquipmentLeaseMember 2019-01-01 2019-06-30 0001299139 TEAR:CRGWarrantsMember 2019-06-30 0001299139 TEAR:CRGWarrantsMember 2018-06-30 0001299139 TEAR:CRGWarrantsMember 2019-01-01 2019-06-30 0001299139 TEAR:CRGWarrantsMember 2018-01-01 2018-06-30 0001299139 2018-12-01 2018-12-31 0001299139 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001299139 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001299139 us-gaap:CommonStockMember 2018-03-31 0001299139 us-gaap:CommonStockMember 2019-03-31 0001299139 us-gaap:PreferredStockMember 2018-04-01 2018-06-30 0001299139 us-gaap:PreferredStockMember 2019-04-01 2019-06-30 0001299139 us-gaap:PreferredStockMember 2018-03-31 0001299139 us-gaap:PreferredStockMember 2019-03-31 0001299139 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001299139 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001299139 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001299139 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001299139 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001299139 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001299139 us-gaap:RetainedEarningsMember 2018-03-31 0001299139 us-gaap:RetainedEarningsMember 2019-03-31 0001299139 2018-04-01 2018-06-30 0001299139 2019-04-01 2019-06-30 0001299139 2018-03-31 0001299139 2019-03-31 0001299139 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001299139 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001299139 us-gaap:PreferredStockMember 2019-01-01 2019-03-31 0001299139 us-gaap:PreferredStockMember 2018-01-01 2018-03-31 0001299139 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001299139 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001299139 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001299139 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001299139 2019-01-01 2019-03-31 0001299139 2018-01-01 2018-03-31 0001299139 TEAR:ReaderEquipmentRentalsMember 2019-04-01 2019-06-30 0001299139 TEAR:ReaderEquipmentRentalsMember 2018-04-01 2018-06-30 0001299139 us-gaap:ProductMember 2019-04-01 2019-06-30 0001299139 us-gaap:ProductMember 2018-04-01 2018-06-30 0001299139 us-gaap:ShippingAndHandlingMember 2019-04-01 2019-06-30 0001299139 us-gaap:ShippingAndHandlingMember 2018-04-01 2018-06-30 0001299139 us-gaap:SellingAndMarketingExpenseMember 2018-04-01 2018-06-30 0001299139 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0001299139 us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-01 2018-06-30 0001299139 us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0001299139 us-gaap:GeneralAndAdministrativeExpenseMember 2018-04-01 2018-06-30 0001299139 us-gaap:SellingAndMarketingExpenseMember 2019-04-01 2019-06-30 0001299139 us-gaap:AccountingStandardsUpdate201801Member 2019-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:AUD 10-Q false

35000000

32014000

18278000

34764000

0.001

10000000

556

160

0.001

9500000

40000000

2114

6818181

556

160

4804545

1954

358000

500000

-158

-220

400000

2452000

-176

-1078

TearLab Corp

11296998

12196998

11296998

12196998

6000

-42000

-119000

42000

119000

742000

214000

-279000

-552000

744000

-1261000

-335000

-243000

845000

-143000

-63000

-263000

2061000

1838000

50000

80000

Non-accelerated Filer --12-31 2019-06-30 2019 Q2 0001299139

9581000

879000

8702000

599000

1000

8702000

9302000

77000

35000

178000

0.20 0.03 0.0425 0.035 0.0475 0.055 0.50

385000

0.0125

500000

200000

0.0068 12560635 false

14513000

15939000

-18566000

-20669000

8000

510235000

-528809000

11000

510380000

-531060000

-23132000

11000

12000

510310000

510429000

-530353000

-533573000

-20032000

10000

12000

510238000

510411000

-529692000

-532399000

-19444000

-21976000

-531060000

-533573000

510380000

510429000

11000

12000

35182000

39071000

3057000

20181000

13000

4000

2363000

2084000

681000

1425000

-2513000

-1544000

-661000

-1174000

-661000

-1174000

-1339000

-883000

-1339000

-883000

true false

111000

119000

14513000

15939000

151000

150000

2000

2024000

1626000

12336000

13484000

690000

356000

1987000

2832000

1186000

1123000

7986998

2012

11296998

556

10796998

12196998

776

160

10438998

11696998

934

380

1000

-1000

1000

-1000

1000

2000

-2000

1000

72000

19000

72000

19000

31000

8000

31000

8000

-28000

-1000

2. SIGNIFICANT ACCOUNTING POLICIES   The Condensed Consolidated Balance Sheet at December 31, 2018 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States (“U.S. GAAP”) for complete financial statements. These unaudited interim condensed consolidated financial statements have been prepared using significant accounting policies that are consistent with the policies used in preparing the Company’s audited consolidated financial statements for the year ended December 31, 2018. The audited financial statements for the year ended December 31, 2018, filed with the SEC with the Company’s annual report on Form 10-K on March 22, 2019 include a summary of significant accounting policies and should be read in conjunction with this Form 10-Q. Management believes that all adjustments necessary for the fair presentation of results, consisting of normal recurring items, have been included in the unaudited condensed consolidated financial statements for the interim periods presented.   Use of Estimates   The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The principal areas of judgment relate to revenue and inventory reserves, allowance for doubtful accounts, impairment of long-lived and intangible assets, and the fair value of stock options and warrants.   Revenue Recognition   Revenue is recognized when obligations under the terms of a contract with our customer are satisfied; generally, this occurs with the transfer of control of our products or services. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services which includes estimates of variable consideration that results from returns, rebates or test card replacements. The Company records allowances for returns or rebates and reports revenue net of such amounts which was $27 and $6 for the three months ended June 30, 2019 and 2018, respectively and $55 and $6 for the six months ended June 30, 2019 and 2018, respectively. Sales and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. The Company’s payment terms are typically upon shipment or net 30.   The Company sells its proprietary TearLab® Osmolality System and related test cards to external customers, who are primarily eye care professionals, for use in osmolality testing procedures. Revenue is primarily derived from the sale of disposable test cards. Products are generally shipped from a distribution and warehousing facility located in San Diego, California. The Company’s sales are currently direct to customers in the United States and to distributors in the rest of the world.   The Company enters into contracts where revenue is derived either from agreements whereby the customer is provided the right to use the TearLab® Osmolarity System (reader equipment) at no separate cost to the customer in consideration for a minimum or implied purchase commitment of disposable test cards over the related contract term (referred to as either “Use Agreements”, “Masters Agreements” or “Flex Agreements”), or from agreements to sell the reader equipment and disposable test cards at their stand-alone selling price with no contractual future purchase commitment (referred to as “Purchase Agreements”).   Use, Masters, and Flex Agreements   Purchase commitments for Use Agreements and Flex Agreements are expressed in the agreement for a specified period of time (generally one to three years). The purchase commitment for Masters Agreements is implied for large physician practices with an expectation of purchasing certain levels of test cards. The Company recovers the cost of providing the reader equipment in the amount charged for disposable test cards. Two performance obligations exist under these contracts, related to the customers’ right to use the reader equipment and orders of test cards. As the customer has the ability and right to operate the reader equipment in a manner it determines as well as obtain the output from using the reader equipment, the revenue related to the reader equipment use performance obligation is recognized in accordance with ASC 842 – Leases, wherein revenue related to the reader equipment is recognized over the defined contract term. Revenue related to disposable test cards is recognized as the disposable test cards are shipped. Based on the nature of these contracts, which provide terms for the future purchase of test cards but do not contractually obligate the customer to do so, each purchase of test cards is treated as its own distinct contract with a performance obligation to provide the test cards ordered, memorialized by the customers’ purchase order/request. Revenue under such agreements is allocated between the lease of the reader equipment and the sale of the disposables based upon each component’s relative standalone selling price, which is estimated using the selling prices of the reader device and test cards under Purchase Agreements, discussed further below.   When reader equipment is placed with a customer at no separate cost, the Company retains title to the equipment and it remains capitalized on the Company’s Consolidated Balance Sheet as equipment classified within fixed assets, net. The equipment is depreciated on a straight-line basis once shipped to a customer location over its estimated useful life and depreciation expense is included in cost of goods sold within the Condensed Consolidated Statements of Operations and Comprehensive Loss.   Purchase Agreements   Revenue recognition for Purchase Agreements is based on the individual performance obligations determined to exist in the contract. Since the reader equipment and the test cards are separate and distinct delivered items, the delivery of each are considered separate performance obligations. The reader equipment and test cards are separately identified under the Purchase Agreements and are sold at their standalone selling price. The Company recognizes revenue for each of the performance obligations only when it determines that all applicable recognition criteria have been met, which is usually upon shipment to the customer. Under Purchase Agreements, the customer is not contractually obligated to purchase additional test cards, and each subsequent order of test cards represents a separate and distinct contract with the performance obligation to provide the test cards ordered.   Amounts billed to customers for shipping and handling of a sales transaction are included as revenue. The Company recognized revenue from shipping and handling of $36 and $38 for the three months ended June 30, 2019 and 2018, respectively. The Company recognized revenue from shipping and handling of $69 and $77 for the six months ended June 30, 2019 and 2018, respectively.   The following table presents our revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Six months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 37%; text-align: left">Product Sales</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,157</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,679</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">10,153</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">11,454</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Reader Equipment Rentals</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">694</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">734</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,381</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,405</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,851</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,413</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,534</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,859</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Arrangements with Multiple Performance Obligations   Our contracts with customers may include multiple performance obligations. For such arrangements, we allocate revenue to each performance obligation based on its relative standalone selling price. We generally determine standalone selling prices based on the separate prices charged to customers for the reader device and test cards under Purchase Agreements.   Return Reserve   Although the Company has a no return policy for its products, the Company has established a return reserve for product sales that contain an implicit right of return. The Company reserves for estimated returns or refunds by reducing revenue at the time of shipment based on historical experience. The reserve of $5 and $6 as of June 30, 2019 and December 31, 2018, respectively, has been recorded as a reduction of revenue and is included in accounts receivable.   Practical Expedients and Exemptions   We generally expense outside sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within sales and marketing expenses.   We do not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.   Leases   On January 1, 2019, the Company adopted the Financial Accounting Standards Board (‘FASB’) Accounting Standards Update (‘ASU’) 2016-02, Leases, which requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous guidance. The original guidance required application on a modified retrospective basis with the earliest period presented. In August 2018, the FASB issued ASU 2018-11, Targeted Improvements to ASC 842, which included an option to not restate comparative periods in transition and elect to use the effective date of ASC 842, Leases, as the date of initial application of transition, which the Company elected. Lease arrangements are determined at the inception of the contract with and included in right-of-use (“ROU”) assets and long-term lease liabilities on the consolidated balance sheets. The adoption of ASC 842 had an immaterial impact on our Condensed Consolidated Statement of Operations and Comprehensive Loss and Condensed Consolidated Statement of Cash Flows for the three and six month periods ended June 30, 2019. Additionally, the Company has elected the package practical expedient with respect to lease definition, classification and direct costs. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 month or less. Additional information and disclosures required by the new standard are contained in Note 8.   Recent accounting pronouncements   In June 2018, the FASB issued Accounting Standards Update (“ASU”) No. 2018-07, “Compensation – Stock Compensation (Topic 718).” ASU 2018-07 simplifies the accounting for nonemployee share-based payment transactions. This ASU is effective for public entities for interim and annual reporting periods beginning after December 15, 2018. The Company adopted ASU 2018-07 effective January 1, 2019 with an immaterial impact to our financial statements.

3. BALANCE SHEET DETAILS   Accounts receivable   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; text-align: left">Trade receivables</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,214</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right">1,324</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(91</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(138</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,123</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,186</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Inventory   Inventory is recorded at the lower of cost and net realizable value on a first-in, first-out basis and consists of finished goods.   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; text-align: left">Finished goods</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">2,832</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right">1,987</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Inventory reserves</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,832</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,987</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The Company evaluates inventory for estimated excess quantities and obsolescence, based on expected future sales levels and projections of future demand, and establishes inventory reserves for obsolete and excess inventories. In addition, the Company assesses the impact of changing technology and market conditions. The Company has entered into a long-term purchase commitment to buy the test cards from MiniFAB (Note 8). As part of its analysis of excess or obsolete inventories, the Company considers future annual minimum purchases, estimated future usage and the expiry dating of the cards to determine if any inventory reserve is needed.   Prepaid expenses and other current assets   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; text-align: left">Prepaid trade shows</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">20</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right">18</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">322</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Manufacturing deposits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">111</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">111</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Subscriptions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">91</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">140</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other fees and services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">690</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Fixed assets   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; text-align: left">Capitalized TearLab equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">6,643</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right">6,922</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Manufacturing equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">317</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">317</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Computer equipment and software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">306</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">846</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Furniture and office equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">368</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">368</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Medical equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,430</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,366</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">9,077</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">9,832</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,451</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,808</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,626</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,024</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Depreciation expense was $191 and $326 during the three months ended June 30, 2019 and 2018, respectively. Depreciation expense was $412 and $679 during the six months ended June 30, 2019 and 2018, respectively.   Accrued liabilities   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; text-align: justify">Due to professionals</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">17</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right">17</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Due to employees and directors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">945</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,289</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Sales and use tax liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">262</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">257</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Royalty liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">278</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">290</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Warranty</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">74</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">537</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">436</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,084</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,363</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

4. INTANGIBLE ASSETS   The Company’s intangible assets consist of the value of TearLab® Technology acquired in the acquisition of TearLab Research, Inc., a wholly-owned subsidiary of the Company and a prescriber list. The TearLab Technology, which consists of a disposable lab card and card reader, supported by an array of patents and patent applications that are either held or in-licensed by the Company. Amortization expense for the three months ended June 30, 2019 and 2018 was $0.1 and $3, respectively. Amortization expense for the six months ended June 30, 2019 and 2018 was $0.2 and $6, respectively.   Intangible assets subject to amortization consist of the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center">Remaining Useful Life</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Gross Value at</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Net Book Value at</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Years)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt; width: 20%">TearLab® technology</td><td style="width: 2%"> </td> <td style="width: 14%; text-align: center">0</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">12,172</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">   (12,172</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Patents and trademarks</td><td> </td> <td style="text-align: center">1</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">271</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(269</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">   2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Prescriber list</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">0</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">90</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(90</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,533</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(12,531</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Gross Value at</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Net Book Value at</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 38%; text-align: left; padding-left: 10pt">TearLab® technology</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right">12,172</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(12,172</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right">    -</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Patents and trademarks</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">271</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(269</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Prescriber list</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">90</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(90</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,533</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(12,531</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The estimated amortization expense for the intangible assets for the remainder of 2019 and thereafter is as follows:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Amortization</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">of intangible</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">assets</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Remainder of 2019</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">     1</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

6. STOCKHOLDERS’ EQUITY   (a) Authorized share capital   On October 12, 2017, the stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 9,500,000 to 40,000,000. Each share of common stock has a par value of $0.001 per share. The total number of authorized shares of preferred stock of the Company is 10,000,000. Each share of preferred stock has a par value of $0.001 per share.   (b) Common and preferred shares   On December 8, 2017, the Company issued 2,013,636 shares of common stock, 2,114 shares of Series A Convertible Preferred Stock (“Preferred Stock”), Series A warrants to purchase 6,818,181 shares of common Stock (“Series A Warrants”) and Series B warrants to purchase 6,818,181 shares of common stock (“Series B Warrants”) for gross proceeds of $3,000, less issuance costs of $596. Additionally, the Company granted the placement agent compensation warrants to purchase 477,273 shares of common stock. The Preferred Stock is convertible, subject to certain limitations, into an aggregate of 4,804,545 shares of common stock, contains no voting rights, participates in any common stock dividends and is treated as if converted upon any ordinary liquidation event.   As of June 30, 2019, 1,954 shares of Series A Preferred Stock have been converted into 4,440,909 shares of common stock.   (c) Stock Incentive Plan   On June 23, 2017, the Company’s stockholders approved an amendment to the 2002 Stock Incentive Plan (the “Stock Incentive Plan”), to increase the total number of shares reserved for issuance to 1,070,000 from 720,000. Stock Incentive Plan shares are available for grant to employees, directors and consultants. Shares granted under the Stock Incentive Plan may be either incentive stock options or non-statutory stock options. Under the terms of the Stock Incentive Plan, the exercise price per share for an incentive stock option shall not be less than the fair market value of a share of stock on the effective date of grant and the exercise price per share for non-statutory stock options shall not be less than 85% of the fair market value of a share of stock on the date of grant. No option granted to a holder of more than 10% of the Company’s common stock shall have an exercise price per share less than 110% of the fair market value of a share of stock on the effective date of grant.   Options granted are typically service-based options. Generally, options expire 10 years after the date of grant. No incentive stock options granted to a 10% owner optionee shall be exercisable after the expiration of five years after the effective date of grant of such option, no option has been granted to a prospective employee, prospective consultant or prospective director prior to the date on which such person commences service, and with the exception of an option granted to an officer, director or consultant, no incentive option shall become exercisable at a rate less than 20% per annum over a period of five years from the effective date of grant of such option unless otherwise approved by the Board.   Share-based payment transactions with employees are recognized in the condensed consolidated financial statements based on their fair value and recognized as compensation expense over the vesting period. The amount of expense recognized during the period is affected by subjective assumptions, including: estimates of the Company’s future volatility, the expected term for its stock options, option exercise behavior, the number of options expected to ultimately vest, and the timing of vesting for the Company’s share-based awards.   The following table sets forth the total stock-based compensation expense resulting from stock options and the employee stock purchase plan included in the Company’s condensed consolidated statements of operations and comprehensive loss (in thousands):   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Six months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Sales and marketing</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(5</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">20</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">38</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Clinical, regulatory and research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">20</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">44</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">39</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Stock-based compensation expense before income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">19</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   (d) Employee Stock Purchase Plan   In July 2014, the Company’s Board of Directors adopted the 2014 Employee Stock Purchase Plan (the “ESPP”) which was approved by the Company’s stockholders in June 2014 at the Company’s Annual Meeting of Stockholders. A total of 28,601 shares of the Company’s common stock were reserved for issuance under the plan, which permits eligible employees to purchase common stock at a discount through payroll deductions. In 2018 the Company’s Board of Directors terminated the ESPP.   (e) Warrants   On October 8, 2015, as part of Amendment No. 2 to the Term Loan Agreement and funding of the $10,000 tranche, CRG received warrants to purchase 35,000 common shares in the Company at a price of $50.00 per share (the “2015 CRG Warrants”). The 2015 CRG Warrants are exercisable any time prior to October 8, 2020. The 2015 CRG Warrants are classified as equity on the Condensed Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018. The 2015 CRG Warrants were valued at $290 upon issuance using the Black-Scholes Merton model assuming volatility of 73%, an expected life of 5.0 years, a risk-free interest rate of 1.71%, and 0% dividend yield. No CRG Warrants were exercised during the six months ended June 30, 2019 or 2018.   On April 7, 2016, as part of Amendment No. 4 to the Term Loan Agreement, the exercise price of the 2015 CRG Warrants was changed to allow the holder to purchase 35,000 common shares in the Company at a price of $15.00 per share and CRG was issued an additional 35,000 warrants to purchase common shares at an exercise price of $15.00 (the “2016 CRG Warrants” and, together with the 2015 CRG Warrants, the “CRG Warrants”). The modification to the terms of the 2015 CRG Warrants resulted in a change in fair value of $54 which was included as interest expense. The change in fair value was calculated using the Black-Scholes Merton model with both exercise prices, assuming volatility of 76%, an expected life of 4.5 years, a risk-free interest rate of 1.06%, and 0% dividend yield. The 2016 CRG Warrants were valued at $106 upon issuance using the Black-Scholes Merton model assuming volatility of 76%, an expected life of 5.0 years, a risk-free interest rate of 1.30% and 0% dividend yield.   On May 9, 2016, the Company issued Series A Warrants to purchase 1,253,500 shares of common stock for $11.25 per common share attached to shares of common and Series A Convertible Preferred Stock issued on the same date. The Series A Warrants can be exercised after May 9, 2017 (the “Initial Exercise Date”) and expire 5 years after the Initial Exercise Date. Fair value of the Series A Warrants, for purposes of allocating the net proceeds of the equity offering, was determined using the Black-Scholes Merton model assuming volatility of 76%, an expected life of 6.0 years, a risk-free interest rate of 1.30%, and 0% dividend yield.   On October 12, 2017, as part of Amendment No. 5 to the Term Loan Agreement, the exercise price of the CRG Warrants was changed to allow the holder to purchase common shares in the Company at a price of $1.50 per share as well as provide broad anti-dilution protection such that the CRG Warrants shall maintain the same 1.22% ownership following any capital raises the Company completed through March 31, 2018. The modification to the terms of the CRG Warrants resulted in a change in fair value of $44 which was included as interest expense. The 2015 CRG Warrants change in fair value was calculated using the Black-Scholes Merton model with both exercise prices, assuming volatility of 94%, an expected life of 2.99 years, a risk-free interest rate of 1.70% and 0% dividend yield. The 2016 CRG Warrants change in fair value was calculated using the Black-Scholes Merton model with both exercise prices, assuming volatility of 90%, an expected life of 3.48 years, a risk-free interest rate of 1.80% and 0% dividend yield.   On December 8, 2017, the Company issued Series A Warrants to purchase 6,818,181 shares of common stock for $0.44 per share and Series B Warrants to purchase 6,818,181 shares of common stock for $0.44 per share in conjunction with shares of common stock and Series A Convertible Preferred stock issued on that same date. The Series A Warrants were exercisable immediately and expire 5 years after the issuance date. Fair Value of the Series A Warrants, for purposes of allocating the net proceeds of the equity offering, was determined using the Black-Scholes Merton model assuming volatility of 88%, an expected life of 5 years, a risk free interest rate of 2.14% and a 0% dividend yield and are classified as equity on the Condensed Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018. The Series B Warrants were exercisable immediately and expired 6 months after the issuance date. Fair value of the Series B Warrants for purposes of allocating the net proceeds of the equity offering, was determined using the Black-Scholes Merton model assuming a volatility of 158.6%, an expected life of 6 months, a risk free rate of 1.45% and a 0% dividend yield and are classified as equity on the Condensed Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018. All Series B Warrants expired on June 7, 2018 with no warrants exercised. In addition, we granted the placement agent compensation warrants to purchase 477,273 shares of common stock at $0.55 per share. The compensation warrants are in the same form as Series A Warrants, excluding the exercise price, and will terminate on the five-year anniversary date. The placement agent warrants are classified as equity on the Condensed Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018.   In connection with the December 2017 offering the Company issued CRG warrants to purchase 83,240 shares of common stock at an exercise price of $1.50 (“2017 CRG Warrants”) as a result of triggering the anti-dilution clause of the debt amendment (see Note 5). The anti-dilution clause is considered down-round protection, however the Company early adopted ASU 2017-11 and therefore the down-round feature is excluded from the consideration of whether the warrants are indexed to the Company’s own stock and therefore the warrants are not required to be liabilities under the guidance. The 2017 CRG Warrants are classified as equity on the Condensed Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018 and were valued at $30 upon issuance using the Black-Scholes Merton model assuming volatility of 88%, an expected life of 5 years, a risk-free interest rate of 2.14% and 0% dividend yield. On April 4, 2018, in connection with Amendment No. 6 to the Term Loan Agreement, the strike price of all existing CRG warrants was reduced to $0.44 per share (see Note 5). The modification to the terms of the CRG Warrants and the 2017 CRG Warrants resulted in a change in fair value of $10 which was included as interest expense.

8. COMMITMENTS AND CONTINGENCIES   Leases   Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, we use an incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option.   The Company has commitments relating to operating leases recognized on a straight-line basis over the term of the lease for rental of two office spaces and various equipment from unrelated parties. Our California office lease was signed May 1, 2018, with a commencement date of July 1, 2018, expires on November 30, 2023 and has an option for a 5-year extension and escalating payments. On December 21, 2018 the Company entered into a fourth amendment to our Texas office lease to extend the term of the lease until December 31, 2019. In addition, the Company has vehicle leases expiring at various times through January 2021, and an equipment lease expiring in December 2021.   The adoption of ASC Topic 842 resulted in the Company recognizing right of use assets of $738 and a lease liability of $739, with the difference due the write-off of prior recorded deferred rent.   The components of lease costs were as follows:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Three months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Six months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 50%; text-align: left">Operating lease costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 21%; text-align: right">87</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 21%; text-align: right">175</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short-term lease costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Variable lease costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">87</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Future minimum lease payments under non-cancellable leases as of June 30, 2019 were as follows:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">2019</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">151</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2020</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">202</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">184</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">169</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">870</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: present value discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(195</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">675</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Weighted average remaining lease term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.8</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Weighted average discount rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">13</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table>   Commitments   On May 1, 2018 with an effective date of July 1, 2017 the Company entered into a Restated License Agreement (the “Agreement”) to its exclusive license agreement for the commercial development of the invention disclosed in UCSD Disclosure Docket No. SD2002-180 and titled “Volume Independent Tear Film Osmometer” (UCSD License Agreement #2003-03-0433), dated as of March 12, 2003, as amended by Amendment 1, dated as of June 9, 2003, Amendment 2, dated as of September 5, 2005, Amendment 3, dated as of July 7, 2006, Amendment 4, dated as of October 9, 2006, and Amendment 5, dated as of July 9, 2007, by and among the Company and The Regents of the University of California (collectively the “Existing License”) to amend certain terms related to royalties under the Agreement and treatment upon a change of control transaction. The Company is required to make royalty payments of anywhere from 3% to 4.25% based on quarterly net sales. Additionally, the Company is required to pay a royalty of 20% of any sublicense fees it receives. Should a change of control transaction occur during the term of the agreement the royalty rates would range anywhere from 3.5% to 4.75% based on quarterly net sales and the Company would have to make a milestone payment of $0.5 million. In addition, if the Company had not commenced commercial sales of the TearLab DiscoveryTM Platform on or before July 1, 2019 the Company would have be required to pay a milestone payment of 1.25% of cumulative net sales for the two-year period following the effective date of the amendment. The Company completed its first commercial sale of the TearLab DiscoveryTM Platform prior to the July 1, 2019 deadline.   Effective October 1, 2006 the Company entered into a second patent license and royalty agreement with the University of California San Diego to obtain an exclusive license to make, use, sell, offer for sale, and import TearLab technology in development. Starting in 2009, the Company was required to make minimum royalty payments of $35 or 5.5% of gross sales per year, whichever is higher. However, if this new technology is combined with existing technology, the maximum royalty payable on the sale of the combined products would be 5.5% of gross sales per year. As the new technology is currently in development, there is no revenue and the minimum royalty payment of $35 is applicable.   Future minimum royalty payments under this agreement as of June 30, 2019 are as follows:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right">35</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">210</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">385</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   On March 7, 2016, the Company, through its subsidiary, TearLab Research, Inc., entered into a supply and development agreement (“Supply Agreement”) with MiniFAB (Aust) Pty Ltd (“MiniFAB”). The agreement is an exclusive supply agreement through June 2021, for the purchase and delivery of individual osmolarity test cards with the freight costs borne by MiniFab. The Company has the benefit of a lower purchase price and certain savings from freight costs will remain in place throughout the agreement. The Supply Agreement requires, in any given 6 calendar months, the Company must place aggregate purchase orders equal to at least 50% of the orders forecasted for that 6-month period at its onset. The Supply Agreement can be extended by either party for a term of five years with the option for the Company to buyout the exclusive supply provision during any extended term. This Supply Agreement replaces the August 2011 agreement between MiniFAB and the Company. On August 9, 2018 the Company entered into an addendum to the 2016 Manufacturing and Supply and Development Agreement with MiniFab. The amendment fixes the price of the osmolarity test cards at their current price until the earlier of: the average monthly order volume of osmolarity cards on a rolling six month average falls below 20,000 cards; or the aggregate product volume in the calendar year commencing 12 months after the launch of the DiscoveryTM product is below 2.4 million cards; or the aggregate product volume in any calendar year after 24 months after the launch of the DiscoveryTM product is below 3.0 million cards at which point the Company and MiniFab will renegotiate pricing.   On August 9, 2018, the Company entered into a manufacturing, supply and development agreement (the “MiniFAB Agreement”) with MiniFAB. Pursuant to the terms of the MiniFAB Agreement, MiniFAB will manufacture and supply test cards for the Company’s next generation platform, the TearLab Discovery™ System. The MiniFAB Agreement is exclusive through the first term of 10 years and automatically renews for an additional term of 5 years unless either party cancels. TearLab will pay for 65% of the capital expenditures under the MiniFAB Agreement (“capex”) as incurred and MiniFAB will pay for the remaining 35% of capex, which will be recoverable from TearLab through an amortized cost component in the price for the product charged to TearLab once the monthly card volumes reach 200,000 per month. The capex amounts are limited to an aggregate of $1.0 million AUD for the initial development and production phase (“Phase 1”) and anticipated to be in the vicinity of $3.0 million AUD for further investment of production capacity (“Phase 2”). In addition, TearLab will be responsible for the payment or reimbursement of all non-recurrent expenditure and tooling, limited to $1.2 million AUD for Phase 1 and estimated at $2.0 million AUD for Phase 2. In December 2018, the Company made an initial capex investment of $317 for a machine that was placed into fixed assets and is being amortized over a 15-year period. The Company has a corresponding $119 of long-term third-party payable for capex to be amortized through the card cost component for the six months ended June 30, 2019.   In the normal course of business, the Company enters into purchase obligations for future goods and services needed for the operations of the business. Such commitments are not in excess of expected requirements and are not reasonably likely to result in performance penalties or payments that would have a material adverse effect on the Company’s liquidity.   Contingencies   We are not currently a party to any litigation, nor are we aware of any pending or threatened litigation against us, that we believe would materially affect our business, operating results, financial condition or cash flows. Our industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, we may be involved in various legal proceedings from time to time.   We initiated a patent infringement lawsuit against i-Med Pharma, Inc. in February 2016 alleging infringement of our Canadian patent. In February 2018, the Federal Court of Canada issued a ruling in favor of i-Med Pharma, Inc. which invalidated specific claims in our Canadian patent which were alleged to be infringed. We are appealed this ruling to the Canadian Federal Appellate Court. As part of the ruling, the Federal Court ruling awarded costs to i-Med Pharma, Inc., for $0.5 million. The final $0.2 million was paid in April 2018. In June 2019 the Canadian Federal Appellate Court dismissed the appeal

9. RELATED PARTY   The Company has an agreement with its Chief Scientific Officer whereas if the Company enters into an agreement with UCSD to reduce the overall royalty rate the Company shall pay to its Chief Scientific Officer a royalty on net sales equal to one and a half percent of the percent change in the UCSD royalty rate. The restated UCSD patent license and royalty agreement (see Note 8) resulted in a royalty due at a rate of 0.68%. Related party royalty expense was $77 and $178 as of June 30, 2019 and 2018, respectively. The Company had $77 and $40 in accrued royalties at June 30, 2019 and December 31, 2018, respectively for the related party.

Use of Estimates   The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The principal areas of judgment relate to revenue and inventory reserves, allowance for doubtful accounts, impairment of long-lived and intangible assets, and the fair value of stock options and warrants.

Arrangements with Multiple Performance Obligations   Our contracts with customers may include multiple performance obligations. For such arrangements, we allocate revenue to each performance obligation based on its relative standalone selling price. We generally determine standalone selling prices based on the separate prices charged to customers for the reader device and test cards under Purchase Agreements. Return Reserve   Although the Company has a no return policy for its products, the Company has established a return reserve for product sales that contain an implicit right of return. The Company reserves for estimated returns or refunds by reducing revenue at the time of shipment based on historical experience. The reserve of $5 and $6 as of June 30, 2019 and December 31, 2018, respectively, has been recorded as a reduction of revenue and is included in accounts receivable. Practical Expedients and Exemptions   We generally expense outside sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within sales and marketing expenses.   We do not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.

Inventory   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; text-align: left">Finished goods</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">2,832</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right">1,987</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Inventory reserves</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,832</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,987</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Prepaid expenses and other current assets   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; text-align: left">Prepaid trade shows</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">20</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right">18</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">322</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Manufacturing deposits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">111</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">111</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Subscriptions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">91</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">140</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other fees and services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">690</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Fixed assets   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; text-align: left">Capitalized TearLab equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">6,643</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right">6,922</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Manufacturing equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">317</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">317</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Computer equipment and software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">306</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">846</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Furniture and office equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">368</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">368</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Medical equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,430</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,366</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">9,077</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">9,832</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Less accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,451</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,808</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,626</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,024</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Accrued liabilities   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; text-align: justify">Due to professionals</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">17</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right">17</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Due to employees and directors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">945</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,289</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Sales and use tax liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">262</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">257</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Royalty liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">278</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">290</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Warranty</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">74</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">537</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">436</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,084</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,363</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

The estimated amortization expense for the intangible assets for the remainder of 2019 and thereafter is as follows:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Amortization</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">of intangible</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">assets</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Remainder of 2019</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">     1</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

The following is a summary of the Term Loan Agreement as of June 30, 2019 and related maturities of outstanding principal:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Principal balance outstanding</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">24,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">PIK interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,971</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Facility fee</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,033</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">less discount on term loan:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">deferred financing fees, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(111</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">detachable warrants, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(129</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">34,764</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion of Term loan</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,486</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total Term Loan</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,278</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Principal due for each of the next two years:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2019</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 78%; text-align: left; padding-bottom: 1.5pt">2020</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 18%; border-bottom: Black 1.5pt solid; text-align: right">35,004</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Total principal due</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,004</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Less: discount on term loan</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(240</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total term loan</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34,764</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

The following table sets forth the total stock-based compensation expense resulting from stock options and the employee stock purchase plan included in the Company’s condensed consolidated statements of operations and comprehensive loss (in thousands):   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Six months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Sales and marketing</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(5</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">20</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">38</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Clinical, regulatory and research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">20</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">44</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">39</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">26</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Stock-based compensation expense before income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">19</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

The following securities were not included in the calculation of diluted earnings per share because their effects were anti-dilutive:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-style: italic; border-bottom: Black 1.5pt solid">(in thousands of shares)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">879</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">599</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,702</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,702</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Convertible preferred shares</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">9,581</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">9,302</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Revenue Recognition   Revenue is recognized when obligations under the terms of a contract with our customer are satisfied; generally, this occurs with the transfer of control of our products or services. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services which includes estimates of variable consideration that results from returns, rebates or test card replacements. The Company records allowances for returns or rebates and reports revenue net of such amounts which was $27 and $6 for the three months ended June 30, 2019 and 2018, respectively and $55 and $6 for the six months ended June 30, 2019 and 2018, respectively. Sales and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. The Company’s payment terms are typically upon shipment or net 30.   The Company sells its proprietary TearLab® Osmolality System and related test cards to external customers, who are primarily eye care professionals, for use in osmolality testing procedures. Revenue is primarily derived from the sale of disposable test cards. Products are generally shipped from a distribution and warehousing facility located in San Diego, California. The Company’s sales are currently direct to customers in the United States and to distributors in the rest of the world.   The Company enters into contracts where revenue is derived either from agreements whereby the customer is provided the right to use the TearLab® Osmolarity System (reader equipment) at no separate cost to the customer in consideration for a minimum or implied purchase commitment of disposable test cards over the related contract term (referred to as either “Use Agreements”, “Masters Agreements” or “Flex Agreements”), or from agreements to sell the reader equipment and disposable test cards at their stand-alone selling price with no contractual future purchase commitment (referred to as “Purchase Agreements”).

202000

184000

164000

169000

870000

35000

P10Y P5Y 1000000 3000000 1200000 2000000

317000

35000

210000

-11000

-21000

500000

11534000

10153000

11454000

1381000

1405000

12859000

69000

77000

6413000

5851000

694000

734000

5157000

5679000

36000

38000

0.35 0.65 The amendment fixes the price of the osmolarity test cards at their current price until the earlier of: the average monthly order volume of osmolarity cards on a rolling six month average falls below 20,000 cards; or the aggregate product volume in the calendar year commencing 12 months after the launch of the DiscoveryTM product is below 2.4 million cards; or the aggregate product volume in any calendar year after 24 months after the launch of the DiscoveryTM product is below 3.0 million cards at which point the Company and MiniFab will renegotiate pricing.

677000

738000

16486000

182000

493000

801000 176000

697000

419000

40000

77000

175000

87000

175000

87000

151000

675000

739000

P3Y9M18D

0.13

TearLab will pay for 65% of the capital expenditures under the MiniFAB Agreement ("capex") as incurred and MiniFAB will pay for the remaining 35% of capex, which will be recoverable from TearLab through an amortized cost component in the price for the product charged to TearLab once the monthly card volumes reach 200,000 per month.

6000

5000

412000

679000

326000

191000

1324000

1214000

138000

91000

1987000

2832000

18000 20000

322000

110000

111000 111000 140000 91000

98000

22000

1000

2000

6922000

13000

846000

368000

1366000

9832000

317000

9077000

6643000

317000

13000

306000

368000

1430000

7808000

7451000

17000

1289000

945000

257000

262000

290000

278000

74000

45000

436000

537000

200

6000

3000

100

P0Y

P1Y

P0Y

12172000

271000

90000

12533000

12172000

271000

90000

-12172000

-269000

-90000

-12531000

-12172000

-269000

-90000

2000

1000

15000000

10000000

2020-12-31

0.13

0.085

0.045

35000

1253500

35000

477273

6818181

83240

477273

50.00

15.00

11.25

15.00

1.50

0.44

1.50

15.00

0.55

P5Y

0.0122

0.03

0.095

3000000 1000000 25000000 38000000 45000000 24000000

2033000

606000

0.05 0.01

24000000

8971000

111000

-129000

34764000

35004000

240000

2013636

3000000

596000

720000

1070000

0.85

1.10

0.10

P10Y

0.20

P5Y

P4Y6M

P5Y

P6Y

P2Y11M26D

P3Y5M23D

P5Y

P6M

P5Y

28601

2020-10-08

290000

54000

106000

44000

30000

0.73

0.76

0.94

0.90

0.88

1.586

0.88

0.0171

0.0106

0.0130

0.0170

0.0180

0.0214

0.0145

0.0214

0.00

0.44 Expire 5 years after the Initial Exercise Date Expire 5 years after the issuance date Expired 6 months after the issuance date

10000

50000

38000

16000

26000

80000

3000

8000

39000

72000

19000

20000

4000

8000

20000

44000

-5000

Expiring at various times through January 2021

Expiring in December 2021

Intangible assets subject to amortization consist of the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center">Remaining Useful Life</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Gross Value at</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Net Book Value at</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Years)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt; width: 20%">TearLab® technology</td><td style="width: 2%"> </td> <td style="width: 14%; text-align: center">0</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">12,172</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">   (12,172</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Patents and trademarks</td><td> </td> <td style="text-align: center">1</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">271</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(269</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">   2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Prescriber list</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">0</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">90</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(90</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,533</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(12,531</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Gross Value at</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Net Book Value at</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 38%; text-align: left; padding-left: 10pt">TearLab® technology</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right">12,172</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(12,172</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right">    -</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Patents and trademarks</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">271</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(269</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Prescriber list</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">90</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(90</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,533</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(12,531</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Use, Masters, and Flex Agreements   Purchase commitments for Use Agreements and Flex Agreements are expressed in the agreement for a specified period of time (generally one to three years). The purchase commitment for Masters Agreements is implied for large physician practices with an expectation of purchasing certain levels of test cards. The Company recovers the cost of providing the reader equipment in the amount charged for disposable test cards. Two performance obligations exist under these contracts, related to the customers’ right to use the reader equipment and orders of test cards. As the customer has the ability and right to operate the reader equipment in a manner it determines as well as obtain the output from using the reader equipment, the revenue related to the reader equipment use performance obligation is recognized in accordance with ASC 842 – Leases, wherein revenue related to the reader equipment is recognized over the defined contract term. Revenue related to disposable test cards is recognized as the disposable test cards are shipped. Based on the nature of these contracts, which provide terms for the future purchase of test cards but do not contractually obligate the customer to do so, each purchase of test cards is treated as its own distinct contract with a performance obligation to provide the test cards ordered, memorialized by the customers’ purchase order/request. Revenue under such agreements is allocated between the lease of the reader equipment and the sale of the disposables based upon each component’s relative standalone selling price, which is estimated using the selling prices of the reader device and test cards under Purchase Agreements, discussed further below.   When reader equipment is placed with a customer at no separate cost, the Company retains title to the equipment and it remains capitalized on the Company’s Consolidated Balance Sheet as equipment classified within fixed assets, net. The equipment is depreciated on a straight-line basis once shipped to a customer location over its estimated useful life and depreciation expense is included in cost of goods sold within the Condensed Consolidated Statements of Operations and Comprehensive Loss. Purchase Agreements   Revenue recognition for Purchase Agreements is based on the individual performance obligations determined to exist in the contract. Since the reader equipment and the test cards are separate and distinct delivered items, the delivery of each are considered separate performance obligations. The reader equipment and test cards are separately identified under the Purchase Agreements and are sold at their standalone selling price. The Company recognizes revenue for each of the performance obligations only when it determines that all applicable recognition criteria have been met, which is usually upon shipment to the customer. Under Purchase Agreements, the customer is not contractually obligated to purchase additional test cards, and each subsequent order of test cards represents a separate and distinct contract with the performance obligation to provide the test cards ordered.   Amounts billed to customers for shipping and handling of a sales transaction are included as revenue. The Company recognized revenue from shipping and handling of $36 and $38 for the three months ended June 30, 2019 and 2018, respectively. The Company recognized revenue from shipping and handling of $69 and $77 for the six months ended June 30, 2019 and 2018, respectively.   The following table presents our revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Six months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 37%; text-align: left">Product Sales</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,157</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,679</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">10,153</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">11,454</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Reader Equipment Rentals</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">694</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">734</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,381</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,405</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,851</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,413</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,534</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,859</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Leases   On January 1, 2019, the Company adopted the Financial Accounting Standards Board (‘FASB’) Accounting Standards Update (‘ASU’) 2016-02, Leases, which requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous guidance. The original guidance required application on a modified retrospective basis with the earliest period presented. In August 2018, the FASB issued ASU 2018-11, Targeted Improvements to ASC 842, which included an option to not restate comparative periods in transition and elect to use the effective date of ASC 842, Leases, as the date of initial application of transition, which the Company elected. Lease arrangements are determined at the inception of the contract with and included in right-of-use (“ROU”) assets and long-term lease liabilities on the consolidated balance sheets. The adoption of ASC 842 had an immaterial impact on our Condensed Consolidated Statement of Operations and Comprehensive Loss and Condensed Consolidated Statement of Cash Flows for the three and six month periods ended June 30, 2019. Additionally, the Company has elected the package practical expedient with respect to lease definition, classification and direct costs. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 month or less. Additional information and disclosures required by the new standard are contained in Note 8.

Recent accounting pronouncements   In June 2018, the FASB issued Accounting Standards Update (“ASU”) No. 2018-07, “Compensation – Stock Compensation (Topic 718).” ASU 2018-07 simplifies the accounting for nonemployee share-based payment transactions. This ASU is effective for public entities for interim and annual reporting periods beginning after December 15, 2018. The Company adopted ASU 2018-07 effective January 1, 2019 with an immaterial impact to our financial statements.

The following table presents our revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Six months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 37%; text-align: left">Product Sales</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,157</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,679</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">10,153</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">11,454</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Reader Equipment Rentals</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">694</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">734</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,381</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,405</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,851</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,413</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,534</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,859</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

7. NET INCOME (LOSS) PER SHARE   Basic earnings per share (“EPS”) excludes dilutive securities and is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding for the year. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted and the resulting additional shares are dilutive because their inclusion decreases the amount of EPS.   The following securities were not included in the calculation of diluted earnings per share because their effects were anti-dilutive:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-style: italic; border-bottom: Black 1.5pt solid">(in thousands of shares)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">879</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">599</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,702</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,702</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Convertible preferred shares</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">9,581</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">9,302</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

The components of lease costs were as follows:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Three months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Six months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 50%; text-align: left">Operating lease costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 21%; text-align: right">87</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 21%; text-align: right">175</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short-term lease costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Variable lease costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">87</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Future minimum lease payments under non-cancellable leases as of June 30, 2019 were as follows:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">2019</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">151</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2020</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">202</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">184</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">169</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">870</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: present value discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(195</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">675</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Weighted average remaining lease term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.8</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Weighted average discount rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">13</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr></table>

-195000

5. TERM LOAN   On March 4, 2015, the Company executed a term loan agreement (the “Term Loan Agreement”) with CRG LP and certain of its affiliate funds (“CRG”) as lenders providing the Company with access of up to $35,000 under the arrangement. The Company received $15,000 in gross proceeds under the arrangement on March 4, 2015, and an additional $10,000 on October 6, 2015. The Term Loan Agreement matures on December 31, 2020 and bears interest at 13% per annum, with quarterly payments of interest only for the first four years. While interest on the loan is accrued at 13% per annum, the Company may elect to make interest-only payments at 8.5% per annum. The unpaid interest of 4.5% is added to the principal of the loan and is subject to additional accrued interest (“PIK interest”). The accrued interest can be deferred and paid together with the principal in the fifth and sixth years.   As part of Amendment No. 2 to the Term Loan Agreement, and funding of the second tranche, CRG received 35,000 warrants dated as of October 6, 2015 to purchase common shares of the Company at a price of $50.00 per share (the “2015 CRG Warrants”). The 2015 CRG Warrants have a five-year life and are classified as equity on the Consolidated Balance Sheets as of June 30, 2019 and 2018. The 2015 CRG Warrants were valued at their issuance date using the Black-Scholes Merton model. The related reduction of the long-term debt will be amortized over the life of the debt. On April 7, 2016, the Company entered into Amendment No. 4 to the Term Loan Agreement and the company issued CRG additional warrants to purchase 35,000 common shares of the Company’s stock at $15.00 per share (the “2016 CRG Warrants” and together with the 2015 CRG Warrants, the “CRG Warrants”), which expire 5 years after issuance.   On October 12, 2017, the Company entered into Amendment No. 5 to the Term Loan Agreement. This amendment reduced the exercise price of all of the CRG Warrants from $15.00 per share to $1.50 per share and provided broad anti-dilution protection such that the CRG Warrants maintained the same 1.22% ownership following any capital raises the Company completed through March 31, 2018.   On April 4, 2018 with an effective date of March 31, 2018, the Company entered into Amendment No. 6 to the Term Loan Agreement. Pursuant to the terms of this amendment, the cash interest payments due in 2018 were deferred and added to the principal balance under the Loan Agreement at the end of each quarter. This amendment also provided for an additional facility fee equal to 3% of the sum of the aggregate amount of the principal drawn under the Term Loan Agreement and any PIK loans issued, so that the total facility fee shall be 9.5%, applicable to the entire balance (the “Facility Fee”). The Facility Fee is being accrued to interest expense using the effective interest method. In addition, this amendment reduced the minimum liquidity covenant to $3 million. Concurrent with the reduction of the liquidity covenant the Company agreed to repay CRG $1.0 million of principal on the Term Loan Agreement in April 2018. Lastly, this amendment reduced the strike price of the existing CRG Warrants to $0.44 per share (see Note 6). The Amendment was accounted for as a modification in accordance with U.S. GAAP.   On November 12, 2018 the Company entered into Amendment No. 7 to the Term Loan Agreement. Pursuant to the terms of the agreement, the Amendment extended the “Interest-Only Period” under the Term Loan Agreement from the sixteenth (16th) payment date to the twentieth (20th) payment date following the first borrowing date, which has the effect of pushing out the principal payments to 2020. In addition, the cash interest payments under the Term Loan Agreement for periods ending on March 31, 2019 and June 30, 2019 will be deferred and added to the principal balance under the Term Loan Agreement at the end of each such quarter. The Company evaluated the amendment and it was accounted for as a modification in accordance with GAAP, with no incremental expense incurred. Additionally, if the Federal Drug Administration (“FDA”) had received and accepted our application for review of our DiscoveryTM Platform on or before June 30, 2019 the Company would have been entitled to pay the interest on the outstanding principal amount of the loans under the Term Loan Agreement payable during the quarter ended September 30, 2019 entirely in the form of a PIK Loan. The Company did not file an updated 510K with the FDA prior to June 30, 2019 and expects it will be required to make an interest payment at the end of the third quarter of 2019. Finally, the Amendment reduced the minimum required revenue for 2018 under the Term Loan Agreement from $25 million to $24 million.   The loan is collateralized by all assets of the Company. Additionally, the terms of the Term Loan Agreement contain various affirmative and negative covenants agreed to by the Company. Among them, the Company must attain minimum certain annual revenue and minimum cash threshold levels. The minimum revenue is $38,000 for 2019 and $45,000 for 2020.   If the Company does not have annual revenue greater or equal to the annual revenue covenant in a calendar year, the Company will have the right within 90 days of the end of the respective calendar year to raise subordinated debt or equity (the “CRG Equity Cure”) equal to twice the difference between the annual revenue and the revenue covenant, with the total proceeds from this financing to be used to reduce the principal of the Term Loan Agreement. In the event of a default, the Company may be required to repay any outstanding amounts earlier than anticipated, and CRG may foreclose on their security interest in the Company’s assets.   At June 30, 2019, the Company was in compliance with all of the covenants.   The Company incurred financing and legal fees associated with the debt of $606, which were recorded as a direct discount to the debt and are being amortized using the effective interest method. The Company presents the debt issuance costs related to the recognized debt liability on the Consolidated Balance Sheet as a reduction of the liability.   The Term Loan Agreement provided for prepayment fees of 5% of the outstanding balance of the loan if the loan was repaid prior to March 31, 2016. The prepayment fee is reduced 1% per year for each subsequent year until maturity.   The following is a summary of the Term Loan Agreement as of June 30, 2019 and related maturities of outstanding principal:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Principal balance outstanding</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">24,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">PIK interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,971</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Facility fee</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,033</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">less discount on term loan:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">deferred financing fees, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(111</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">detachable warrants, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(129</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">34,764</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion of Term loan</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,486</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total Term Loan</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,278</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Principal due for each of the next two years:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2019</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 78%; text-align: left; padding-bottom: 1.5pt">2020</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 18%; border-bottom: Black 1.5pt solid; text-align: right">35,004</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Total principal due</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,004</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Less: discount on term loan</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(240</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total term loan</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34,764</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Yes Yes false

3000

700000

-905000

7272000

8473000

9173000

6367000

8473000

9173000

80000

-1000000

7289000

8116000

3793000

3689000

1870000

1978000

959000

995000

1881000

2038000

996000

1007000

3299000

3385000

1340000

1455000

7050000

7401000

3295000

3457000

239000

715000

498000

232000

-2755000

-2254000

-1149000

-1405000

3000

-5000

-10000

-1000

-2752000

-2259000

-1159000

-1406000

11800331

10070652

10609131

12041442

-0.21

-0.15

-0.06

-0.10

1000000

3971000 4190000 2355000 2041000 274000 553000 265000 121000 P15Y 55000 6000 6000 27000

4440909

EX-101.SCH 7 tear-20190630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Balance Sheet Details link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Term Loan link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Net Income (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Related Party link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Balance Sheet Details (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Term Loan (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Net Income (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Basis of Presentation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Significant Accounting Policies - Schedule of Disaggregated Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Balance Sheet Details (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Balance Sheet Details - Schedule of Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Balance Sheet Details - Schedule of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Balance Sheet Details - Summary of Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Balance Sheet Details - Schedule of Fixed Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Balance Sheet Details - Schedule of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Intangible Assets - Schedule of Amortization of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Intangible Assets - Schedule of Estimated Amortization Expense of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Term Loan (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Term Loan - Schedule of Term Loan (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Term Loan - Schedule of Maturities of Outstanding Principal of Term Loan (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Stockholders' Equity - Schedule of Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Net Income (Loss) Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Costs (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-cancellable Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Royalty Payments (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Related Party (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 tear-20190630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 tear-20190630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 tear-20190630_lab.xml XBRL LABEL FILE Type of Arrangement and Non-arrangement Transactions [Axis] 2002 Stock Incentive Plan [Member] Title of Individual [Axis] Employees, Directors and Consultants [Member] Award Type [Axis] Non-Statutory Stock Options [Member] Range [Axis] Maximum [Member] Extinguishment of Debt [Axis] Term Loan Agreement [Member] Related Party [Axis] CRG LP [Member] Minimum [Member] Employee Stock Purchase Plan 2014 [Member] Financial Instrument [Axis] Interest-Only Payment [Member] Officer Director Or Consultant [Member] Term Loan Agreement [Member] Vesting [Axis] Tranche One [Member] Class of Warrant or Right [Axis] CRG Warrants [Member] Award Date [Axis] September 30, 2019 [Member] Antidilutive Securities [Axis] Stock Option [Member] Warrants [Member] Supply Agreement [Member] Sale of Stock [Axis] MiniFAB [Member] Equity Components [Axis] CRG LP Additional Warrants [Member] Black-Scholes Merton Model [Member] Series A Warrants [Member] Convertible Preferred Shares [Member] Property, Plant and Equipment, Type [Axis] Capitalized TearLab Equipment [Member] Leasehold Improvements [Member] Computer Equipment and Software [Member] Furniture and Office Equipment [Member] Medical Equipment [Member] Finite-Lived Intangible Assets by Major Class [Axis] TearLab Technology [Member] Patents and Trademarks [Member] Prescriber List [Member] Income Statement Location [Axis] Sales and Marketing [Member] Clinical, Regulatory and Research and Development [Member] General and Administrative [Member] Series A Convertible Preferred Stock [Member] Series B Warrants [Member] Placement Agent Warrants [Member] Common Stock [Member] Restated License Agreement [Member] Legal Entity [Axis] i-Med Pharma, Inc. [Member] Unpaid Interest With Principal [Member] Product and Service [Axis] Product Sales [Member] Reader Equipment Rentals [Member] Series A Convertible Preferred Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Manufacturing Equipment [Member] MiniFAB Agreement [Member] Mini FAB [Member] TearLab [Member] Scenario [Axis] Phase 1 [Member] AUD [Member] Phase 2 [Member] Shipping and Handling [Member] Asset Class [Axis] Indefinite-lived Intangible Assets [Member] 2019 [Member] 2020 [Member] Debt Instrument [Axis] Class of Stock [Axis] Series A Preferred Stock [Member] Warrants [Member] Valuation Approach and Technique [Axis] Valuation Technique, Option Pricing Model [Member] Vehicle Leases [Member] Equipment Lease [Member] Adjustments for New Accounting Pronouncements [Axis] Adoption of ASC Topic 842 [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current assets Cash Accounts receivable, net Inventory Prepaid expenses and other current assets Total current assets Fixed assets, net Intangible assets, net Right of use assets Other non-current assets Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities Accounts payable Accrued liabilities Deferred revenue/rent Current portion of long-term debt Current portion of lease liability Total current liabilities Long-term debt, net of current portion Long-term lease liability, net of current portion Long-term third party payable Total liabilities Commitments and contingencies (Note 8) Stockholders' deficit Capital stock Preferred Stock, $0.001 par value, 10,000,000 shares authorized, 160 and 556 issued and outstanding at June 30, 2019 and December 31, 2018, respectively Common stock, $0.001 par value, 40,000,000 shares authorized, 12,196,998 and 11,296,998 issued and outstanding at June 30, 2019 and December 31, 2018, respectively Additional paid-in capital Accumulated deficit Total stockholders' deficit Total liabilities and stockholders' deficit Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Statement [Table] Statement [Line Items] Revenue Total revenue Cost of goods sold Cost of goods sold (excluding amortization of intangible assets) Cost of goods sold - reader equipment depreciation Gross profit Operating expenses Sales and marketing Clinical, regulatory and research & development General and administrative Total operating expenses Income from operations Other income (expense) Interest income Other, net Total other income (expense) Net loss and comprehensive loss Weighted average shares outstanding - basic and fully diluted Net loss per share Balance Balance, Shares Series A Convertible Preferred conversion to common Series A Convertible Preferred conversion to common, shares Stock-based compensation Common stock warrants issued Net loss and comprehensive loss Balance Balance, Shares Statement of Cash Flows [Abstract] OPERATING ACTIVITIES Net loss for the period Adjustments to reconcile net loss to cash used in operating activities: Stock-based compensation Depreciation of fixed assets Amortization of intangible assets Deferred interest on long-term debt Amortization of debt discount Loss on disposal of equipment Changes in operating assets and liabilities: Accounts receivable, net Inventory Prepaid expenses and other assets Other non-current assets Accounts payable Accrued liabilities Deferred rent/revenue Cash provided by operating activities EX-101.PRE 11 tear-20190630_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2019	Aug. 02, 2019
Document And Entity Information
Entity Registrant Name	TearLab Corp
Entity Central Index Key	0001299139
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		12,560,635
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current assets
Cash	$ 9,173	$ 8,473
Accounts receivable, net	1,123	1,186
Inventory	2,832	1,987
Prepaid expenses and other current assets	356	690
Total current assets	13,484	12,336
Fixed assets, net	1,626	2,024
Intangible assets, net	2	2
Right of use assets	677
Other non-current assets	150	151
Total assets	15,939	14,513
Current liabilities
Accounts payable	1,425	681
Accrued liabilities	2,084	2,363
Deferred revenue/rent	4	13
Current portion of long-term debt	16,486
Current portion of lease liability	182
Total current liabilities	20,181	3,057
Long-term debt, net of current portion	18,278	32,014
Long-term lease liability, net of current portion	493
Long-term third party payable	119	111
Total liabilities	39,071	35,182
Commitments and contingencies (Note 8)
Stockholders' deficit
Capital stock
Preferred Stock, $0.001 par value, 10,000,000 shares authorized, 160 and 556 issued and outstanding at June 30, 2019 and December 31, 2018, respectively
Common stock, $0.001 par value, 40,000,000 shares authorized, 12,196,998 and 11,296,998 issued and outstanding at June 30, 2019 and December 31, 2018, respectively	12	11
Additional paid-in capital	510,429	510,380
Accumulated deficit	(533,573)	(531,060)
Total stockholders' deficit	(23,132)	(20,669)
Total liabilities and stockholders' deficit	$ 15,939	$ 14,513

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	160	556
Preferred stock, shares outstanding	160	556
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	12,196,998	11,296,998
Common stock, shares outstanding	12,196,998	11,296,998

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue
Total revenue	$ 5,851	$ 6,413	$ 11,534	$ 12,859
Cost of goods sold
Cost of goods sold (excluding amortization of intangible assets)	2,041	2,355	3,971	4,190
Cost of goods sold - reader equipment depreciation	121	265	274	553
Gross profit	3,689	3,793	7,289	8,116
Operating expenses
Sales and marketing	995	959	1,870	1,978
Clinical, regulatory and research & development	1,007	996	1,881	2,038
General and administrative	1,455	1,340	3,299	3,385
Total operating expenses	3,457	3,295	7,050	7,401
Income from operations	232	498	239	715
Other income (expense)
Interest income	(1,405)	(1,149)	(2,755)	(2,254)
Other, net	(1)	(10)	3	(5)
Total other income (expense)	(1,406)	(1,159)	(2,752)	(2,259)
Net loss and comprehensive loss	$ (1,174)	$ (661)	$ (2,513)	$ (1,544)
Weighted average shares outstanding - basic and fully diluted	12,041,442	10,609,131	11,800,331	10,070,652
Net loss per share	$ (0.10)	$ (0.06)	$ (0.21)	$ (0.15)
Product Sales [Member]
Revenue
Total revenue	$ 5,157	$ 5,679	$ 10,153	$ 11,454
Reader Equipment Rentals [Member]
Revenue
Total revenue	$ 694	$ 734	$ 1,381	$ 1,405

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Series A Convertible Preferred Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017	$ 8		$ 510,235	$ (528,809)	$ (18,566)
Balance, Shares at Dec. 31, 2017	7,986,998	2,012
Series A Convertible Preferred conversion to common	$ 2		(2)
Series A Convertible Preferred conversion to common, shares	2,452,000	(1,078)
Stock-based compensation			8		8
Common stock warrants issued			(3)		(3)
Net loss and comprehensive loss				(883)	(883)
Balance at Mar. 31, 2018	$ 10		510,238	(529,692)	(19,444)
Balance, Shares at Mar. 31, 2018	10,438,998	934
Balance at Dec. 31, 2017	$ 8		510,235	(528,809)	(18,566)
Balance, Shares at Dec. 31, 2017	7,986,998	2,012
Net loss and comprehensive loss					(1,544)
Balance at Jun. 30, 2018	$ 11		510,310	(530,353)	(20,032)
Balance, Shares at Jun. 30, 2018	10,796,998	776
Balance at Mar. 31, 2018	$ 10		510,238	(529,692)	(19,444)
Balance, Shares at Mar. 31, 2018	10,438,998	934
Series A Convertible Preferred conversion to common	$ 1				1
Series A Convertible Preferred conversion to common, shares	358,000	(158)
Stock-based compensation			72		72
Net loss and comprehensive loss				(661)	(661)
Balance at Jun. 30, 2018	$ 11		510,310	(530,353)	(20,032)
Balance, Shares at Jun. 30, 2018	10,796,998	776
Balance at Dec. 31, 2018	$ 11		510,380	(531,060)	(20,669)
Balance, Shares at Dec. 31, 2018	11,296,998	556
Series A Convertible Preferred conversion to common	$ 1				1
Series A Convertible Preferred conversion to common, shares	400,000	(176)
Stock-based compensation			31		31
Net loss and comprehensive loss				(1,339)	(1,339)
Balance at Mar. 31, 2019	$ 12		510,411	(532,399)	(21,976)
Balance, Shares at Mar. 31, 2019	11,696,998	380
Balance at Dec. 31, 2018	$ 11		510,380	(531,060)	(20,669)
Balance, Shares at Dec. 31, 2018	11,296,998	556
Net loss and comprehensive loss					(2,513)
Balance at Jun. 30, 2019	$ 12		510,429	(533,573)	(23,132)
Balance, Shares at Jun. 30, 2019	12,196,998	160
Balance at Mar. 31, 2019	$ 12		510,411	(532,399)	(21,976)
Balance, Shares at Mar. 31, 2019	11,696,998	380
Series A Convertible Preferred conversion to common			(1)		(1)
Series A Convertible Preferred conversion to common, shares	500,000	(220)
Stock-based compensation			19		19
Net loss and comprehensive loss				(1,174)	(1,174)
Balance at Jun. 30, 2019	$ 12		$ 510,429	$ (533,573)	$ (23,132)
Balance, Shares at Jun. 30, 2019	12,196,998	160

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
OPERATING ACTIVITIES
Net loss for the period	$ (2,513)	$ (1,544)
Adjustments to reconcile net loss to cash used in operating activities:
Stock-based compensation	50	80
Depreciation of fixed assets	412	679
Amortization of intangible assets		6
Deferred interest on long-term debt	2,061	1,838
Amortization of debt discount	697	419
Loss on disposal of equipment	28	1
Changes in operating assets and liabilities:
Accounts receivable, net	63	263
Inventory	(845)	143
Prepaid expenses and other assets	335	243
Other non-current assets		(80)
Accounts payable	744	(1,261)
Accrued liabilities	(279)	(552)
Deferred rent/revenue	(11)	(21)
Cash provided by operating activities	742	214
INVESTING ACTIVITIES
Additions to fixed assets	(42)	(119)
Cash used in investing activities	(42)	(119)
FINANCING ACTIVITIES
Payment on term loan		(1,000)
Cash used in financing activities		(1,000)
Increase (decrease) in cash during the period	700	(905)
Cash, beginning of period	8,473	7,272
Cash, end of period	9,173	6,367
Supplemental cash flow information
Right-of-use assets acquired through operating leases	801
Cash paid for operating leases	$ 176

XML 18 R7.htm IDEA: XBRL DOCUMENT

Basis of Presentation

6 Months Ended

Jun. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

1. BASIS OF PRESENTATION

Nature of Operations

Liquidity and Going Concern

XML 19 R8.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Significant Accounting Policies

2. SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

Revenue Recognition

Use, Masters, and Flex Agreements

Purchase Agreements

The following table presents our revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues:

	Three months ended				Six months ended
	June 30,				June 30,
	2019		2018		2019		2018

Product Sales	$	5,157	$	5,679	$	10,153	$	11,454
Reader Equipment Rentals		694		734		1,381		1,405
	$	5,851	$	6,413	$	11,534	$	12,859

Arrangements with Multiple Performance Obligations

Return Reserve

Practical Expedients and Exemptions

We generally expense outside sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within sales and marketing expenses.

Leases

Recent accounting pronouncements

XML 20 R9.htm IDEA: XBRL DOCUMENT

Balance Sheet Details

6 Months Ended

Jun. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Balance Sheet Details

3. BALANCE SHEET DETAILS

Accounts receivable

	June 30, 2019			December 31, 2018

Trade receivables	$	1,214		$	1,324
Allowance for doubtful accounts		(91	)		(138	)
	$	1,123		$	1,186

Inventory

Inventory is recorded at the lower of cost and net realizable value on a first-in, first-out basis and consists of finished goods.

	June 30, 2019		December 31, 2018

Finished goods	$	2,832	$	1,987
Inventory reserves		-		-
	$	2,832	$	1,987

Prepaid expenses and other current assets

	June 30, 2019		December 31, 2018
Prepaid trade shows	$	20	$	18
Prepaid insurance		110		322
Manufacturing deposits		111		111
Subscriptions		91		140
Other fees and services		22		98
Other current assets		2		1
	$	356	$	690

Fixed assets

	June 30, 2019			December 31, 2018
Capitalized TearLab equipment	$	6,643		$	6,922
Manufacturing equipment		317			317
Leasehold improvements		13			13
Computer equipment and software		306			846
Furniture and office equipment		368			368
Medical equipment		1,430			1,366
	$	9,077		$	9,832
Less accumulated depreciation		(7,451	)		(7,808	)
	$	1,626		$	2,024

Accrued liabilities

	June 30, 2019		December 31, 2018
Due to professionals	$	17	$	17
Due to employees and directors		945		1,289
Sales and use tax liabilities		262		257
Royalty liability		278		290
Warranty		45		74
Other		537		436
	$	2,084	$	2,363

XML 21 R10.htm IDEA: XBRL DOCUMENT

Intangible Assets

6 Months Ended

Jun. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

4. INTANGIBLE ASSETS

Intangible assets subject to amortization consist of the following:

	Remaining Useful Life	Gross Value at		Accumulated			Net Book Value at
	(Years)	June 30, 2019		Amortization			June 30, 2019

TearLab® technology	0	$	12,172	$	(12,172	)	$	-
Patents and trademarks	1		271		(269	)		2
Prescriber list	0		90		(90	)		-
Total		$	12,533	$	(12,531	)	$	2

	Gross Value at		Accumulated			Net Book Value at
	December 31, 2018		Amortization			December 31, 2018

TearLab® technology	$	12,172	$	(12,172	)	$	-
Patents and trademarks		271		(269	)		2
Prescriber list		90		(90	)		-
Total	$	12,533	$	(12,531	)	$	2

The estimated amortization expense for the intangible assets for the remainder of 2019 and thereafter is as follows:

	Amortization
	of intangible
	assets

Remainder of 2019	$	1
Thereafter		1
	$	2

XML 22 R11.htm IDEA: XBRL DOCUMENT

Term Loan

6 Months Ended

Jun. 30, 2019

Debt Disclosure [Abstract]

Term Loan

5. TERM LOAN

At June 30, 2019, the Company was in compliance with all of the covenants.

The following is a summary of the Term Loan Agreement as of June 30, 2019 and related maturities of outstanding principal:

Principal balance outstanding	$	24,000
PIK interest		8,971
Facility fee		2,033
less discount on term loan:
deferred financing fees, net		(111	)
detachable warrants, net		(129	)
	$	34,764
Less: current portion of Term loan		(16,486	)
Total Term Loan	$	18,278

Principal due for each of the next two years:

2019	$	-
2020		35,004
Total principal due		35,004
Less: discount on term loan		(240	)
Total term loan	$	34,764

XML 23 R12.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

6 Months Ended

Jun. 30, 2019

Equity [Abstract]

Stockholders' Equity

6. STOCKHOLDERS’ EQUITY

(a) Authorized share capital

(b) Common and preferred shares

As of June 30, 2019, 1,954 shares of Series A Preferred Stock have been converted into 4,440,909 shares of common stock.

(c) Stock Incentive Plan

	Three months ended					Six months ended
	June 30,					June 30,
	2019			2018		2019		2018

Sales and marketing	$	(5	)	$	20	$	3	$	38
Clinical, regulatory and research and development		4			8		8		16
General and administrative		20			44		39		26
Stock-based compensation expense before income taxes	$	19		$	72	$	50	$	80

(d) Employee Stock Purchase Plan

(e) Warrants

XML 24 R13.htm IDEA: XBRL DOCUMENT

Net Income (Loss) Per Share

6 Months Ended

Jun. 30, 2019

Earnings Per Share [Abstract]

Net Income (Loss) Per Share

7. NET INCOME (LOSS) PER SHARE

The following securities were not included in the calculation of diluted earnings per share because their effects were anti-dilutive:

(in thousands of shares)	As of June 30,
	2019		2018
Stock options		879		599
Warrants		8,702		8,702
Convertible preferred shares		-		1

Total		9,581		9,302

XML 25 R14.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Jun. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

8. COMMITMENTS AND CONTINGENCIES

Leases

The adoption of ASC Topic 842 resulted in the Company recognizing right of use assets of $738 and a lease liability of $739, with the difference due the write-off of prior recorded deferred rent.

The components of lease costs were as follows:

	Three months ended		Six months ended
	June 30, 2019		June 30, 2019
Operating lease costs	$	87	$	175
Short-term lease costs		-		-
Variable lease costs		-		-
	$	87	$	175

Future minimum lease payments under non-cancellable leases as of June 30, 2019 were as follows:

2019	$	151
2020		202
2021		184
2022		164
2023		169
Total lease payments		870
Less: present value discount		(195	)
Present value of lease liabilities	$	675
Weighted average remaining lease term		3.8
Weighted average discount rate		13	%

Commitments

Future minimum royalty payments under this agreement as of June 30, 2019 are as follows:

2020		35
2021		35
2022		35
2023		35
2024		35
Thereafter		210
Total	$	385

Contingencies

XML 26 R15.htm IDEA: XBRL DOCUMENT

Related Party

6 Months Ended

Jun. 30, 2019

Related Party

9. RELATED PARTY

XML 27 R16.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Use of Estimates

Use of Estimates

Revenue Recognition

Revenue Recognition

Use, Masters, and Flex Agreements

Use, Masters, and Flex Agreements

Purchase Agreements

Purchase Agreements

The following table presents our revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues:

	Three months ended				Six months ended
	June 30,				June 30,
	2019		2018		2019		2018

Product Sales	$	5,157	$	5,679	$	10,153	$	11,454
Reader Equipment Rentals		694		734		1,381		1,405
	$	5,851	$	6,413	$	11,534	$	12,859

Arrangements with Multiple Performance Obligations

Arrangements with Multiple Performance Obligations

Return Reserve

Return Reserve

Practical Expedients and Exemptions

Practical Expedients and Exemptions

We generally expense outside sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within sales and marketing expenses.

Leases

Leases

Recent Accounting Pronouncements

Recent accounting pronouncements

XML 28 R17.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Schedule of Disaggregated Revenues

The following table presents our revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues:

	Three months ended				Six months ended
	June 30,				June 30,
	2019		2018		2019		2018

Product Sales	$	5,157	$	5,679	$	10,153	$	11,454
Reader Equipment Rentals		694		734		1,381		1,405
	$	5,851	$	6,413	$	11,534	$	12,859

XML 29 R18.htm IDEA: XBRL DOCUMENT

Balance Sheet Details (Tables)

6 Months Ended

Jun. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Accounts Receivable

Accounts receivable

	June 30, 2019			December 31, 2018

Trade receivables	$	1,214		$	1,324
Allowance for doubtful accounts		(91	)		(138	)
	$	1,123		$	1,186

Schedule of Inventory

Inventory

	June 30, 2019		December 31, 2018

Finished goods	$	2,832	$	1,987
Inventory reserves		-		-
	$	2,832	$	1,987

Summary of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets

	June 30, 2019		December 31, 2018
Prepaid trade shows	$	20	$	18
Prepaid insurance		110		322
Manufacturing deposits		111		111
Subscriptions		91		140
Other fees and services		22		98
Other current assets		2		1
	$	356	$	690

Schedule of Fixed Assets

Fixed assets

	June 30, 2019			December 31, 2018
Capitalized TearLab equipment	$	6,643		$	6,922
Manufacturing equipment		317			317
Leasehold improvements		13			13
Computer equipment and software		306			846
Furniture and office equipment		368			368
Medical equipment		1,430			1,366
	$	9,077		$	9,832
Less accumulated depreciation		(7,451	)		(7,808	)
	$	1,626		$	2,024

Schedule of Accrued Liabilities

Accrued liabilities

	June 30, 2019		December 31, 2018
Due to professionals	$	17	$	17
Due to employees and directors		945		1,289
Sales and use tax liabilities		262		257
Royalty liability		278		290
Warranty		45		74
Other		537		436
	$	2,084	$	2,363

XML 30 R19.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Amortization of Intangible Assets

Intangible assets subject to amortization consist of the following:

	Remaining Useful Life	Gross Value at		Accumulated			Net Book Value at
	(Years)	June 30, 2019		Amortization			June 30, 2019

TearLab® technology	0	$	12,172	$	(12,172	)	$	-
Patents and trademarks	1		271		(269	)		2
Prescriber list	0		90		(90	)		-
Total		$	12,533	$	(12,531	)	$	2

	Gross Value at		Accumulated			Net Book Value at
	December 31, 2018		Amortization			December 31, 2018

TearLab® technology	$	12,172	$	(12,172	)	$	-
Patents and trademarks		271		(269	)		2
Prescriber list		90		(90	)		-
Total	$	12,533	$	(12,531	)	$	2

Schedule of Estimated Amortization Expense of Intangible Assets

The estimated amortization expense for the intangible assets for the remainder of 2019 and thereafter is as follows:

	Amortization
	of intangible
	assets

Remainder of 2019	$	1
Thereafter		1
	$	2

XML 31 R20.htm IDEA: XBRL DOCUMENT

Term Loan (Tables)

6 Months Ended

Jun. 30, 2019

Debt Disclosure [Abstract]

Schedule of Term Loan

The following is a summary of the Term Loan Agreement as of June 30, 2019 and related maturities of outstanding principal:

Principal balance outstanding	$	24,000
PIK interest		8,971
Facility fee		2,033
less discount on term loan:
deferred financing fees, net		(111	)
detachable warrants, net		(129	)
	$	34,764
Less: current portion of Term loan		(16,486	)
Total Term Loan	$	18,278

Schedule of Maturities of Outstanding Principal of Term Loan

Principal due for each of the next two years:

2019	$	-
2020		35,004
Total principal due		35,004
Less: discount on term loan		(240	)
Total term loan	$	34,764

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

XML 32 R21.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2019

Equity [Abstract]

Schedule of Stock-Based Compensation Expense

	Three months ended					Six months ended
	June 30,					June 30,
	2019			2018		2019		2018

Sales and marketing	$	(5	)	$	20	$	3	$	38
Clinical, regulatory and research and development		4			8		8		16
General and administrative		20			44		39		26
Stock-based compensation expense before income taxes	$	19		$	72	$	50	$	80

XML 33 R22.htm IDEA: XBRL DOCUMENT

Net Income (Loss) Per Share (Tables)

6 Months Ended

Jun. 30, 2019

Earnings Per Share [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following securities were not included in the calculation of diluted earnings per share because their effects were anti-dilutive:

(in thousands of shares)	As of June 30,
	2019		2018
Stock options		879		599
Warrants		8,702		8,702
Convertible preferred shares		-		1

Total		9,581		9,302

XML 34 R23.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

6 Months Ended

Jun. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

Schedule of Components of Lease Costs

The components of lease costs were as follows:

	Three months ended		Six months ended
	June 30, 2019		June 30, 2019
Operating lease costs	$	87	$	175
Short-term lease costs		-		-
Variable lease costs		-		-
	$	87	$	175

Schedule of Future Minimum Lease Payments Under Non-cancellable Leases

Future minimum lease payments under non-cancellable leases as of June 30, 2019 were as follows:

2019	$	151
2020		202
2021		184
2022		164
2023		169
Total lease payments		870
Less: present value discount		(195	)
Present value of lease liabilities	$	675
Weighted average remaining lease term		3.8
Weighted average discount rate		13	%

Schedule of Future Minimum Royalty Payments

Future minimum royalty payments under this agreement as of June 30, 2019 are as follows:

2020		35
2021		35
2022		35
2023		35
2024		35
Thereafter		210
Total	$	385

XML 35 R24.htm IDEA: XBRL DOCUMENT

Basis of Presentation (Details Narrative) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net income (loss)	$ 1,174	$ 1,339	$ 661	$ 883	$ 2,513	$ 1,544

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 36 R25.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Allowances for returns or rebates and reports revenue net	$ 27	$ 6	$ 55	$ 6
Revenue recognized	5,851	6,413	11,534	12,859
Reserve of product sales	5		5		$ 6
Shipping and Handling [Member]
Revenue recognized	$ 36	$ 38	$ 69	$ 77

XML 37 R26.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Schedule of Disaggregated Revenues (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Total revenue	$ 5,851	$ 6,413	$ 11,534	$ 12,859
Product Sales [Member]
Total revenue	5,157	5,679	10,153	11,454
Reader Equipment Rentals [Member]
Total revenue	$ 694	$ 734	$ 1,381	$ 1,405

XML 38 R27.htm IDEA: XBRL DOCUMENT

Balance Sheet Details (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Depreciation expense	$ 191	$ 326	$ 412	$ 679

XML 39 R28.htm IDEA: XBRL DOCUMENT

Balance Sheet Details - Schedule of Accounts Receivable (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Trade receivables	$ 1,214	$ 1,324
Allowance for doubtful accounts	(91)	(138)
Accounts receivable net	$ 1,123	$ 1,186

XML 40 R29.htm IDEA: XBRL DOCUMENT

Balance Sheet Details - Schedule of Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Finished goods	$ 2,832	$ 1,987
Inventory reserves
Inventory net	$ 2,832	$ 1,987

XML 41 R30.htm IDEA: XBRL DOCUMENT

Balance Sheet Details - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prepaid trade shows	$ 20	$ 18
Prepaid insurance	110	322
Manufacturing deposits	111	111
Subscriptions	91	140
Other fees and services	22	98
Other current assets	2	1
Prepaid expense and other current assets	$ 356	$ 690

XML 42 R31.htm IDEA: XBRL DOCUMENT

Balance Sheet Details - Schedule of Fixed Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Property plant and equipment, gross	$ 9,077	$ 9,832
Less accumulated depreciation	(7,451)	(7,808)
Property plant and equipment net	1,626	2,024
Capitalized TearLab Equipment [Member]
Property plant and equipment, gross	6,643	6,922
Manufacturing Equipment [Member]
Property plant and equipment, gross	317	317
Leasehold Improvements [Member]
Property plant and equipment, gross	13	13
Computer Equipment and Software [Member]
Property plant and equipment, gross	306	846
Furniture and Office Equipment [Member]
Property plant and equipment, gross	368	368
Medical Equipment [Member]
Property plant and equipment, gross	$ 1,430	$ 1,366

XML 43 R32.htm IDEA: XBRL DOCUMENT

Balance Sheet Details - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Due to professionals	$ 17	$ 17
Due to employees and directors	945	1,289
Sales and use tax liabilities	262	257
Royalty liability	278	290
Warranty	45	74
Other	537	436
Accrued liabilities current	$ 2,084	$ 2,363

XML 44 R33.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
Intangible Assets (Details Narrative) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 100	$ 3,000	$ 200	$ 6,000

XML 45 R34.htm IDEA: XBRL DOCUMENT

Intangible Assets - Schedule of Amortization of Intangible Assets (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Gross Value	$ 12,533	$ 12,533
Accumulated Amortization	(12,531)	(12,531)
Net Book Value	$ 2	2
TearLab Technology [Member]
Remaining Useful Life (Years)	0 years
Gross Value	$ 12,172	12,172
Accumulated Amortization	(12,172)	(12,172)
Net Book Value
Patents and Trademarks [Member]
Remaining Useful Life (Years)	1 year
Gross Value	$ 271	271
Accumulated Amortization	(269)	(269)
Net Book Value	$ 2	2
Prescriber List [Member]
Remaining Useful Life (Years)	0 years
Gross Value	$ 90	90
Accumulated Amortization	(90)	(90)
Net Book Value

XML 46 R35.htm IDEA: XBRL DOCUMENT

Intangible Assets - Schedule of Estimated Amortization Expense of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Total	$ 2	$ 2
Indefinite-lived Intangible Assets [Member]
Remainder of 2019	1
Thereafter	1
Total	$ 2

XML 47 R36.htm IDEA: XBRL DOCUMENT

Term Loan (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands				6 Months Ended
	Apr. 04, 2018	Oct. 06, 2015	Mar. 04, 2015	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Oct. 12, 2017	Jun. 30, 2016	Apr. 07, 2016	Oct. 08, 2015
Long-term debt				$ 18,278	$ 32,014
Financing and legal fees to long-term debt				2,033
Term Loan Agreement [Member] \| 2019 [Member]
Term loan minimum annual revenue threshold				38,000
Term Loan Agreement [Member] \| 2020 [Member]
Term loan minimum annual revenue threshold				$ 45,000
CRG Warrants [Member]
Warrants to purchase common shares									35,000	35,000
Warrants exercise price									$ 15.00	$ 50.00
Warrants term				5 years		5 years
Term Loan Agreement [Member] \| CRG LP Additional Warrants [Member]
Warrants to purchase common shares									35,000
Warrants exercise price							$ 1.50		$ 15.00
Warrants term									5 years
Ownership percentage							1.22%
CRG LP [Member] \| Term Loan Agreement [Member]
Additional facility fee percentage on principal	3.00%
Facility fee percentage on principal	9.50%
Minimum liquidity covenant amount	$ 3,000
Payment of liquidity covenant	$ 1,000
CRG LP [Member] \| CRG Warrants [Member] \| Term Loan Agreement [Member]
Warrants exercise price	$ 0.44
Term Loan Agreement [Member] \| CRG LP [Member]
Long-term debt			$ 35,000
Proceeds from issuance of long-term debt		$ 10,000	$ 15,000
Debt instrument date			Dec. 31, 2020
Debt instrument interest rate percentage			13.00%
Warrants to purchase common shares		35,000
Warrants exercise price		$ 50.00
Ownership percentage							1.22%
Financing and legal fees to long-term debt				$ 606
Percentage of prepayment fee								5.00%
Percentage of reduction in annual prepayment fee								1.00%
Term Loan Agreement [Member] \| CRG LP [Member] \| September 30, 2019 [Member]
Term loan minimum annual revenue threshold				25,000
Term loan minimum reduced annual revenue threshold				$ 24,000
Term Loan Agreement [Member] \| CRG LP [Member] \| Maximum [Member]
Warrants exercise price							$ 15.00
Term Loan Agreement [Member] \| CRG LP [Member] \| Minimum [Member]
Warrants exercise price							$ 1.50
Term Loan Agreement [Member] \| CRG LP [Member] \| Interest-Only Payment [Member]
Debt instrument interest rate percentage			8.50%
Term Loan Agreement [Member] \| CRG LP [Member] \| Unpaid Interest With Principal [Member]
Debt instrument interest rate percentage			4.50%

XML 48 R37.htm IDEA: XBRL DOCUMENT

Term Loan - Schedule of Term Loan (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
Principal balance outstanding	$ 24,000
PIK interest	8,971
Facility fee	2,033
Less discount on term loan: deferred financing fees, net	(111)
Less discount on term loan: detachable warrants, net	(129)
Term Loan	34,764
Less, current portion of Term loan	(16,486)
Total Term Loan	$ 18,278	$ 32,014

XML 49 R38.htm IDEA: XBRL DOCUMENT

Term Loan - Schedule of Maturities of Outstanding Principal of Term Loan (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Total principal due	$ 34,764
Total term loan	18,278	$ 32,014
Term Loan Agreement [Member]
2019
2020	35,004
Total principal due	35,004
Less: discount on term loan	(240)
Total term loan	$ 34,764

XML 50 R39.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands								3 Months Ended				6 Months Ended		12 Months Ended
	Apr. 04, 2018	Dec. 08, 2017	Oct. 12, 2017	Jun. 23, 2017	May 09, 2016	Apr. 07, 2016	Oct. 08, 2015	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Common stock shares authorized			9,500,000					40,000,000				40,000,000		40,000,000
Common stock par value			$ 0.001					$ 0.001				$ 0.001		$ 0.001
Preferred stock shares authorized			10,000,000					10,000,000				10,000,000		10,000,000
Preferred stock par value			$ 0.001					$ 0.001				$ 0.001		$ 0.001
Stock issued during period, shares new issue		2,013,636
Preferred stock, issued								160				160		556
2002 Stock Incentive Plan [Member]
Share-based compensation common stock purchase price percentage												10.00%
Share-based compensation expiration period												10 years
Expected weighted-average period												5 years
2002 Stock Incentive Plan [Member] \| Maximum [Member]
Share-based compensation common stock purchase price percentage				110.00%
2002 Stock Incentive Plan [Member] \| Maximum [Member] \| Officer Director Or Consultant [Member]
Percentage of options exercisable at a rate														20.00%
2002 Stock Incentive Plan [Member] \| Maximum [Member] \| Non-Statutory Stock Options [Member]
Share-based compensation common stock purchase price percentage				85.00%
2002 Stock Incentive Plan [Member] \| Minimum [Member]
Share-based compensation common stock purchase price percentage				10.00%
2002 Stock Incentive Plan [Member] \| Employees, Directors and Consultants [Member]
Share-based compensation number of shares reserved for issuance				720,000
2002 Stock Incentive Plan [Member] \| Employees, Directors and Consultants [Member] \| Maximum [Member]
Share-based compensation number of shares reserved for issuance				1,070,000
Employee Stock Purchase Plan 2014 [Member]
Common stock capital shares reserved for future issuance								28,601				28,601
Term Loan Agreement [Member] \| Tranche One [Member]
Proceeds from issuance of long-term debt							$ 10,000
Common Stock [Member]
Number of shares converted								500,000	400,000	358,000	2,452,000
Number of shares converted into common stock												4,440,909
Series A Preferred Stock [Member]
Number of shares converted												1,954
Series A Convertible Preferred Stock [Member]
Preferred stock, issued		2,114
Series A Warrants [Member]
Preferred stock, issued		6,818,181
Series A Warrants [Member] \| Black-Scholes Merton Model [Member]
Class of warrant or right number of securities called by warrants or rights		6,818,181			1,253,500
Expected weighted-average period		5 years			6 years
Class of warrant or right exercise price of warrants or rights		$ 0.44			$ 11.25
Fair value assumptions, volatility percentage		88.00%			76.00%
Fair value assumptions, risk-free interest rate		2.14%			1.30%
Fair value assumptions, dividend yield		0.00%			0.00%
Warrant expiration date, description		Expire 5 years after the issuance date			Expire 5 years after the Initial Exercise Date
Series B Warrants [Member]
Preferred stock, issued		6,818,181
Proceeds from issuance or sale of equity		$ 3,000
Payments of stock issuance costs		$ 596
Series B Warrants [Member] \| Black-Scholes Merton Model [Member]
Class of warrant or right number of securities called by warrants or rights		6,818,181
Expected weighted-average period		6 months
Class of warrant or right exercise price of warrants or rights		$ 0.44
Fair value assumptions, volatility percentage		158.60%
Fair value assumptions, risk-free interest rate		1.45%
Fair value assumptions, dividend yield		0.00%
Warrant expiration date, description		Expired 6 months after the issuance date
Placement Agent Warrants [Member]
Class of warrant or right number of securities called by warrants or rights		477,273
Common Stock [Member]
Number of shares converted		4,804,545
CRG Warrants [Member]
Class of warrant or right number of securities called by warrants or rights						35,000	35,000
Expected weighted-average period							5 years
Class of warrant or right exercise price of warrants or rights						$ 15.00	$ 50.00
Warrants exercisable date							Oct. 08, 2020
Fair value of warrants							$ 290
Fair value assumptions, volatility percentage							73.00%
Fair value assumptions, risk-free interest rate							1.71%
Fair value assumptions, dividend yield							0.00%
Proceeds from warrant exercise
CRG Warrants [Member] \| Black-Scholes Merton Model [Member]
Class of warrant or right number of securities called by warrants or rights															83,240
Expected weighted-average period												5 years		5 years
Class of warrant or right exercise price of warrants or rights															$ 1.50
Fair value of warrants												$ 30		$ 30
Fair value assumptions, volatility percentage												88.00%		88.00%
Fair value assumptions, risk-free interest rate												2.14%		2.14%
Fair value assumptions, dividend yield												0.00%		0.00%
CRG Warrants [Member] \| Term Loan Agreement [Member]
Reduced warrants per share	$ 0.44
Interest expense	$ 10
CRG Warrants [Member] \| Term Loan Agreement [Member] \| Black-Scholes Merton Model [Member]
Expected weighted-average period			3 years 5 months 23 days			5 years
Fair value of warrants						$ 106
Fair value assumptions, volatility percentage			90.00%			76.00%
Fair value assumptions, risk-free interest rate			1.80%			1.30%
Fair value assumptions, dividend yield			0.00%			0.00%
CRG LP Additional Warrants [Member] \| Term Loan Agreement [Member]
Class of warrant or right number of securities called by warrants or rights						35,000
Class of warrant or right exercise price of warrants or rights			$ 1.50			$ 15.00
Ownership percentage			1.22%
CRG LP Additional Warrants [Member] \| Term Loan Agreement [Member] \| Black-Scholes Merton Model [Member]
Expected weighted-average period			2 years 11 months 26 days			4 years 6 months
Fair value of warrants			$ 44			$ 54
Fair value assumptions, volatility percentage			94.00%			76.00%
Fair value assumptions, risk-free interest rate			1.70%			1.06%
Fair value assumptions, dividend yield			0.00%			0.00%
Warrants [Member] \| Black-Scholes Merton Model [Member]
Class of warrant or right number of securities called by warrants or rights								477,273				477,273
Class of warrant or right exercise price of warrants or rights								$ 0.55				$ 0.55
Warrants [Member] \| Black-Scholes Merton Model [Member] \| Valuation Technique, Option Pricing Model [Member]
Expected weighted-average period												5 years

XML 51 R40.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Stock-based compensation expense before income taxes	$ 19	$ 72	$ 50	$ 80
Sales and Marketing [Member]
Stock-based compensation expense before income taxes	(5)	20	3	38
Clinical, Regulatory and Research and Development [Member]
Stock-based compensation expense before income taxes	4	8	8	16
General and Administrative [Member]
Stock-based compensation expense before income taxes	$ 20	$ 44	$ 39	$ 26

XML 52 R41.htm IDEA: XBRL DOCUMENT

Net Income (Loss) Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Antidilutive securities number of shares	9,581,000	9,302,000
Stock Option [Member]
Antidilutive securities number of shares	879,000	599,000
Warrants [Member]
Antidilutive securities number of shares	8,702,000	8,702,000
Convertible Preferred Shares [Member]
Antidilutive securities number of shares		1,000

XML 53 R42.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative) $ in Thousands, $ in Thousands						1 Months Ended			6 Months Ended
	Aug. 09, 2019 AUD ($)	Aug. 09, 2018	May 01, 2018	Mar. 07, 2016	Oct. 01, 2006 USD ($)	Dec. 31, 2018 USD ($)	Apr. 30, 2018 USD ($)	Feb. 28, 2018 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)
Operating lease term description									The Company has commitments relating to operating leases recognized on a straight-line basis over the term of the lease for rental of two office spaces and various equipment from unrelated parties. Our California office lease was signed May 1, 2018, with a commencement date of July 1, 2018, expires on November 30, 2023 and has an option for a 5-year extension and escalating payments. On December 21, 2018 the Company entered into a fourth amendment to our Texas office lease to extend the term of the lease until December 31, 2019
Right of use asset									$ 677
Lease liabilities									675
Royalty payments					$ 35				77	$ 178
Maximum royalty payable on sale of combined products					5.50%
Initial capex investment						$ 317
Amortization Period						15 years
Long-term third-party payable						$ 111			119
i-Med Pharma, Inc. [Member]
Loss contingency damages paid							$ 200	$ 500
Restated License Agreement [Member]
Royalty payment, percentage			20.00%
Revenue milestone payments									$ 500
Revenue milestone payment percentage									1.25%
Restated License Agreement [Member] \| Minimum [Member]
Royalty payment, percentage			3.00%						3.50%
Restated License Agreement [Member] \| Maximum [Member]
Royalty payment, percentage			4.25%						4.75%
Supply Agreement [Member] \| MiniFAB [Member]
Minimum percentage of purchase				50.00%
Supply Agreement Pricing description				The amendment fixes the price of the osmolarity test cards at their current price until the earlier of: the average monthly order volume of osmolarity cards on a rolling six month average falls below 20,000 cards; or the aggregate product volume in the calendar year commencing 12 months after the launch of the DiscoveryTM product is below 2.4 million cards; or the aggregate product volume in any calendar year after 24 months after the launch of the DiscoveryTM product is below 3.0 million cards at which point the Company and MiniFab will renegotiate pricing.
MiniFAB Agreement [Member]
Initial agreement term		10 years
Additional agreement term		5 years
MiniFAB Agreement [Member] \| Phase 1 [Member] \| AUD [Member]
Capital expenditure limitation	$ 1,000
Payment or reimbursement of non-recurrent expenditure and tooling	1,200
MiniFAB Agreement [Member] \| Phase 2 [Member] \| AUD [Member]
Capital expenditure limitation	3,000
Payment or reimbursement of non-recurrent expenditure and tooling	$ 2,000
MiniFAB Agreement [Member] \| TearLab [Member]
Percentage of capital expenditures payable		65.00%
Terms of capital expenditure recovery		TearLab will pay for 65% of the capital expenditures under the MiniFAB Agreement ("capex") as incurred and MiniFAB will pay for the remaining 35% of capex, which will be recoverable from TearLab through an amortized cost component in the price for the product charged to TearLab once the monthly card volumes reach 200,000 per month.
MiniFAB Agreement [Member] \| MiniFAB [Member]
Percentage of capital expenditures payable	35.00%
Adoption of ASC Topic 842 [Member]
Right of use asset									$ 738
Lease liabilities									$ 739
Vehicle Leases [Member]
Operating lease term description									Expiring at various times through January 2021
Equipment Lease [Member]
Operating lease term description									Expiring in December 2021

XML 54 R43.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Schedule of Components of Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Operating lease costs	$ 87	$ 175
Short-term lease costs
Variable lease costs
Lease costs	$ 87	$ 175

XML 55 R44.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-cancellable Leases (Details) $ in Thousands	Jun. 30, 2019 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2019	$ 151
2020	202
2021	184
2022	164
2023	169
Total lease payments	870
Less present value discount	(195)
Present value of lease liabilities	$ 675
Weighted average remaining lease term	3 years 9 months 18 days
Weighted average discount rate	13.00%

XML 56 R45.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Schedule of Future Minimum Royalty Payments (Details) $ in Thousands	Jun. 30, 2019 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2020	$ 35
2021	35
2022	35
2023	35
2024	35
Thereafter	210
Total	$ 385

XML 57 R46.htm IDEA: XBRL DOCUMENT

Related Party (Details Narrative) - USD ($) $ in Thousands		6 Months Ended
Related Party (Details Narrative) - USD ($) $ in Thousands	Oct. 01, 2006	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Related Party Transactions [Abstract]
Royalty rate		0.68%
Royalty expense	$ 35	$ 77	$ 178
Accrued royalties		$ 77		$ 40

EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 186 320 1 false 64 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://tearlab.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://tearlab.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://tearlab.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://tearlab.com/role/StatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) Sheet http://tearlab.com/role/StatementsOfStockholdersDeficit Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://tearlab.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Basis of Presentation Sheet http://tearlab.com/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Significant Accounting Policies Sheet http://tearlab.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Balance Sheet Details Sheet http://tearlab.com/role/BalanceSheetDetails Balance Sheet Details Notes 9 false false R10.htm 00000010 - Disclosure - Intangible Assets Sheet http://tearlab.com/role/IntangibleAssets Intangible Assets Notes 10 false false R11.htm 00000011 - Disclosure - Term Loan Sheet http://tearlab.com/role/TermLoan Term Loan Notes 11 false false R12.htm 00000012 - Disclosure - Stockholders' Equity Sheet http://tearlab.com/role/StockholdersEquity Stockholders' Equity Notes 12 false false R13.htm 00000013 - Disclosure - Net Income (Loss) Per Share Sheet http://tearlab.com/role/NetIncomeLossPerShare Net Income (Loss) Per Share Notes 13 false false R14.htm 00000014 - Disclosure - Commitments and Contingencies Sheet http://tearlab.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 00000015 - Disclosure - Related Party Sheet http://tearlab.com/role/RelatedParty Related Party Notes 15 false false R16.htm 00000016 - Disclosure - Significant Accounting Policies (Policies) Sheet http://tearlab.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://tearlab.com/role/SignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Significant Accounting Policies (Tables) Sheet http://tearlab.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://tearlab.com/role/SignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Balance Sheet Details (Tables) Sheet http://tearlab.com/role/BalanceSheetDetailsTables Balance Sheet Details (Tables) Tables http://tearlab.com/role/BalanceSheetDetails 18 false false R19.htm 00000019 - Disclosure - Intangible Assets (Tables) Sheet http://tearlab.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://tearlab.com/role/IntangibleAssets 19 false false R20.htm 00000020 - Disclosure - Term Loan (Tables) Sheet http://tearlab.com/role/TermLoanTables Term Loan (Tables) Tables http://tearlab.com/role/TermLoan 20 false false R21.htm 00000021 - Disclosure - Stockholders' Equity (Tables) Sheet http://tearlab.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://tearlab.com/role/StockholdersEquity 21 false false R22.htm 00000022 - Disclosure - Net Income (Loss) Per Share (Tables) Sheet http://tearlab.com/role/NetIncomeLossPerShareTables Net Income (Loss) Per Share (Tables) Tables http://tearlab.com/role/NetIncomeLossPerShare 22 false false R23.htm 00000023 - Disclosure - Commitments and Contingencies (Tables) Sheet http://tearlab.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://tearlab.com/role/CommitmentsAndContingencies 23 false false R24.htm 00000024 - Disclosure - Basis of Presentation (Details Narrative) Sheet http://tearlab.com/role/BasisOfPresentationDetailsNarrative Basis of Presentation (Details Narrative) Details http://tearlab.com/role/BasisOfPresentation 24 false false R25.htm 00000025 - Disclosure - Significant Accounting Policies (Details Narrative) Sheet http://tearlab.com/role/SignificantAccountingPoliciesDetailsNarrative Significant Accounting Policies (Details Narrative) Details http://tearlab.com/role/SignificantAccountingPoliciesTables 25 false false R26.htm 00000026 - Disclosure - Significant Accounting Policies - Schedule of Disaggregated Revenues (Details) Sheet http://tearlab.com/role/SignificantAccountingPolicies-ScheduleOfDisaggregatedRevenuesDetails Significant Accounting Policies - Schedule of Disaggregated Revenues (Details) Details 26 false false R27.htm 00000027 - Disclosure - Balance Sheet Details (Details Narrative) Sheet http://tearlab.com/role/BalanceSheetDetailsDetailsNarrative Balance Sheet Details (Details Narrative) Details http://tearlab.com/role/BalanceSheetDetailsTables 27 false false R28.htm 00000028 - Disclosure - Balance Sheet Details - Schedule of Accounts Receivable (Details) Sheet http://tearlab.com/role/BalanceSheetDetails-ScheduleOfAccountsReceivableDetails Balance Sheet Details - Schedule of Accounts Receivable (Details) Details 28 false false R29.htm 00000029 - Disclosure - Balance Sheet Details - Schedule of Inventory (Details) Sheet http://tearlab.com/role/BalanceSheetDetails-ScheduleOfInventoryDetails Balance Sheet Details - Schedule of Inventory (Details) Details 29 false false R30.htm 00000030 - Disclosure - Balance Sheet Details - Summary of Prepaid Expenses and Other Current Assets (Details) Sheet http://tearlab.com/role/BalanceSheetDetails-SummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails Balance Sheet Details - Summary of Prepaid Expenses and Other Current Assets (Details) Details 30 false false R31.htm 00000031 - Disclosure - Balance Sheet Details - Schedule of Fixed Assets (Details) Sheet http://tearlab.com/role/BalanceSheetDetails-ScheduleOfFixedAssetsDetails Balance Sheet Details - Schedule of Fixed Assets (Details) Details 31 false false R32.htm 00000032 - Disclosure - Balance Sheet Details - Schedule of Accrued Liabilities (Details) Sheet http://tearlab.com/role/BalanceSheetDetails-ScheduleOfAccruedLiabilitiesDetails Balance Sheet Details - Schedule of Accrued Liabilities (Details) Details 32 false false R33.htm 00000033 - Disclosure - Intangible Assets (Details Narrative) Sheet http://tearlab.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) Details http://tearlab.com/role/IntangibleAssetsTables 33 false false R34.htm 00000034 - Disclosure - Intangible Assets - Schedule of Amortization of Intangible Assets (Details) Sheet http://tearlab.com/role/IntangibleAssets-ScheduleOfAmortizationOfIntangibleAssetsDetails Intangible Assets - Schedule of Amortization of Intangible Assets (Details) Details 34 false false R35.htm 00000035 - Disclosure - Intangible Assets - Schedule of Estimated Amortization Expense of Intangible Assets (Details) Sheet http://tearlab.com/role/IntangibleAssets-ScheduleOfEstimatedAmortizationExpenseOfIntangibleAssetsDetails Intangible Assets - Schedule of Estimated Amortization Expense of Intangible Assets (Details) Details 35 false false R36.htm 00000036 - Disclosure - Term Loan (Details Narrative) Sheet http://tearlab.com/role/TermLoanDetailsNarrative Term Loan (Details Narrative) Details http://tearlab.com/role/TermLoanTables 36 false false R37.htm 00000037 - Disclosure - Term Loan - Schedule of Term Loan (Details) Sheet http://tearlab.com/role/TermLoan-ScheduleOfTermLoanDetails Term Loan - Schedule of Term Loan (Details) Details 37 false false R38.htm 00000038 - Disclosure - Term Loan - Schedule of Maturities of Outstanding Principal of Term Loan (Details) Sheet http://tearlab.com/role/TermLoan-ScheduleOfMaturitiesOfOutstandingPrincipalOfTermLoanDetails Term Loan - Schedule of Maturities of Outstanding Principal of Term Loan (Details) Details 38 false false R39.htm 00000039 - Disclosure - Stockholders' Equity (Details Narrative) Sheet http://tearlab.com/role/StockholdersEquityDetailsNarrative Stockholders' Equity (Details Narrative) Details http://tearlab.com/role/StockholdersEquityTables 39 false false R40.htm 00000040 - Disclosure - Stockholders' Equity - Schedule of Stock-Based Compensation Expense (Details) Sheet http://tearlab.com/role/StockholdersEquity-ScheduleOfStock-basedCompensationExpenseDetails Stockholders' Equity - Schedule of Stock-Based Compensation Expense (Details) Details 40 false false R41.htm 00000041 - Disclosure - Net Income (Loss) Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://tearlab.com/role/NetIncomeLossPerShare-ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Net Income (Loss) Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details http://tearlab.com/role/NetIncomeLossPerShareTables 41 false false R42.htm 00000042 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://tearlab.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://tearlab.com/role/CommitmentsAndContingenciesTables 42 false false R43.htm 00000043 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Costs (Details) Sheet http://tearlab.com/role/CommitmentsAndContingencies-ScheduleOfComponentsOfLeaseCostsDetails Commitments and Contingencies - Schedule of Components of Lease Costs (Details) Details 43 false false R44.htm 00000044 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-cancellable Leases (Details) Sheet http://tearlab.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancellableLeasesDetails Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-cancellable Leases (Details) Details 44 false false R45.htm 00000045 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Royalty Payments (Details) Sheet http://tearlab.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumRoyaltyPaymentsDetails Commitments and Contingencies - Schedule of Future Minimum Royalty Payments (Details) Details 45 false false R46.htm 00000046 - Disclosure - Related Party (Details Narrative) Sheet http://tearlab.com/role/RelatedPartyDetailsNarrative Related Party (Details Narrative) Details http://tearlab.com/role/RelatedParty 46 false false All Reports Book All Reports tear-20190630.xml tear-20190630.xsd tear-20190630_cal.xml tear-20190630_def.xml tear-20190630_lab.xml tear-20190630_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://fasb.org/srt/2019-01-31 true true ZIP 63 0001493152-19-011990-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-19-011990-xbrl.zip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�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ǳQDPH-<@7%[GT!CKWS =>Y5U;$K>!_Y5<%5OAWHO#RK40:@ M+V5QRXK8L 7UB]@*N1)I.DT[!W9Q6.WCA77:1$SIN.JTVKU%CA&54CE*(UTM MER3%M-OYN*+;?0]#.SDU8#65+UPEG+O40YTBNJ)HJWKH*P)7!18I;PFFY@U> MC5"PS5PCP"U/IA+ >&& I_" ^7N=8-2)[CJIN<_)\VU1YG"N$_J[:2@UB\)J M R=.-9>84$!, VU5(C=+_+QQP!KU=<78>_ZX*//J89/KPFKP.9AW3[(;IQFY M]\RF -- ._H96+/HL"G5+PZVW\<=03F&NZ?25L?]SP#K>(I-7\+WQ>B,Q M4Q]8(^X$7HV8V%I!6S/""]@:FOOPX75!3I>8>269W!V83B#CXAM$0X8ZM8$= M1CO5R4%CDPVD)LZFE$9"'/'57M1K-SSP9TH)^_XEJ4Q;,#HA<*U@0J@+=2I% M$9>-.PZW^Z7]V8%[Y'5I &L73[A*(W5W(+>*4)Z1W> DP[0_:[WAQ<]-KHU- M&%9+>2!5K[%RE<&Q@+9UC1U@K M!;*9O/: ^U8!L?DKT7ST:H*/\)M #]'0!!^#!=W@][4LN["CGX,M3#6@M@V^ M_0U8,RO E,;E$G'[%!]8+PKN>I!'\?;26,MZ06A5;D6IW#1,UN(XO>+O2(_E MS?2T7//H@.(3XB7SH=XKN^^M1;NTYKBQ!OFZFM==-1#WU 2(%]>&CU8*8)4; M(&IK_@7(ILX$^#4E*2D>3L4QRT8;0\9WU'O=/!852ZN[$W."T?,55? MW#HUX#6&#UQ=^U2&>[^(MKJ'6J=\+4C-M_#84M421$DG%6R]8H;8,T45@44- M([XI%Z0@DI*'W@P:HKI+GF\PCY/L1P)%/ H;#*"UM)C(PN6''JB=*$P'2:6H M,^G7"G].JAJ+T%'G.7[VOT'FKPJLY>;B5AJRPD>H-7$DKNIR*P!OF#EVYB%O MR7OMQ8,X!;GAN93+95/A157ANEJD?VL(Q=G=BI;-PVJG)\DU>HZ(=EY25VM:A:%U8). MG&JDY&J%-DP#L:D+1K-<4\P!B6>UMZORJ=XDU9D=K5,#8=D&WD =C47./@=IUNUW)'$5ONMKGO]Y1=+::3 M!=E2%J"F%AJI1.U2=T_EW:IL*N9ILO__0@I<8VS<^[((PVH:#Z1J;MCW/\7= M>!QAOGMBY3/NR!M%(3>#!J^[J(VP#?]_R4ASM3QAGB*ISY.4Y*1^.2G7 M:U+S(I]C;+G&NI,56$WWFB)8,K$M6P-HB?$H+E>!-FRZ2LDFR:-%!EPWZTO" M5@>9*.$C+M@"<+'FZ7&4%K:+PVI*+ZRFV&EYIX725@TE0B^.!]C&45DJA5'= M"*,HK-9QXC3&?EEJ&B?:68XX=Y*<611%D^3M8P2V7L?5JLPS\TF:30M66\V! MK#UWR_FYV[KM6HE01[1]M5%W!B"TX0W.FA1GNS6E51ETB_H@=S>6FG<>U[$"\M6$TZ![(]\E+=M^RFUQ>.2[0G)L.R":[R2K@H)%]' MA;2VI%T5;G-ZX;:W*>U,\%#4;0<=MVZ4ACU/"/TER1M6R%-<)^F*1_?JSB"^ M8-6]<2G :D1/M-.FXVKHD>OQILMZ3?34JAXAMK*/WA/;0+=GS^QOI.( %[5S M-#4IP6JX&8CM_:Z-YXOP5ALE;"T1;RSMZ#*\4;D^E*/,_5RL!K"#E)]L2T]Q6X\XULB\H5*S"YQ]KPAK%N6!:>0 M[8J\0QY6R_B!-705?@M/JHE^$72',L#5<,VL48&5I.8 4Z;H95$ M4C1NWM NE)# 8JAZG1"LNK<@5-+Y]<&3A&SDA\&;6GS];D5H_3(X85@XSZ]F MZ,)JJ_G U:?%K07TP[LC%/VL:_'UU-!&_2^P6F *2SGB^'H:.5BJR+,IUEBG MI$JUAQ8Z(5C5;$&H"Y'(AR2Y/,Q:X3B7MTH>B>Q366;5;9EG9\]IWF2D>%BL M2UJ3OXO27BTO6+F+!Q[L0MYH4YIG-S.P&O!595 NA)4R$3ANW!X-?8RHC-R(>^#U7F>ET\)DZG.2RKCT54\ MC<8]?^G O)\;O&% J_:L1K=3.ML"L!;;$;[2H+T=<;V62DLR@XBP)5X;4&FM M/[.*M;WZV@>Q/_R6W^?!&G%4"MWQH@F>[BQ1(Q^X!9KJ^"%)-K^YPI?9Y'[[ M$+T%O."Y@I_'=.KGO;$!0GD#*M,6=%2"2^]3-( M52NF6'XC"M.*KQ?'>=;-4K_]"*:B+>#4"(!;T7] 4A@MZIJ2^Z861[!UB:X3 M&%1G*PN_UG'IP.P4=JB6GB+3)PGQ2(WTB995=4W+)='. (.? 56]#M6TEH4, MDD*1ZK9_J"KBM53Z$5\1 E3/9FQ*#M_^?6TG&KO.+XJT7.-+1@)KK6_%(-:[ M!IVYYJ4P^I:+_R%2]7\IBW(,ON6#KA&,PH":PHU1DX2^5-JD58K5+.+64'75 MU%7-9IQ):F2C$(!- # W!B_?-V:.^JBG2-I,69_^\BC M0I\,@D(;.YTB":@1'0"UW:\-B-V]+5OP%GG ,ET)&QY3'IJC'1%CN;T)*?@\ M>56;=):L"H.;RPZDXRTRK=1SXX]F!*C](94XTF]#8\I*'1:^W MV>^.4'\BCZY(+A8SGY)J*\__<$?$1:'N;Y':F\W#E-\V.\7R?R^*12JN>%0W M.,7D<9HJ?HX>H-:?!7=*@DX9?=NI_X&/K)T%M#4!IA$OBD?&PY(:=M.L"J"; M38?3L[T&JF#:J0U5AK5C_Z+(KNH5IN91=S=+H%MV5@$\F[R+!-,:$^.N M,(>B'C*HA1>@N <@]^#G-+Q6%71+VQ%[-JULQJT5:"W:S0[,UYL_A[9*H%O1 MA'7N[-GJ0VHXVO 4J];S*!\]Z,UG@NO?@MP"BG_ ]077(@PB+1])AK./+U_9 M*HN-,]UNTR*MR:.Q*?VU 37H#J"5_3A<(Q$,LC."[E_0M]P.:]T_H.W^Z=96 MK!M2NO;UUP;4OCN -D2PD1M#TDB_VCR22]:C M_IQ-F(+5?;F_7NW/>$7^H0LNRG>@N!%8W?2<%$F1[MI--=J FG0' MT#.[:6\J?C?E*/E_^'3PF.18;(Y5-25IC3/^@[@&/_S#0%*^75#=S'8;].PY M7?&M;A[(XFRYQ*EVI@Z+ !#/(A5<%QK\2+)U8/$;3\M?^1.P_1O(P4)"6D6 M#D>H!X8Z9(A#0Q+;6^1^7R)Y/)#DGVC9;)B&>%M9L$F8+9-:=[HLM*-CR.\# M.KV.4NR#L7[+[ X1$I"$YA 4VJ**=03?/5-BSLIIV=S7RR973T1L5_;G& T MTNZ&6SEV5X]^CE!O6OAP,I(OXD>'L:]6=PR7#9_OLG_.,?\'-I:-7I+.V?78EVU C;[W M(FFZ=?J_(<;RX5>.8.ZI=,=H+ MUA7NZXN"^6WB!?C7HHUH@3-=!!=O)5 =PA>KOD_TJD=HH(PZ[5C]@J\7>3?5 M=HKN1T#-H&)2N@.7.!)C3^Q7 #+"VWG#\]VV4;F[+<@;O$Y(D6%ZM3QG%$CR M?\.)]D'ZSL8 -=KKRV!^=R!-'B%I%'6Y'CJS?(79&N:7":5IQ&T#)L=I8UL5 MSK/PQFB@ ;YSVR-FC#L=SS6Z>\+Y(Y,HBWH5_7&0O?BO:/*WU];[:>18^YF, M390GITORJ_NF^B/35P9[:DM "S$7GPT1W:L%=[$TVHHIW9@L( MS 8\9W58K^:WX%;O332A!N[,-I06(#;B8EEC>DZ6\YMQK/D&&M( >$Y3)MP$ M$C; -:9WVT%OJIDMHVF#X9\NV3^Q/W=_8O_%7R:RO_P_4$L#!!0 ( )5^ M"4_A[U:^MS@ !NB P 5 =&5A&UL[7U;-YD+O5;7O"%T=?I[;;?19*L?GG__O7U]?L@7#NO M8?0M_MX-8=T]A6GDHFU?S]?CZ>CCA_//'W[Z]&%T_N&_1O_U<71U\_#]VXPP M/7A9_JO'Y[//__RP_DOYQ__'_"#B9.D\?:#']Y^IE_[\.$\ M)_^;CX-OO]!_O3@Q&A%X@OB7MQC__5V%S==/WX?1_/U'0O7^_][?/;D+M'3. M<$!AA_ MB;)LOYH@)_*=%Z(?R_?T=^$/ND2!?3 J$DEHV*V;C_83PZ$6%] M@1+L.K[2F)B4O0R03BY$$8DGL\F*KC\$B9C 0]><""U0$.,UN@MCJ1#5>^J= M@:4W!)+<9FM@8\H>EJ055TV)B%1+\,BR_,2)]D*DRW6V70A)BU@I@%(>QGB M%/ED$?3(+B@'D=56_YK4R]JD98T2?O'9(1-_OT'7N]"UK,(&*B74LL3"QB:F MZG6YA0V(W5K3T@M4- F=OF48-CX J>XE&390< >Z#,AB]CTX$3T'K*7;G$(7 M^E=%U<%WZDP_&V?4R^&E/IK,KG#LS.<1FM.M<8K6*$BW(]N+.\5OZ-H>U-4- MW(6N(5&#TFL9;%5:RS!*\+^RC9[.:^:H5)GIVK]N9J_C M!"_IKE@=53'%=3"_U_=Z/8FHJJ>,KM?!5236^"YTF/(>= WXWDG2*%ME)K-) MFF2WC=0LBS Q\E>.WP=+G;^AZ0RI;):#>] TX(HLLU^>T3NX[#J$S,3JI(1: MXKU]0=]!NKH&DY."A_V42OH)N84N7;^Y?NHA[R8*EW2@:5(LTM=.%!#UVO8$ M%,IA1Z'[>*^JXQVZTLU"1?94LF&0WUW=(:*:EV$,WN!Z_,0!6;Y)R:*)[G& ME^DR&]"CL\F(O@9DWCZ$P9E+K4C?IP>RK$&_ NEA *;$-0TWCI]LRO'J$XOX M0[U?6:A.:@BM:)"KBA?MCOR@1H+>$D04P2L[HJ/=+]:#_)AV\2'_YWQT-BJI MJG\DQL,H[V)4[:,8>#ET/W1KH_5I#$P82:V7Z_'T=]%8QR]Q$CGN]CZ?,(G\ MK/O?*2V,]'V7P5+)QD2T65A.C-SOY^'ZO8?P>\H _4/&R=F'\R(HY]_(CW[/ M!S%% P)L/QZ)!N?&?.EG^C"5#N/]@D=R:71N1=.-AO<.PZ_C^(?2%4?7YK M( H_VH2"C'>3NV\^M"E:44=F,,]#P86;,(<"",Q/-@$#D8%!<&Z#!-&1DU,) M41>G&*<('!X%$)R_V@>.6 8&PCER263P/(Z'5VF@(A.)G^Z!@E MX_L7:8P#% N7K$9#( *?[4. R;%!!*Z7*)J3%?-+%+XF"^HI= +A7. 0@,]Q M]D$B%(%):-Z>R2$_QI2)W.H6XL)H#07%PM,UGWF3R]4"^3Y@CM3;05&PZK3- M9]BDJ1LNEV&0W>)E%T]QY$^D2"[$'#/)A5E@B($X/7 M'GP1;*O)+I2#'?..LT: ?$]R4BB"VMPB>R((EHX=8%ZEZ#FLI%,@7$. E)!! M0=3F^]@31)!4[ "PPBEH^X.#,P"WQK%L?X T\8S8*!$1%.1#^$*Z@ Q.G&]Z M_G5Q(O?@-OYX" =)%^"&XBR^=%:8S/VO 19=UM1;0;'1YA51GT8,+NV0_V.Y M3F<\2<) F8VA:&ASA"BC(>#9#E J+XID@;FMEE XM#D[.NTQ+&[MP&+L>=E5 MG>,_.MB[#8JI+/"Z\PB@R&AS="@C(^'=#H"F-/%<@+PR(>;8==-EFIT9&K71 MVEA!:,$1TM; !I>('0CRRUE!;#8X0MI\%3U89\=RA)*9K=U#.N XV^K.@,JF M5QTP^82270VT]I[RT[[O*4??U;YR>E]YH*,"D?HDRL;L959;L^2?[/3 IQ_N M>TPU"=FQ^=;'G"8.2)Q%[X;N,X586NI#'] MA+-GV.JBL!51Z]<^H;X,@8M./0?= 4D$XUJ$) MW_Z$1*:?B/:#GMT;7VN@LEV/2V#Z]6B?:-FXWRDF#..QUF6GTWCGT!]FL&WN MP.?X+8.TIE8>2T/.X]D=\))\9D'.Z'B=E3)BG^M_@)WK=Y\9A;/1[D-9%8[: MIT;T6Y8D4LKK.&W'+C_;EV+T62%E@%^B:*=;.JU-%C+!)1 T/*WUGFH MOJ*T 0(R6=$M^:/@"IS5U@XHV(K$0Z R_&H4:'\HQ%%208#\K2E]\B.:L,!+ MW818IRA:8Q>-WS!+]J0IN^40),\=?,7U8D;LF?L['U%\%2X=' AESVIN& "N M;'D0L'C8.3+-INZ@X[M'RQ<4\9>?1C-CWCVQ1#FN!0:'^YK&G-)>4^00QK=9 M0.@K*,>/N<*E-&(28_XX%4'+V;#I/#)%:Q2D") ILMW2&J]VRV)HQ0"PF;0* M@KRH:9 -\#><+"[3."%67;3-QT+3'I#_><_.FQ0EMBV,5: M(VM\V+)ED,':T$/>MD\-BS2; ,-20&*-9UN&I)1M.^;2$_)]NE0'WKT3?4.5 M 0M\;0(:TSD.Y6(/P;S8A-.4B)&,@>;DOB)&KQ]F:[04*@F9Z22'JFB!I& ' M8%]00'CSR4C'WA('635L6EY0"IF4T'@.1%74@**P [<69U\##25*HY6S1_--R$E- 9SYH(!Q-MC\C=TT'Y# M-$4_\L9KHIIS])#2Z]_)+ MTK,0Y7C@Q=ND9%_MI(@K:[=J?\92/8#783V)V MK,?E0_,ROA\,KY30>')(,(Y &=@5V5M]@]Q,#5 +Y_VQ2SAOM?=_'Q7]6Q+" M6PG@[I8Z"D1N0VSI(,-[E> Y!?O:$G)Z\&#?[BCDJD2?&(0!7; X$^Y9%'#C*;61% J MP,'EV [SN_YV6A[)S6IM.AZR"RPBOCL?I,DQ["6,D?FC-"?YF@Q>"9DU\9(* M.(,D8<=4;*9>DZ'%:V\Z3K(+3&+>[<#G0*GFS-^8:L@NMD(1#LE:ZT2)^=51 MX26YS8E2I# "7H@/&,7+,"#[;9R%3V<:.U[20FSYCQ/DG8M,2RFI-8NH#&6P M&.Q81%O#S;6T$VIM4M.AYMU1XXG!#M3&WA]IG*?R?PXY)E7&P8L3HRS- PKB M3.I31#:0&">HB+M_S):0*7+#>9#U(DE2K?_+@PE_/Q0(PU&YWYPH#B:3O+"9U(^!S;@0$:$[O:\P; %HO^>YW*9-=^K(G:S87 MS?;FV%%B=NR@>@,4=0&UA]1UQB]:=.U2,<;I\2IPL8]JS#Z'OM$=;*U(,(Y KLN&O0)+4'46S3ODYM+FZ#PB_ MO6D[E#/IE,+K)VF.-H_X <$]3$:=?M\"%N]NJC7C^5@+B4R[L0\(-$!X=J!< MUT@ZOBL,BR^*>PI2$?=F3F&GO0"6 S.Q8'XCU4P:7N_], M<80()T3#D\VC[Q K.?"V)1'X6*OT83QITQZ A9VY/I93!EQX?:P,"L%*UFN+ MNN2.=#;(KE-WQ38*[ MT!&$+<&HH;@>.H(1 A)[!X%(ZVCW#H;8^E@'X'JBS8G9FYZH2V[H>P=EE_Z? MFE!KQT?9U2"1$7:)*M-?$/.J_H-*R_SU:_O47A1FNWYS%TXP1U,R+:YG,R2L M,GC@<4!U5G]: OB>90:K/[6&;^631\\X_I1O^=-IN,)[V8_ZTTW8J>-']KHZ7:W\3-J.7TK[ M-IB%T3('7/YD%=H!5*_T9ZR ZY6B=#35PIW2'/KA+(V+AP*%M\Y[7A!%G2^V M_OP[:GGP:AJK=@*%2Y\K6U'V87=>M:*7'7P<[)$S,@PI$0$4%7UI*;JC(A>$ M^?(!M*Y!/)D]5GK<#JZ6I>"OH[,1W1_\,$XC1/Z24=)4!#5:@_6?HKD3% \2 M=HD3*$2!5QWB9%:WP'@GS;M5U5)NH/S\#24(]8T*)7D8G["73@^63W0TP*AY(IF0/8Y MT^QS>S_,*$<9Z:BD/>V'UNZ'5KEB'?1+N(T/]^Y;]*KD_W\ M0W.R[\A&!9W!IZUAZ+UBG]8K;W*S&[-\0BMV8_:E/F=X@/D*(C8\33LAVGZ1 M#Q62^5E(9E=!,]1P/4TGO_0G#V5'D9. MD.4OKO1AML0AAS,5$TZQ&\,U':4C!4P_U7X,S\E..#.*0ZJ+SOSLG2*?!@T_ M.A'/7ORQ.5T+DE%.8[+*WF[HSY$3Q 0=&G@BGY%R2J/% ]F#4YJ!2IT8GGY0 M'%N%!I7E9'ZZ">\UA!=TYS\I7M"-OBO_9#*__Q'=U7V-T61V'2=X2?1.$(C8 M;#>TNS?YE.F7O4S_!*Y^6^LO"!P,735Y\/,^CK&$@[=FG\;SR2@#V M(D!=(UOM$Q$6/9I[D#/5PS&>S%UM[>LF)#MLPSL4QPCED=)@0U!(9#PONZK5!Q"!'5@]H-<*G MMO0E=SNTB)L9$Z G$%K3KF2=F@"7G1U8US:^1CYU]1U#WH=I+_3!C B0+,V? M+YI/142'B]:SQ]9+*!L.%G^Z)U%$47&"[O :M49:+=18E-N!3NK]>CV"1U1] MB-6N-3Z<"7BZ21,JD^X*T^]73)\M^M @'7(WOV.4[_4$.\7'UIO9[:L]&W:( M(WB^MS,UZ.!N S*D-$]OKV*N\6F']*@/+@N[EN/)[-XAS:MEL=<,; MVI/I9;4CL&J",K]&ME_.B5;+UAMGUF-.&Q;.(;[JW.K0]7+EAQN$GE"TQO1& MA>CKA1-3I\V2;KCY'/"SL10W0VXX#S(W3I;",G/N*,W*WC]I^MT;Z-6H;HF; MG][,5Z:B&=YZKBUX:VK%1#^.1Z<5ATR08 _[:4),\"?D%IO)]1M-AHN\/,!Z MN4I+WT^'UZHZOF5ZNJL]<]4G;?,S7O R4#3O6V_,A:]D;9CY?[KGLEF<'=UH MH$8WE^ ('L!*A&';^2GWG=SC "_3Y93*VJ\4Z6GDW54_5.W5O>F35A_JT*ND MM2A/'"45Q2%_:RH-^='OY=NIU/%W;P9NB! <_Q]DH2\.EYN26ZFBD#[W[-+T M7?A>RK$_^[;LZHP$V$6$W(,348U>LW/'?&QEOV FQ!Y]5\;;;;L[1=Q9''%7 M.]:)@M5KS8XX*HXID)Y+V]D4S Z;_*U<&M*P=JN6@2.*<-\JR@6')UH7&%F@YU)TE+6B-8 #[W\[@4?ZGW-7FE+M^"3&\@:().F6>J">$+^\$+S(F65$E=A1"LH9L\ R8F'@426D$*]'],N0+YA M5LNTT55 =GB#)3F2\DLGJG=Q3-_5>\_.&W^N=>K,M#-/#O,^W'4]]!?5/]@EC9+[V)XOC*9JEP39*?\/7"Q"QZ6M&7J'I ML:B*TT?E7(RD1?$YZNFM?7!4?G'K[#FY>$XNGI.+Y^3B.1V=]SXZ&_ !G8[. MUAV=B_')CLN-9L;.8!V.R$P.M>4P= CCV]?)>4A'S!5NGO=/1&+L%*0B:#D; MIZ-MAZ.M00]&KT=;>W(\P6ZB&779F=F>K+I_/H6A2 1TA8AND7'14?+YK+9G^]G[014NU130B\&,.-;W7=1?F.T^X@5CHO3V@#S[%24XTL4 MQG&1FDKJW>'2'?'Z 1.9'1;?]B[F)HRNPO0EF:5^>_QRM-6Z,6WE:46_BT1[ M#G&T8IUX0$F'5:)*9?J>Z["+1%M>G8V.)"0G3)M-CFV*0Z&ET4K_!+$TMEV? M[(LAV!=;N&C&FIC 2//@")S]O/9';$^(162'';$=XZ^.GV:<%N4Z(% R:([9 M0I#+:OCFP)9'=GQ34Q(JT4N#W.Y9\CBZ[3U=+IUHDSUOHTEHB[1B<9F,MK!N MBIQF@HW_4RN;%W?CSS]9O(.C'QV57\U>NV??'14?WJ:,/-D%.NT";B6E#)_G MR/&(VH2O A="7E.(U_P8=WHQQS9M],4H;P,R,^F4%-V+-EL>\Z;.DXNVNF39 MY^Z=()W19]$1#N97:!7&.(%-+#'E46[%8.X/@=Q3^A*[$>GL^B ?-3#?A*@ MM0#)Z?7 G^;U0)?X:79EHHO-,_DVYV'!+C193CP@G$#\:'E^T!]N=*#<1PDR M/JO$=N"FH)_@FEL5)O=\P\!Q'U1JO3V3%L2*VGY<&$L/H#/MGE/0NZJC "P1 M30Z=FB\)!H:8Q+3SK2,.$#G8<4+,DH;2:@>WRU44KG-+1_;,1TADV@O7 3(( M6S:!EB?P1M%3.$M>B4P:98UD\ ')33O?N@.I)!\[()W,9MA%\B6S/,BPFYOV MM76'3,B_KMT*>=AU?. ^Q6ELV@'6=8<2\F['G."REL60=["["SK3QAWX81U, M ': -7;==)GZ-.2J^FB(_-E'A8>E6F>/RQH?UOZ^8-JJ!"M WT(=?C =ET5A M<)V8RK3%NO]Z<,R1=(*ZSL(+B5;9)^#;//J-4>4CIWN)(=Q+%,"1&3)#<4R& MZO@W"('>Y@GICC'"#LBZ3=9%6Y,PXWC@V8PE\"TX7: U9DG M)3N@+'+__$93FP3))ANSXU_Z#ME/9AAY@!@C8 >FG9%ZXXR4I&@']'DL5,LD M!X8(\NE,NS#UAPO*9&8'OAV@W1_5088)J@ ZN"-YX^H$EAOK4ZOTZJZ;9K2? M'7FQZ#/B5^S[1!U:'"M47E7LQN3T]OY(XZP(X4T857V(@NG-)S%]@.H$7W,: MRR1B/E==D[>J;>^>/,,I.7.)07*5.!H2;$E]VA.8*AKP; M$.SE(;I*G=D!ZX=]!D..IMQ/6&\1:3J,W(70>B'\XTP#H?;VK0-VE$?JT$Y M$DGH>H5-UH>\%GF6;V'I1-_$N'ON?P]'TW^= =CL71:.RF MIOWA?0A?( ,['&,")J>(LD4SG5>#.6]E39-;C+HE' ME%.:7C7[0-+"F$3!:"N1=3#O5Y>^3*_'?< J$93U0 OC F5TIF\=^P!07#34 M'@_F=9S@95/-BMP+BA[-'U4]FMMOUWV;Q==//LZ3C_/DXSSY. ?@XW1P1#/I MHHM-IE80CR:?9$"8"+BPQ%M9#K X#B.'SG5O$DR1FT;TF?"%$^/X:Q"^T/S' ME-7;8)4FY-=AX&(_?_A1Y4[JUM3V13OT0JKK/!7I71Y65&B$4;8++,"?:;_ M1?*@%$ANVN6@>QJU4E4K"-7ZHQ##L,[=+P0S&O@4NX[_#V*Q=SL$@SLW_*2B MET.QHB2'J!KC68(BRL1-)7G+5I)&,SMDSM 5ML"MNM;8/L>] M#C3JF M9F#,_I5L$O7[%3O0EVAS0PWZE8 5T_DV2!"1?#()_,U3$F&^J;"]@>,0F [- MTS$)6K>/0F'988(\1I@PM7)\,*1\"M.Y/PZ J4Q<=H"ZW:5HALED0_-IAT'V M*$:X]TK([%B#U9RG;$XJBFC27U.9^_TC>$G[ MK,TW)](1ODN.#MVF!2D+U9G,BA19DVB*YPO)04! 8IG*BQ8B 1>5G$FV(2-; MBH1$=J CU3@(4)I];=,OQ>?$[W49[8#+TE]U+4L K:DYX'B<:GJ)FSG\QIZ' MDRPM+DS*8AK3&X&JQ"$2T+(WQ%%267W(WYHK#_G1[U,GF/.JYI'?5WYMQVHB M7NOK(Z[,/1-2Y2IY.4JH1FN6;%UH;(&60]7A^P!)]-YYP\MT*9)IHPGX1J3W MA:(IM)9(FKU/A":V2;$X^+S --WH-GQ=A&CN! M1Z<\#E""D-@)JM0#=%'3EAF3]_$KXD60G%!! 9?VS-;)F,6S'F>0N#.;4EJ"AQL0.<66E"7CMA_(650$YK.LY4I<0C4!!V3$0ZHEWLP[U# M2]XG&[K(\ $3T0SF':F<<1L!*D.*IF2<&:O>(XI<*N Y&#!Q'X/)>:/[R+O8E#AG6/DD7HW09KE!<:FKP&*(H7> 79A!6Z,!W= 09162R: MSOF[0 5H1 20D4[Z]@7$#-MS@$Y9GLP9]-4 MW _A\CRN 5IMH3]P+\/A,>5,R.(Z_ Z3!<++1K%& 5GNQ\LP9?IY*)6,R%QH MA=(<@_&N2?"/SB9_Q-_Z/$?H(@)S\19* I?SK,N]7,9/J!(NC!^H=\)&Y!<[-CJZRX> MLG]QMP^F3ZA" (7*O&]#PK.N;6-K&$QFI;X\1FB5KZQD%%.V1SA;?F&T4 @, MNA@4N#D8&METI3*Z#?(I6QL, !)9!\9O\-5Q@BG>OQE.&QSQW'<56WG J%X;MII72/,K[ML ?*2QYB\-,(M\O\ M%CT/992&$("(3=\S*X&F( X[\#NX/:?M5+3/Y!*8= .-_K@J1IUG4T"789S$ MA38*DU++Z$S?12NB#!&".MB?<[ #-*>WVON S;$VMS49:.;'Q'$7=#$IKV?8 M^%$Z.9GI^V08?#!>;%I&86%5G0*HM!V^E*:2)%QJH*MDE:M+E8#'2T7K1-M) MK3.(E_O&._:W" XR?E7;36]G1'L,8B5&;&MZFC^H%Q&!F&:)JH0F[/(_P8[R M/T./\KOOT;]5OCC:?O)TXM? PJFFPZFFPZFF0_-L+G[]R&H[(!18P[>C@D-] M9 _.4OH@DD]A!R!\M1*"4F7$FGQP=K@'1?HQE!H-54MR9_A,RTL<8G)MC1[% M"H?[]SS$)V7[R'!P&G$;T.$_OX:]:$&E-].S6P?T+6'9!W?/+BSS3\MZ=5^Q M"A(:MTR^!DY>-1-Y]/2ACB,A]YI!^*XOS)!JRVZ.>F\ZK:T;^/\JXL*S.:#TKNBFJVL\$!,D@7%%O@)]>3 M94X/BUU/I^3@W.3@AOU1I^3@ )9TY?&*R)EN?!D&:T1,3*)$CZ79D>W"DA1> M,&+3MIEB4FLUF6@*SBX& GLJ3]EB4U?PQ4*&>J+Z,/J)ZI MB .MMK+.H$!]AY&.-6+MVAN$=8'^?%6J?CA5J3*)H% ;[:Q2E:V3MP%-DH+7 MZ-&7K&+\YL93CO50ITHF#$W[Q_5RY8<;A++//Z:1NW#B[.NDZ0]".$"44&2T M^7%[0$9!1)HW^<.4<_NH[7SX)RSG!JHK^DQCV":SV\##:^RECL^O,\QI:L<> M)*TYS!E]Y?;8M.1_P\EBBOQ,<#0A]'-X31;D9,,]4[*XDG5B&"T^$'+ 9*SI ML13*)3B^PA%R"15=/B[)"%(_D=X40(G-61%=!,W?IV!"TG*&.E52WT5HF)#J MJ9+Z("JI:UE!3I74-25C'7(E]:P (W4- (H#[YH-8=UEC[R2?<;DK=&"\'=! M3HD>=7$B,2$/ZO5\S0X=8.IO\XI*"_]Z M#-D'>CO@)"EIO\G\"9.5V"E)J61$YE.%:]3WJH4+DYX=*V]FNU-F:?WFBFOC M8E/]C7A95NG#COD*6K-5V*J$WUH"IFPY9K6U QQUE10 IW>=G,QFV$51>9*= M1+MSK'"I!-!!5TMM@8)\9:JN=6 )V+'<_8KB! =S\7I6:V3'G M6+5Q5R+/ MS0+]PL)#10!;=E.A0@ &+!JBW#\-)/< M,W(7 ?YG*G%*\-K;L8C!-@X."Y8D$V@/3[J?<"GL0$6L8U)TK-IPVL/+C[NT M9#19$\2+&Y=%?A_0%S3:8C5DZBB%3R8?.];!2I!HMGG&XS19A!'-R<0'4D@T ME 2 ,ZM"^#8!UYRQ)M$F72\K%;#(XHROD$P\XD'D_5/013#Q[W^F 4^LV5T M@TDB"!/ L0&M/L>A](-),:@FD.$K0!ZJ&\E<-V %4!.('588:[7*65!;JDL:TQER]EJFZXP/?X8^1J&+D!??$"E1 MWFAY,[(H.33$+G][) )93FLZ48\"V%!!6#(KM_F@MVO*MC2= #(AE>F*17"P M ,S; 1,SU\5#2L_:9/#(+?)[7SJ^C[R+39GKHFBHFB51I6/3Z9S@9Z-^1#C\ MM3K/C1<3? J]S[>D(F4>\LY%IV4IJ>D\4@IG9: 8CA;QW A1AWM+9SS_Q;Y@ M-R1@QUHO#>[BQ79M%[/<$[!VL$^O2F["Z M=RI0O27OXHO%D O CE6:I6Z1; M+W(N7YI<;I]A1I@8M+.JHQ%%] VM1+LT?=/X0V0U_=(J^8%KV/7;"D=9X]R9 MH4&AVI^ ZH]YGU_O 96O/JGH6IGB7OP$#C8H7;5@U5A#)1F MMRAL14@%!=M\^!^$>[VE8@JG:7Q*PA\ILVYK8TG(X?)6L*M'>M0'M)WCY)%Z-T&:U0<4%X#%-$<@KM+ M /ZBI-"%\=>QX!5*62YVP%G:670##&(!:*V&4&C,^ZPX/#( ,%Z"_NS)79!5 M@,;.9K\\:]V1%$P4Y>6WO%1+U/_P 52BGORX^-@HG.5-SC)C:53]WJCXX+:B M_:F.O=IQ@?F(^U3'_H"2;ZT/ISKVA]Q@R'*'=@.D7Z("%.9E$!(-"!#=.]$W1).W%'NTO+2?C-+TNV^0 M-K8J_<'D88?!32,:R!@69+A7:(W\<$49!0(((C;]FKL+A@I2L0/&+X@<[!R? MC'?L+7& J8%$J^H @022FWZ?W05*);8SSI''MNG+#T;0^E-KZ[@$[.: M0,P?I!]0DJOJ71AO_6:5L_0X2+"'_93JX>[AV_6;ZZ?D&]2I3-E+\[%,9M=. M%)!=9-N3\+!]WCQLD\&,\M&,OJ/C^*#^YYKYL6&W8&D2H3. MCPY(+[3*P0[' WN$D&H4VEQ":=B9TQ HH M$#O0VW/)'R_#5/2PO*?N3:^@<#]$G^(T[Z:@K]QP4M8F)HI-?=4H< E/Q0G^ M@2Y,E%NVK^%CT]=0Z7'D!/3FOM+GUB\PVG9KTD,@XG[+D]QMH-B-#>?80?H2 M.L%UBJC_8H6V/71'7)B)"X;R6QI M^DS840^KD=@""6B*=*>!=MF==_9-<;%Y9E/3I[L>I"Z2@27'N^V+W/@FC![0 MZ]AUZ1&#YJ..PH#\T239 MK>W J)-^-B!D\V>%WWC'#5'&P',B+_ZZ\HA:DO8_?SB7(0FF M(A [EM""N]TS3?%2R6ENQW0#+8D<#BK[L KG5NJ M'=F!H% ;FY--E44]UOD4Q53MO#OLTB"L\3Q"V0B$-J.,R'1IB8YZ6'\]"9&+ M)O/]*5VM_ T,"TY;XXE=>\! * 9-HK\G!X^;\05,]KS&QK.B]B!\L2"T[/YQ ME%3V&O*WYCY#?O3[E++!V>7)[RN_MF-/$._J]1%7;$$34N7J>CE*2W;;NM#8 M M5YT@!)E,Z?9;H4R;31Q-BNV9192Z),7LPM ??.FU2T]2;&RA_)1PCG$X+\H3D/ MR(]^OT-SQ[\.$II0@+TFD5:M1I9HMG 58HV[LD$=3L3Y +@+"FE2;V%8N"RY MM21;'[&>Y>"9_/C.>1$N!XTVYHHRM&32GO1,?C2=OV_OD?>X<**EPIO)'7RFF>6C)%^/X&L0KY.(9 M1AYWK:7CYSM;B1UKZ:1*(8R":C6RK#0R5VRBDRQ;[-EQ%L]2S=+K)4DH2+W9$%9F]L@K56]M3LX<\[(" M[]@)O$??"2"!BGJ^9H<.,/57-05S)_[U;"OCKU?"5;#R>_-EDS1J<77];,G$ MCJ7S#L4Q0I,5HF]6@GD6#2C.N%Q02@F!R!I_]P24@!UPU8>9E?R9S+[&>? G M'RP)V6#>J('8KR UT(K:=3;OL/.2E06!XELA,!T?WA'9%LN:;/9IN''\9%.L MZL)\VEG8"[>YZ8AP8-)S";O:HD9\%"=A@(H/Q\_A!;IWO'Q+_;H*@\L%W6UO M@V* W$L"Y7Y,QY?"<.DL(%W3 JU1D*+FL.3S0TYG.O@-6AT * [K()"*Z2Y M\YKMC%W\J^X.; 9U+5=YT,%NL:0'\TF07PF20\(+&:SW&(5>ZC)KY&4S6JT/ M(! &*R]T8$KSGI(%W53K8)>E[ 57S%P*( &ZRM(6= J[D:P*2T^2FPU>6D> M !U0](:K>8(%H.OF+\ )=OSM &B%7][5'[,I^(QG5LXB/C6)=NQYF$H!)EUN M:ZB #9ZBA>/7>SE26;**HN/99D[&DA(Y%7L)[]($2&P^:@B$@)HL- %",8]9 MWY\B-URCB'<& ] 9C^^'P0"6@"8$VA^^PTNIR9Q6IH+E9" MS<#B\FC'7+A*T7,X13Y]O_GH1%E>R# HYC)_'DC(H."8KU (XG_X=TBT&L(N MD=SFRED2@Y,8E]C+ZC$++G9EA%"H#9[8H:QPYZ4]R2HKE35H@$(8T$:3679- M=AG&22PLF/%)+8EEO63&[GOT;]D71]DGK2B"\:=+<5F_(J5 0"^$\[:& S+Z MR'')%X$=>^O3@NS]]& )@(C5UG0@1B]Y2+DRL .C7YT(4P<+ ")&4],!%7T@ MQ)6 '0 !@%$'1)NSJ0] 1$"HF9])F#A^P_BTTI:Y2:F_H+C0RO@O8Q^^DD]% MQ"(_P. MG=G4=.SU7B#RV;)W1A[@&96VF^?^9YSHA=6!9Y@.L']#]&T@\L;DJ.#,47YT M+7])G=/G4"V ]&0Z>KQ_]8#+S\:IWAA]N3I-G005P9<=T6?V9#J 73OZ OD- MY>J\9E_4GT&*WX*BS M4E2(C\&IJR"E8U8)ZJA*%EUUHDI]#$Y>%3D=M5;@V1Y*L2,^!I^O@I3L.&?R M!CR>)2C: ]DF_3&X>-5D=:137E$5!NX7%K.FP=%X8&=#Y=G(ICB[/]#:40E> M[ZXJ:OZ#GYK^@Z*+4=;'U@,PVG9CTA=09:]:!TM^_)=3:DC;1?U1G#N76@O# M)W"H5!F9NJH&UL4$L! A0#% M @ E7X)3R!'H=;")P AVT" !4 ( !(] '1E87(M,C Q M.3 V,S!?9&5F+GAM;%!+ 0(4 Q0 ( )5^"4_I'G8[+U, /6#! 5 M " 1CX !T96%R+3(P,3DP-C,P7VQA8BYX;6Q02P$"% ,4 M" "5?@E/X>]6OK&UL4$L%!@ & 8 B@$ &2$ 0 $! end